<SEC-DOCUMENT>0001213900-18-006399.txt : 20180516
<SEC-HEADER>0001213900-18-006399.hdr.sgml : 20180516
<ACCEPTANCE-DATETIME>20180515211522
ACCESSION NUMBER:		0001213900-18-006399
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180516
DATE AS OF CHANGE:		20180515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54716
		FILM NUMBER:		18838646

	BUSINESS ADDRESS:	
		STREET 1:		10006 LIATRIS LANE
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55347
		BUSINESS PHONE:		(952) 237-7412

	MAIL ADDRESS:	
		STREET 1:		10006 LIATRIS LANE
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55347

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0318_neuroonemedical.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746; Quarterly Report Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">for the Quarterly Period Ended March 31,
2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">-OR-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744; Transition Report Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">for the transaction period from _________
to________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number<B>: 000-54716</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NeuroOne Medical Technologies Corporation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>27-0863354</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction of</FONT><BR>
    <FONT STYLE="font-size: 10pt">Incorporation or Organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT><BR>
    <FONT STYLE="font-size: 10pt">Identification Number)</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>10006 Liatris Lane, Eden
    Prairie, MN </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>55347</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s Telephone Number, Including
Area Code: <B>952-237-7412</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B><BR>
(Former name or former address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the issuer
(1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes&nbsp;&#9746;&nbsp;No&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes&nbsp;&#9746;&nbsp;No&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo;, &ldquo;smaller reporting
company&rdquo;, and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 12%"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD NOWRAP STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&nbsp;&#9744; No&nbsp;&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of outstanding shares of the
registrant&rsquo;s common stock as of May 14, 2018 was 8,014,994.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 86%; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">PART 1 &ndash; FINANCIAL INFORMATION</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Item 1. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Financial Statements</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Condensed Consolidated Balance Sheets as
    of March 31, 2018 (unaudited) and December 31, 2017</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Condensed Consolidated Statements of Operations
    for the three months ended March 31, 2018 and 2017 (unaudited)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Condensed Consolidated Statements of Cash
    Flows for the three months ended March 31, 2018 and 2017 (unaudited)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Notes to Condensed Consolidated Financial
    Statements (unaudited)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Item 2. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis
    of Financial Condition and Results of Operations</FONT></TD>
    <TD STYLE="text-align: center">21</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Quantitative and Qualitative Disclosures
    About Market Risk</FONT></TD>
    <TD STYLE="text-align: center">30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Controls and Procedures</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-size: 10pt">PART II &ndash; OTHER INFORMATION</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Legal Proceedings</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Item 1A.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Item 2. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Unregistered Sales of Equity Securities and
    Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Item 3. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Defaults Upon Senior Securities</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Item 4. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Mine Safety Disclosures</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Item 5. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Other Information</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Item 6. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Exhibits</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">SIGNATURES</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1. Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March&nbsp;31,</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December&nbsp;31,</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current assets:</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%; padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,198</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,467</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,146</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,146</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current assets</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,344</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,613</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">211,420</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">216,372</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">243,764</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">249,985</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liabilities and Stockholders&rsquo; Deficit</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current liabilities:</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,522,874</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,021,617</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term promissory notes and unsecured loan, net of discount</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">369,124</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,000</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes, net and accrued interest</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,505,089</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,168,340</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Premium conversion derivatives</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">607,173</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">462,174</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current liabilities</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,004,260</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,905,131</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant liability</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,634,059</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,381,465</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,638,319</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,286,596</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and contingencies (Note 4)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo; deficit:</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2018 and December 31, 2017; no shares issued or outstanding as of March 31, 2018 and December 31, 2017.</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2018 and December 31, 2017; and 7,864,994 shares issued and outstanding as of March 31, 2018 and December 31, 2017.</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,865</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,865</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid&ndash;in capital</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">279,150</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">280,320</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,681,570</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,324,796</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stockholders&rsquo; deficit</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,394,555</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,036,611</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities and stockholders&rsquo; deficit</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">243,764</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">249,985</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to condensed consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Statements of
Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the three months ended</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March 31,</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses:</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%; padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">992,435</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">444,016</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,045</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,041</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097,480</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">516,057</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,097,480</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(516,057</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(193,034</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(213,550</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change in fair value for the warrant liability and premium conversion derivatives</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,960</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on short-term notes extinguishment</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(186,220</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,356,774</FONT></TD>
    <TD STYLE="line-height: 107%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(729,575</FONT></TD>
    <TD STYLE="line-height: 107%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share:</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.17</FONT></TD>
    <TD STYLE="line-height: 107%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.14</FONT></TD>
    <TD STYLE="line-height: 107%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares used in per share calculations:</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,864,994</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,216,565</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to condensed consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Statements of
Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,356,774</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(729,575</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,952</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,007</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based services expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,437</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash interest on short-term and convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,116</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,887</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash discount amortization on convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,918</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,541</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Note issuance costs attributed to warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,803</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Revaluation of premium conversion derivatives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Revaluation of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(123,992</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(215</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Loss on short-term notes extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186,220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Change in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,823</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">246,822</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">107,627</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(591,269</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(350,919</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,427</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds from issuance of warrants associated with short-term and convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,864</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182,693</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">(Repayment) proceeds from short term unsecured loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance costs related to convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,130</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Issuance costs related to warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,870</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">590,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">315,120</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net decrease in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,269</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,799</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Cash at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">522,217</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Cash at end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25,198</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">486,418</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">Supplemental non-cash financing and investing transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Bifurcation of premium conversion derivative related to convertible promissory notes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">91,298</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">72,732</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Accrued issuance costs attributed to convertible promissory notes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">16,645</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Accrued issuance costs attributed to warrant liability</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,803</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to condensed consolidated financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
1 &ndash; Organization and Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne Medical Technologies Corporation
(the &ldquo;Company&rdquo;), a Delaware Corporation, was originally incorporated as Original Source Entertainment, Inc. under the
laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition (as defined below), the Company completed
a series of steps contemplated by a Plan of Conversion pursuant to which the Company, among other things, changed its name to NeuroOne
Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased
its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware. On July 20, 2017,
the Company, through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&ldquo;NeuroOne&rdquo;)
in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &ldquo;Acquisition&rdquo;).
The Acquisition was accounted for as a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in
this transaction. As such, the historical financial statements of NeuroOne reflect operations of the Company for all periods presented
prior to the date of the Acquisition. The accompanying condensed consolidated financial statements subsequent to the Acquisition
include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to the Acquisition, the Company&rsquo;s
operating activities became the same as those of NeuroOne, an early-stage medical technology company developing comprehensive
neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy,
Parkinson&rsquo;s disease, essential tremors, and other brain related disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, the Company has recorded no product
sales and has a limited expense history. The Company is a development stage company and its activities to date have included raising
capital to fund the development of its proprietary technology and seek regulatory clearances required to initiate commercial activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is based in Eden Prairie,
Minnesota.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acquisition of NeuroOne, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Acquisition was consummated on July
20, 2017 (the &ldquo;Closing&rdquo;) and, pursuant to the terms of the merger agreement, (i) all outstanding shares of common
stock of NeuroOne, par value $0.0001 per share (the &ldquo;NeuroOne Shares&rdquo;), were exchanged for shares of the Company&rsquo;s
common stock, par value $0.001 per share (the &ldquo;Company Shares&rdquo;), based on the exchange ratio of 17.0103706 Company
Shares for every one NeuroOne Share (the &ldquo;Exchange Ratio&rdquo;), resulting in the Company issuing, on July 20, 2017, an
aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne
were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective
exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options, (iii)
all warrants of NeuroOne were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible
promissory notes of NeuroOne. NeuroOne options had been issued pursuant to the NeuroOne 2016 Equity Incentive Plan. Pursuant to
the merger agreement, the Company assumed the NeuroOne 2016 Equity Incentive Plan upon the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Acquisition, the Company
acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became the Company&rsquo;s wholly-owned
subsidiary. Also at the Closing, Mr. Samad (the majority owner of the Company prior to the Acquisition) tendered for cancellation
3,500,000 Company Shares held by him as part of the conditions to Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issued and outstanding common stock
share amounts, options for common stock and per share amounts contained in the consolidated financial statements were retroactively
adjusted to reflect the Exchange Ratio for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed
consolidated financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Certain information and footnote disclosures normally
included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been
condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements may not include
all disclosures required by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the
information presented not misleading. These unaudited condensed consolidated financial statements should be read in
conjunction with the audited financial statements and the notes thereto for the fiscal year ended December 31, 2017 included
in the Annual Report on Form 10-K for the year ended December 31, 2017. The condensed balance sheet at December 31, 2017 was
derived from the audited financial statements of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the opinion of management, all adjustments,
consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations,
and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily
indicative of the operating results for the full fiscal year or any future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period balances have been reclassified to conform
to the current period presentation. Specifically, the Company reclassified all fair market valuation adjustments related to the
warrant liability and to the premium conversion derivative from interest expense to a separate line item on the condensed consolidated
statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
2 &ndash; Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed consolidated
financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred
losses since inception and had an accumulated deficit of $6,681,570 as of March 31, 2018. The Company does not have adequate liquidity
to fund its operations throughout fiscal 2018 without raising additional funds. These factors raise substantial doubt about its
ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might
result from the outcome of this condition. Management intends to continue to seek additional financing to fund operations. If the
Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company
and the development of its technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through March 31, 2018, the Company has
completed a $115,000 unsecured loan financing, a $253,000 short-term promissory note financing (which notes were amended and restated
to become convertible promissory notes as described below), a $1,625,120 convertible promissory note financing of a planned $2.5
million subscription and a second $1,140,000 convertible promissory note financing of a planned $2 million subscription. See Note
13 &ndash; Subsequent Events for financings that have closed after March 31, 2018. The Company does not have adequate liquidity
to fund its operations throughout fiscal 2018 without raising additional funds. Management intends to continue to seek additional
debt and/or equity financing to fund operations. However, if the Company is unable to raise additional funds, or the Company&rsquo;s
anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend
the time period that existing resources can fund the Company&rsquo;s operations. If management is unable to obtain the necessary
capital, it may have to cease operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
3 &ndash; Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Management&rsquo;s Use of
Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the
reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentration of Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially
subject the Company to a concentration of credit risk consist of cash. The Company&rsquo;s cash is held by one financial institution
in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial
institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of
March 31, 2018, the Company did not have any deposits in excess of federally insured amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s accounting for fair
value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial
statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy
that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted
quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements
involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 1 Inputs: Unadjusted quoted prices in active markets for
    identical assets or liabilities accessible to the Company at the measurement date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 2 Inputs: Other than quoted prices included in Level 1
    inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the
    asset or liability.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 3 Inputs: Unobservable inputs for the asset or liability
    used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which
    there is little, if any, market activity for the asset or liability at measurement date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2018 and December 31,
2017, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because
of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory
notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability
and the premium conversion derivatives associated with the short-term and convertible promissory notes of the Company were based
on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected
returns by market participants for similar instruments and are based on Level&nbsp;3 inputs. There were no transfers between fair
value hierarchy levels during the three months ended March 31, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of financial instruments measured on a recurring
basis is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March 31,&nbsp;2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,634,059</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,634,059</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Premium conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">607,173</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">607,173</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total liabilities at fair value</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,241,232</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,241,232</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December&nbsp;31,&nbsp;2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,381,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,381,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Premium conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">462,174</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">462,174</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total liabilities at fair value</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,843,639</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,843,639</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a roll-forward
of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable
level&nbsp;3 inputs for the three month periods ended March 31, 2018 and 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Warrant liability</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Balance as of beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,381,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">345,960</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Value assigned to warrants in connection with convertible promissory and short-term notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">376,586</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182,693</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(123,992</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(215</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,634,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">528,438</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Premium debt conversion derivatives</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Balance as of beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">462,174</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">137,650</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Value assigned to the underlying derivatives in connection with convertible promissory and short-term
    notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,967</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,732</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value of premium debt conversion derivatives</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,032</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">183</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">607,173</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">210,565</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual Property </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into
two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how.
Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life
of the acquired technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Impairment of Long-Lived Assets
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates its long-lived assets,
which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that
the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining
whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset
is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair
value of the impaired asset. Through March 31, 2018, the Company has not impaired any long-lived assets.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Debt Issuance Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Debt issuance costs are recorded as a
reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated
using the straight-line method over the term of the short term notes and convertible promissory notes, which approximates the
effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are charged
to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development
activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other
contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be
used in future research and development activities are expensed when the activity is performed or when the goods have been received,
rather than when payment is made, in accordance with ASC 730, <I>Research and Development</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued warrants to
purchase equity securities in connection with the issuance or amendment of short-term and convertible promissory notes. The
Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in
cases where warrant pricing protections in future equity financings are not available to other common stockholders.
Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense
in the accompanying condensed consolidated statements of operations. The Company adjusts the liability for changes in fair
value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future
equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at
which point the warrants will be classified in stockholders&rsquo; (deficit) equity provided that there are sufficient
authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require
settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is
recognized in the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Premium Debt Conversion Derivatives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates all conversion and
redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from
the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding
discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the
host debt instrument using the straight-line method which approximates the effective interest method.&nbsp; The separated embedded
derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated
embedded derivative at each reporting period in the condensed consolidated statements of operations. The Company determined that
the redemption features under the amended short-term promissory notes and convertible promissory notes qualified as embedded derivatives
and were separated from their debt hosts.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the Company, income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base
and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred
tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset
will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Loss Per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, basic loss per share
of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted earnings or loss per share of
common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased
to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&rsquo;s short-term
notes, convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted
earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the short-term
notes and convertible promissory notes utilizing the if-converted method was not applicable during the three month periods ended
March 31, 2018 and 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock
equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss
reported for the three month periods ended March 31, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares
were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three
month periods ended March 31, 2018 and 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Warrants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">189,750</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">597,283</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365,716</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">There are additional potential warrants to be included which
    will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in
    the future.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, the FASB issued ASU
2017-09, <I>Compensation - Stock Compensation (Topic 718):&nbsp;Scope of Modification Accounting (ASU
2016-09)</I>,&nbsp;which provides guidance about which changes to the terms or conditions of a share-based payment award
require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods
beginning after December 15, 2017. The Company has adopted this standard for the three months ended March 31, 2018. The
adoption of this standard did not have any impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the FASB issued ASU No.
2017-11, <I>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</I>, which changes the accounting
and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a
cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is
effective for annual periods beginning after December&nbsp;15, 2018 for public business entities, including interim periods within
those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and
has not yet determined its impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
4 &ndash; Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject
to litigation and claims arising in the ordinary course of business.&nbsp; In May 2017, NeuroOne received a letter from PMT, the
former employer of Mark Christianson and Wade Fredrickson.&nbsp; PMT claimed that these officers had breached their restrictive
covenant obligations with PMT by virtue of their work for NeuroOne and such officer&rsquo;s prior work during employment with
the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and
state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference
with the contracts.&nbsp; The letter demanded that Mr. Fredrickson (who is no longer with the Company), Mr. Christianson and NeuroOne
cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne
provide the former employer access to NeuroOne&rsquo;s systems to demonstrate that it is not using trade secrets or proprietary
information nor competing with the former employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, we were served with
a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson.&nbsp;
In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure
obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil
conspiracy, tortiously interfered with PMT&rsquo;s contracts and prospective economic advantage, and breached a covenant of good
faith and fair dealing.&nbsp; Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence,
made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the
tort of conversion and statutory civil theft.&nbsp; Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne
were unjustly enriched and engaged in unfair competition.&nbsp; PMT asks the Court to impose a constructive trust over the shares
held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&rsquo;
fees, costs and interest.&nbsp; The Company, NeuroOne and Mr. Christianson (who has not worked for PMT since 2012) intend to defend
themselves vigorously.&nbsp;&nbsp;The outcome and potential loss related to this matter is unknown as of March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no insurance coverage
to protect against any losses that the Company may experience due to this claim. Furthermore, Mr. Christianson is a key officer
and the loss of his services would be detrimental to the Company&rsquo;s operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
5 &ndash; Intangibles</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets consisted of the following
at March 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful Life</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify">Net Intangibles, December 31, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">12-13 Years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">216,372</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Net Intangibles, March 31, 2018</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">211,420</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense was $4,952 and $5,007
for the three months ended March 31, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
6 &ndash; Accrued Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses consisted of the following
at March 31, 2018 and December 31, 2017:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March 31,</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December 31,</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued&nbsp;license fees</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,000</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,000</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued services</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">868,811</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,339</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued issuance costs</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,083</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,083</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued payroll</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">251,543</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">223,195</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other (1)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">254,437</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,522,874</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,021,617</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Accrued expenses include an obligation to issue stock awards and stock options to consultants
that have met vesting requirements as of March 31, 2018 in the amount of $254,437. See Note 10 &ndash; Stock-Based Compensation
for further detail.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
7 &ndash; Short-Term Promissory Notes and Unsecured Loan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Short-Term Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2017, the Company&rsquo;s
Board of Directors (the &ldquo;Board&rdquo;) authorized, and the Company issued short-term unsecured and interest-free
promissory notes (the &ldquo;Short-Term Notes&rdquo;) for aggregate gross proceeds of $253,000 prior to issuance costs of
$3,030 which were discounted from the Short-Term Notes and were amortized ratably to interest expense over the original term
of the Short-Term Notes up though November 2017. On November 30, 2017, the Short-Term Notes were amended to extend the
maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase
warrants (&ldquo;Original Warrants&rdquo;). The Original Warrants had a term of 5 years and an exercise price of $1.80 and
would have been immediately exercisable upon maturity of the Short-Term Notes prior to the amendment described below. The
November 30, 2017 amendment resulted in a substantial modification to the Short-Term Notes and was accounted for under the
provisions of extinguishment accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Short-Term Notes
were subsequently amended and restated on March 12, 2018 (the &ldquo;Amended and Restated Short-Term Notes&rdquo;). The Amended and Restated Short-Term Notes became convertible
promissory notes that bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and
accrued and unpaid interest thereon on the maturity date of July 31, 2018 (the &ldquo;Short-Term Note Maturity Date&rdquo;).
Pursuant to the terms of each Amended and Restated Short-Term Note and a consent signed by the Company and each holder, the
Original Warrants under the Short-Term Notes were modified whereby each subscriber received a replacement warrant
(the &ldquo;Replacement Warrant&rdquo;) upon the issuance of the Amended and Restated Short-Term Note, in lieu of the
Original Warrant. In addition, each holder was issued an additional warrant (the &ldquo;Additional Warrant&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company raises more than
$3,000,000 in an equity or equity-linked financing before July 31, 2018 (the &ldquo;Short-Term Note Qualified
Financing&rdquo;), the outstanding principal and accrued interest (the &ldquo;Outstanding Balance&rdquo;) on the Amended and
Restated Short-Term Notes shall automatically convert into the securities issued by the Company in the Short-Term Note
Qualified Financing (the &ldquo;New Round Stock&rdquo;) based on the greater number of such securities resulting from either
(i) the Outstanding Balance divided by $1.80 or (ii) the Outstanding Balance multiplied by 1.25, divided by the price paid
per security in the Short-Term Note Qualified Financing. If a change of control transaction occurs prior to the earlier of a
Short-Term Note Qualified Financing or the Short-Term Note Maturity Date, the Amended and Restated Short-Term Notes
would, at the election of the holders of a majority of the outstanding principal of the Amended and Restated Short-Term
Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common
stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common
stock as determined by the Board as if in connection with the granting of
stock-based compensation or in a private sale to a third party in an arms&rsquo; length transaction or (ii) at the per share
consideration to be paid in such transaction. The date of a conversion under a Short-Term Note Qualified Financing or a
change of control transaction under the terms of the Amended and Restated Short-Term Notes is referred to herein as the
&ldquo;Conversion Date&rdquo;.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Replacement Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Replacement Warrant grants the
holder the option to purchase up to the number of shares of capital stock of the Company equal to the New Round Stock issued
or issuable upon the conversion of the Amended and Restated Short-Term Note held by such holder at a per share exercise price
equal to either (i) the actual per share price of New Round Stock if the Amended and Restated Short-Term Notes converted in
connection with a Short-Term Note Qualified Financing or (ii) the price at which the Amended and Restated Short-Term Notes
converted in connection with a change of control transaction. The Replacement Warrants are exercisable commencing on the
Conversion Date and expire on November 21, 2021. The exercise price and number of the shares issuable upon exercising the
Replacement Warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split,
recapitalization, reorganization or similar transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Replacement Warrants were deemed
to be a free-standing instrument and were accounted for as a liability given the variable number of shares issuable in
connection with a possible change of control conversion event. The Company recorded an initial liability of $137,722 upon
issuance with an offset to extinguishment loss described further below. The fair value changes of the warrant liability
associated with the Short-Term Notes are recorded at each reporting date in the condensed consolidated statements of
operations which amounted to a benefit of $(2,371) for the three months ended March 31, 2018. A Monte Carlo simulation model
was used to estimate the aggregate fair value of the Replacement Warrants as of March 31, 2018. Input assumptions used were
as follows: risk-free interest rate of 2.45 percent; expected volatility of 50 percent; expected life of 3.64 years; and
expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was
according to a separate independent third-party valuation analysis since there was no active trading market for the
Company&rsquo;s common stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Additional Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Additional Warrant grants the holder
the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying
(i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share
exercise price of $1.80. The Additional Warrants are exercisable commencing on the Conversion Date and expire on November 21,
2021. The exercise price and number of the shares issuable upon exercising the Additional Warrants are subject to adjustment in
the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as
described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Additional Warrants were deemed
to be a free-standing instrument and were accounted for as equity as there were no variable terms. The Additional Warrants
amounted to 189,750 shares as of both the March 12, 2018 amendment date and as of March 31, 2018 with terms that largely
parallel the provisions of the Original Warrants except that the Additional Warrants are exercisable on the Conversion Date
as opposed to the Short-Term Note Maturity Date and the expiration date was moved up to November 21, 2021 from July 31, 2023.
The fair value differential between the Original Warrants and the Additional Warrants was a reduction of $22,624. The fair
value change was recorded as a reduction to additional paid-in capital in the accompanying condensed balance sheets and was
included as part of the extinguishment loss discussed further below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Premium Conversion Derivative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the March 2018 amendment, the Short-Term
Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurs at a price under $2.25
per common share. The Company determined that the redemption feature under the Short-Term Notes qualified as an embedded derivative
and was reflected as a liability in the amount of $49,668 at the time of the March 12, 2018 amendment with a corresponding offset
to extinguishment loss which is described further below. Subsequent to the amendment, the embedded derivative is accounted for
separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative
associated with the Short-Term Notes in the condensed consolidated statements of operations for an expense of $43 for the three
months ended March 31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The March 2018 amendment resulted in a
substantial modification to the Short-Term Notes whereby additional conversion features and warrant coverage were added. The Company
recorded the Short-Term Note amendment under the provisions of extinguishment accounting. A loss on Short-Term Notes extinguishment
in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2018 was recorded in
the amount of $186,220, which represented the difference between the carrying value of the Short-Term Notes over the combined
fair values of the Short-Term Notes, premium conversion derivative, Replacement Warrant and Additional Warrants on the date of
the amendment. The fair value decrease of the Short-Term Notes (inclusive of principal and interest, non-bifurcated embedded conversion
feature and the Additional Warrants) relative to its adjusted carrying value at the time of the amendment was $1,170 which was
recorded as a reduction to additional paid-in capital on the accompanying condensed balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Short-Term Note subscription
agreement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any
portion of the Short-Term Notes and associated warrants, and the right to purchase the Short-Term Notes and associated warrants
on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15
days of receiving written notice. The Company has granted subscribers indemnification rights with respect to its representations,
warranties, covenants and agreements under the Short-Term Note subscription agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unsecured Loans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2018, the Company received
cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from an existing stockholder. The loan
is interest free and requires that the Company repay the principal in full on the earlier to occur of (i) March 20, 2019 or (ii)
the closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan includes
customary events of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, NeuroOne received a $50,000
short-term unsecured loan in November 2016 from the placement agent for its convertible promissory note financing (see Note 8
&ndash; Convertible Promissory Notes and Warrant Agreements). NeuroOne incurred no fees or interest costs for this temporary loan
and it was repaid in full in February 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
8 &ndash; Convertible Promissory Notes and Warrant Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> March 31,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<BR> December 31,<BR>
    2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">2016 convertible promissory notes, net of discounts</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,578,239</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,543,652</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2017 convertible promissory notes, net of discounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">753,637</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">504,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accrued interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">173,213</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">120,223</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,505,089</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,168,340</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2016 Convertible Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2016 and as amended in June
2017, the Board authorized the Company to issue convertible promissory notes (the &ldquo;Convertible
Notes&rdquo;) and common stock purchase warrants (the &ldquo;Warrants&rdquo;) for aggregate gross proceeds of up to $2.5 million
and entered into subscription agreements with subscribers (the &ldquo;2016 Private Placement&rdquo;). The Company amended the
Convertible Notes and Warrants again on November 20, 2017 to extend the maturity date of the Convertible Notes from November 21,
2017 to July 31, 2018 and to change the terms of the underlying Warrants that include the removal of down-round pricing protection
provisions as described more fully below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2018, the Company
issued a total of $1,625,120 of Convertible Notes and Warrants to investors. The Convertible Notes are unsecured. The
Convertible Notes bear interest at a fixed rate of 8 percent per annum and require the Company to repay the principal and
accrued and unpaid interest thereon at the earlier of July 31, 2018 or the consummation of the next equity or equity-linked
round of financing resulting in more than $3.0 million in gross proceeds (a &ldquo;Qualified Financing&rdquo;). If a
Qualified Financing occurs before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible
Notes automatically converts into the securities issued by the Company in such financing based on the greater number of
securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or
the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per
security in the Qualified Financing. If the Company fails to complete a Qualified Financing by July 31, 2018, the Convertible
Notes will be immediately due and payable on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a change of control transaction or
initial public offering occurs prior to a Qualified Financing, the Convertible Notes would, at the election of the holders of
a majority of the outstanding principal of the Convertible Notes, either become payable on demand as of the closing date of such
transaction, or become convertible into shares of common stock immediately prior to such transaction at a price per share equal
to the lesser of the per share value as determined by the Board as if in connection with the granting
of stock based compensation, or in a private sale to a third party in an arms-length transaction, or at the per share consideration
to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&rsquo;s
stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all
or substantially all of the assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the June 2017 amendment, the
Warrants granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number
of shares equal to the number of shares received by the holders upon the conversion of the Convertible Notes, or (ii) if exercised
prior to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued
interest on the Convertible Note held by such warrant holder divided by $1.80. The Warrants were immediately exercisable on the
date of issuance and expired on November 21, 2021. In June 2017, however, the Company amended the terms of the Warrants under
the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the
related Convertible Notes. The amount of warrant shares to be issued are now contingent and are based on the number of shares
of common stock received by the holder of the Convertible Notes upon conversion of such holder&rsquo;s Convertible Notes, and
at an exercise price equal to the same price per share of the securities issued in the Qualified Financing. The Warrants expire
on November 21, 2021 in the event of a Qualified Financing or expire unissued if the notes have not been converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants were deemed to be a free-standing
instrument and were accounted for as a liability given the variable number of shares issuable in connection with a possible change
of control conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the Warrants. Input
assumptions used were as follows: risk-free interest rate of 2.45 and 2.08 percent as of March 31, 2018 and December 31, 2017,
respectively; expected volatility of 50 percent as of March 31, 2018 and December 31, 2017; expected life of 3.64 and 3.89 years
as of March 31, 2018 and December 31, 2017, respectively; and expected dividend yield of 0 percent as of March 31, 2018 and December
31, 2017. The underlying stock price used in the analysis was on a non-marketable basis and was according to a separate independent
third-party valuation analysis since there was no active trading market for the Company&rsquo;s common stock.&nbsp;The Convertible
Note proceeds assigned to the Warrants were zero and $182,693 during the three months ended March 31, 2018 and 2017, respectively,
which represented their fair value at issuance, and were discounted from the Convertible Notes and reflected as a warrant liability.
The discount was amortized to interest expense over the original term of the Convertible Notes using the straight-line method
which approximates the effective interest method. The amortization expense was zero and $118,862 for the three months ended March
31, 2018 and 2017, respectively. The Company also recorded the fair value changes of the warrant liability associated with the
Convertible Notes in the condensed consolidated statements of operations which amounted to a benefit of $(130,976) and $(215)
for the three months ended March 31, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The November 2017 amendment resulted in
a substantial modification to the original Convertible Notes whereby the maturity date was extended, and the terms associated
with the Warrants were revised. The fair value of the underlying convertible notes was $97,223 lower than the carrying value of
the Convertible Notes on the date of the modification. The $97,223 difference was recorded as a discount to the debt and is being
amortized over the amended term of the Convertible Notes. The amortization recorded during the three months ended March 31, 2018
and 2017 was $34,585 and zero, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of their issuance, the Convertible
Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share.
The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated
from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes
in the amount of zero and $72,732 during the three months ended March 31, 2018 and 2017, respectively. The discount was being
amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximates
the effective interest method. The amortization expense was zero and $47,318 for the three months ended March 31, 2018 and 2017,
respectively. The embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair
value changes of the premium debt conversion derivative associated with the Convertible Notes in the condensed consolidated statements
of operations for an expense of $2,666 and $183 for the three months ended March 31, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Convertible Notes,
the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610
for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &ldquo;placement
agent warrant&rdquo;) which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855
on date of Convertible Note issuance, and (iii) legal expenses of $33,450. The placement agent warrant is issuable at the time
the private placement transaction closes which has not occurred as of March 31, 2018. The placement agent warrant will be immediately
exercisable on the date of issuance and will expire five years following the date of issuance. The placement agent is to receive
a placement agent warrant to purchase shares of common stock in an amount equal to 8% of the common stock (or common stock equivalents)
purchased by investors in the private placement transaction. As of March 31, 2018 and December 31, 2017, the Company has an obligation
to issue a placement agent warrant for the purchase of approximately 63,000 shares of common stock. The Company recorded an issuance
cost discount to the Convertible Notes in the amount of zero and $16,645 during the three months ended March 31, 2018 and 2017,
respectively, of which zero and $12,361 was amortized to interest expense during the three months ended March 31, 2018 and 2017,
respectively. The balance of the issuance costs in the amount of zero and $15,803 was attributed to the Warrants and was immediately
recorded as interest expense upon issuance during the three months ended March 31, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Convertible Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2017, the Company initially
entered into a subscription agreement (with certain investors (the &ldquo;Subscribers&rdquo;), pursuant to which the Company,
in a private placement (the &ldquo;Private Placement&rdquo;), agreed to issue and sell to the Subscribers 8% convertible promissory
notes (each, a &ldquo;Note&rdquo; and collectively, the &ldquo;2017 Convertible Notes&rdquo;) and warrants (the &ldquo;New Warrants&rdquo;)
to purchase shares of the Company&rsquo;s capital stock in the event of a conversion event. The number of shares and pricing per
share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering
conversion event. In November 2017, the Board approved an increase in the authorized subscription from $1,000,000 to $1,500,000.
The subscription agreement and the 2017 Convertible Notes were amended on December 14, 2017 to move up the maturity date from
October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision in the event of a
qualified financing as described more fully below. In May 2018, the Board approved an increase in the authorized subscription
from $1,500,000 to $2,000,000 and extended the offering period from five months to eight months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial closing of the Private Placement
was consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible
Notes in an aggregate principal amount of $1,140,000 to the Subscribers through March 31, 2018. The Company may conduct any number
of additional closings so long as the final closing occurs on or before the eight-month anniversary of the initial closing date
and the amount does not exceed $2,000,000 or a higher amount determined by the Board. See Note 13 &ndash; Subsequent
Events for closings that occurred after March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Convertible Notes bear
interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest
thereon on December 31, 2018 (the &ldquo;2017 Convertible Notes Maturity Date&rdquo;). If the Company consummates an equity
round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the &ldquo;2017 Convertible
Notes Qualified Financing&rdquo;), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes
shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal
to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the
securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The New Warrants also become exercisable
upon a 2017 Convertible Notes Qualified Financing for an amount of shares equal to the number of shares received by the
holder in the 2017 Convertible Notes Qualified Financing at the same price per share of the securities issued in the 2017
Convertible Notes Qualified Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the December 2017 amendment,
if the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued
and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company
in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued
interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible
Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable
in conjunction with the 2017 Convertible Notes Qualified Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, if a change of control
transaction occurs prior to the earlier of a 2017 Convertible Notes Qualified Financing or the 2017 Convertible
Notes Maturity Date, the 2017 Convertible Notes would, at the election of the holders of a majority of the outstanding
principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction, or
become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser
of (i) the per share value of the common stock as determined by  the Board as if in connection with the granting
of stock based compensation or in a private sale to a third party in an arms-length transaction or (ii) at the per share
consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which
the Company&rsquo;s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the
disposition of all or substantially all of the Company&rsquo;s assets. The New Warrants also become exercisable upon a change
of control transaction for an amount of shares equal to the number of shares received by the holder upon conversion in
connection with such transaction at the same price per share that the 2017 Convertible Notes converted in the change of
control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The December 2017 amendment resulted in
a substantial modification to the original 2017 Convertible Notes whereby the maturity date was moved up to December 2018 from
October 2022 and the terms associated with the embedded features were revised as described previously. The fair value of the underlying
Convertible Notes was $27,371 lower than the face amount of the 2017 Convertible Notes. The $27,371 difference was recorded as
a discount to the debt and is being amortized over the amended term of the 2017 Convertible Notes. The amortization recorded during
the three months ended March 31, 2018 was $6,432.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Convertible Notes contain a
conversion discount in the event of a 2017 Convertible Notes Qualified Financing to equal the outstanding principal and accrued
interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017
Convertible Notes Qualified Financing. The embedded feature qualified as an embedded derivative and was separated from its debt
host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the 2017 Convertible Notes in the
amount of $91,298 for the convertible debt issued during the three months ended March 31, 2018. The discount is being amortized
to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective
interest method. The amortization expense was $27,021 for the three months ended March 31, 2018. The embedded derivative is accounted
for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative
associated with all of the 2017 Convertible Notes in the condensed consolidated statements of operations which amounted to an
expense of $1,323 for the three months ended March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The New Warrants were deemed to be
a free-standing instrument and were accounted for as a liability given the variable number of shares issuable in
connection with a change of control conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair
value of the New Warrants. Input assumptions used were as follows: risk-free interest rate of 2.57 and 2.22 percent as of
March 31, 2018 and December 31, 2017, respectively; expected volatility of 50 percent as of March 31, 2018 and December 31,
2017; expected life of 5.21 and 5.38 years as of March 31, 2018 and December 31, 2017, respectively; and expected dividend
yield of 0 percent as of March 31, 2018 and December 31, 2017. The underlying stock price used in the analysis was on a
non-marketable basis and was according to a separate independent third-party valuation analysis as there has been very
limited trading with the Company&rsquo;s common stock since the Acquisition on July 20, 2017. The 2017 Convertible Note
proceeds assigned to the New Warrants were $238,864 during the three month period ended March 31, 2018, which represented
their fair value at issuance and were discounted from the 2017 Convertible Notes and reflected as a warrant liability. The
discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method
which approximates the effective interest method. The amortization expense was $70,505 for the three month period ended March
31, 2018. The Company also recorded the fair value changes of the warrant liability associated with &nbsp;all of the 2017
Convertible Notes in the condensed consolidated statements of operations which amounted to an expense of $9,355 for the three
months ended March 31, 2018.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2017 Convertible
Notes, the Company incurred original cost of issuance in the amount of $5,283 which consisted of legal costs and was recorded as
an issuance cost discount to the 2017 Convertible Notes, of which $375 was amortized to interest expense during the three months
ended March 31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2016 and 2017 Convertible Note Subscription
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the subscription agreements
entered into in connection with the 2016 Private Placement and the Private Placement, the Company is entitled to receive notice
in the event a holder elects to sell or receives a bona fide offer for any portion of the Convertible Notes and associated Warrants
or any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right to purchase the Convertible Notes and
associated Warrants or the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide
offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has
granted the subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under
the respective subscription agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
9 &ndash; Investment Banker Fee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investment Banker Fee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne paid a $50,000 non-refundable
fee to an investment banker in December 2016 to raise equity financing. NeuroOne subsequently concluded that the investment banker
was not expected to raise any equity and therefore expensed the fee in March 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
10 &ndash; Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne formally adopted an equity incentive
plan (&ldquo;the 2016 Plan&rdquo;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition.
In addition, the Company adopted a 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;) on April 17, 2017. The 2016 and 2017
Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company.
The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for
issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards
in the second quarter of 2017, under the 2016 Plan. During the three month periods ended March 31, 2018 and 2017, no stock options
or restricted stock award grants were formally issued. See stock-based award liability section below for stock-based award grants
committed, but not formally issued as of March 31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31,
2018 and 2017, there was no vesting of formally issued stock options or restricted stock awards. No stock options were forfeited
during the three months ended March 31, 2018 and 2017. As of March 31, 2018, 1,711,096 shares were available for future issuance
on a combined basis under the 2016 and 2017 Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no unrecognized stock-based
compensation cost for stock options and restricted common stock as of March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock-Based Award Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2018, the Company had
a formal obligation to issue future restricted common stock and common stock options relating to two consulting agreements. The
estimated liability associated with the vested portions of these awards was recorded in accrued expenses in the accompanying condensed
consolidated balance sheets as of March 31, 2018. The corresponding stock-based services expense related to the stock-based award
liability was included in general and administrative and research and development costs as follows in the accompanying condensed
statements of operations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Three Months <BR>
Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<BR>
    2018</TD><TD NOWRAP STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">252,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,437</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total stock-based compensation</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">254,437</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A total of up to 250,000 shares of
common stock was committed as a result of one consulting agreement for investor relation services executed in February 2018, but
none of the underlying shares of common stock were issued as of March 31, 2018. The portion of the stock award that had met performance
vesting conditions as of March 31, 2018 amounted to 100,000 common shares and were issued on April 26, 2018. The amount of compensation
expense totaling $252,000 related to the vested common shares was based on the fair value of the underlying common stock at point
of vesting which was $2.52 per share on a non-marketable basis. The common stock fair value was according to a separate independent
third-party valuation analysis since there was no active trading market for the Company&rsquo;s common stock. The remaining 150,000
shares of the stock award will vest and be issued in 50,000 share quarterly tranches beginning in May 2018. The first 50,000 tranche
of shares was issued on May 7, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Company recorded stock-based
services expense related to unissued stock options associated with a second consulting agreement whereby the number of option shares
and pricing will not be set until the occurrence of the award date which is defined as the earlier to occur of a public offering,
qualified financing, or June 30, 2018. The number of option shares under the agreement is based on a $3,000 monthly compensation
amount divided by the fair value of the underlying common stock on the award date. The exercise price will also be set at the
fair value of the underlying common stock on the award date. The liability associated with the unissued options was based on an
option share equivalent estimate that reflects the portion of the award where performance vesting conditions have been met as
of March 31, 2018 and was based on the fair value of the Company&rsquo;s common stock on March 31, 2018 as the award date has
not occurred. The common stock fair value on March 31, 2018 was $2.30 per share and was determined based on a separate independent
third-party valuation analysis since there was no active trading market for the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average assumptions used
in the Black-Scholes option-pricing model are as follows for the stock- option liability during the three month periods ended
March 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Expected stock price volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">47.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected life of options (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.6</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the issuance of all of the
unissued options associated with the stock-based award liabilities, the estimated number of shares available for future
issuance as of March 31, 2018 would be reduced from 1,711,096 shares to 1,704,574 as a result of the potential stock option
issuance under the second consulting agreement. The 250,000 shares of common stock issuable under the February 2018
consulting agreement were not eligible for issuance under either of the 2016 or 2017 Plans as the consulting contract was not
with an individual. See Note 12 - Stockholders&rsquo; Deficit for additional information.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
11 &ndash; Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rate for the three months
ended March 31, 2018 and 2017 was zero percent. As a result of the analysis of all available evidence as of&nbsp;March 31, 2018&nbsp;and&nbsp;December&nbsp;31,
2017, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported&nbsp;no&nbsp;income
tax benefit during the&nbsp;three months ended&nbsp;March 31, 2018 and 2017. If the Company&rsquo;s assumptions change and the
Company believes that it will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation
allowance on deferred tax assets will be recognized as a reduction of future income tax expense.&nbsp;&nbsp;If the assumptions
do not change, each period the Company could record an additional valuation allowance on any increases in the deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the Tax Cuts and
Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&rsquo;s consolidated
financial statements include, but are not limited to, a U.S. federal corporate tax rate decrease from 35% to 21% effective for
tax years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and
the valuation allowance recorded to reflect the new federal corporate tax rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements, continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
12 &ndash; Stockholders&rsquo; Deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has 100,000,000 shares of
common stock authorized, par value $0.001 per share, of which 7,864,994 shares were issued and outstanding at March 31, 2018 and
December 31, 2017. In connection with the February 2018 consulting contract discussed in Note 10 &ndash; Stock-based Compensation,
up to 250,000 shares of common stock are issuable under the contract. Upon issuance, these shares are subject to restrictions
pursuant to the provisions of Rule&nbsp;144. On April 26, 2018 and May 7, 2018, 100,000 and 50,000 shares of common stock were
issued under the contract, respectively, and subject to the restrictions under the provisions of Rule 144.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"><B>NOTE
13 &ndash; Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>2017 Convertible Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued additional 2017 Convertible
Notes and New Warrants to investors for aggregate gross proceeds of $350,000 from April 13, 2018 to May 8, 2018. &nbsp;The additional
convertible notes and warrants issued have identical terms to the 2017 Convertible Notes and New Warrants disclosed in Note 8
- Convertible Promissory Notes and Warrant Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, on May 8, 2018, the
Board approved an increase in the maximum amount of aggregate 2017 Convertible Notes offered from $1,500,000 to
$2,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Issuance of Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between April 26, 2018 and May 7, 2018,
the Company issued 150,000 shares of common stock to an investor relations firm in consideration for consulting services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2. Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><I>The following
discussion of our financial condition and results of operations should be read in conjunction with the financial statements and
notes included in Part I &ldquo;Financial Information&rdquo;, Item I &ldquo;Financial Statements&rdquo; of this Quarterly Report
on Form 10-Q (the &ldquo;Report&rdquo;) and the audited financial statements and related footnotes included in our Annual Report
on Form 10-K for the year ended December 31, 2017. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Certain statements
contained in this Report are not statements of historical fact and are forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;). Forward-looking statements give current expectations or forecasts of future events or our future financial or operating
performance. We may, in some cases, use words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of those terms, and similar
expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking
statements reflect our management&rsquo;s beliefs and views with respect to future events, are based on estimates and assumptions
as of the date of this Report and are subject to risks and uncertainties, many of which are beyond our control, that could cause
our actual results to differ materially from those in these forward-looking statements. We discuss many of these risks in greater
detail under Part I, Item 1A &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2017
and subsequent reports filed with or furnished to the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Moreover, we
operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements
we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any forward-looking
statement made by us in this Report speaks only as of the date hereof or as of the date specified herein. We undertake no obligation
to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except
as may be required by applicable laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were originally
incorporated in the State of Nevada on August 20, 2009 as Original Source Entertainment, Inc. (&ldquo;OSE&rdquo;). OSE was originally
formed to license songs to the television and movie industry. From our inception and prior to the acquisition of NeuroOne, Inc.
(&ldquo;NeuroOne&rdquo;) on July 20, 2017 (the &ldquo;Acquisition&rdquo;), as described more fully below, our operations have been
primarily limited to organizational, start-up, and capital formation activities. Upon completion of the Acquisition, more fully
described below, our operations consist of the development of comprehensive neuromodulation cEEG and sEEG monitoring, ablation,
and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&rsquo;s disease, dystonia, essential tremors,
and other brain related disorders. Our cortical strip technology under development has only been used by the Mayo clinic in five
patients for research purposes and has not been tested in any clinical trials. We are based in Eden Prairie, Minnesota.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Acquisition was
accounted for as a capital transaction, or reverse recapitalization. As a result, the financial information contained in this Report
reflect solely the operations of our wholly-owned subsidiary, NeuroOne, and its predecessor NeuroOne LLC (the &ldquo;LLC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our primary
activities have been limited to, and our limited resources have been dedicated to, performing business and financial planning,
raising capital, recruiting personnel, negotiating with business partners and the licensors of our intellectual property and conducting
research and development activities. Our cortical strip, grid electrode and depth electrode technology is still under development,
we do not yet have regulatory approval in any jurisdiction to sell any products and we have not generated any revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred
losses since inception. As of March 31, 2018, we had an accumulated deficit of $6.7 million, primarily as a result of expenses
incurred in connection with our research and development programs and from general and administrative expenses associated with
our operations. We expect to continue to incur significant operating expenses and net losses for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect to
generate revenue from product sales unless and until we obtain marketing authorization to sell our cortical strip, grid electrode
and depth electrode technology from applicable regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our source of cash
to date has been proceeds from the issuances of notes and warrants and unsecured loans. See &ldquo;&mdash;Liquidity and Capital
Resources&mdash;Historical Capital Resources&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At March 31, 2018,
we had $25,198 in cash deposits. Our existing cash and cash equivalents will not be sufficient to fund our operating expenses
in 2018. We need to obtain substantial additional funding in connection with our continuing operations through public or private
equity or debt financings or other sources, which may include collaborations with third parties. However, we may be unable to
raise additional funds when needed on favorable terms or at all. Our failure to raise such capital as and when needed would have
a negative impact on our financial condition and our ability to develop and commercialize our cortical strip, grid electrode and
depth electrode technology and future products and our ability to pursue our business strategy. See &ldquo;&mdash;Liquidity and
Capital Resources&mdash;Funding Requirements and Outlook&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acquisition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 20, 2017, we entered into a Merger Agreement with NeuroOne and OSOK Acquisition Company to acquire
NeuroOne (the &ldquo;Merger Agreement&rdquo;). The transactions contemplated by the Merger Agreement were consummated on July
20, 2017 and, pursuant to the terms of the Merger Agreement, (i)&nbsp;all outstanding shares of common stock of NeuroOne (&ldquo;NeuroOne
Shares&rdquo;) were exchanged for shares of the Company&rsquo;s common stock (&ldquo;Common Stock&rdquo;), based on the exchange
ratio of 17.0103706 shares of Common Stock, for every one NeuroOne Share, which totaled 6,291,994 shares of Common Stock, for
all of the then-outstanding NeuroOne Shares, (ii)&nbsp;all NeuroOne options were replaced with options (&ldquo;Company Options&rdquo;)
based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, (iii) all NeuroOne warrants were
replaced with warrants to purchase Common Stock of the Company (&ldquo;Company Warrants&rdquo;) and (iv) we assumed the outstanding
convertible promissory notes of NeuroOne. Accordingly, we acquired 100% of NeuroOne in exchange for the issuance of shares of
our Common Stock and NeuroOne became our wholly-owned subsidiary. Our sole business is the business of NeuroOne. Our management&rsquo;s
discussion and analysis below is based on the financial results of NeuroOne. Except as otherwise indicated herein, all share and
per share information in this &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
section gives retroactive effect to the exchange of NeuroOne Shares, NeuroOne Options and NeuroOne Warrants for shares of Common
Stock, Company Options and Company Warrants, respectively, in the Acquisition, as well as the corresponding exercise price adjustments
for such Company Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><B>Financial
Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not
generated any revenue. We do not expect to generate revenue unless or until we develop, obtain regulatory approval for and commercialize
our cortical strip, grid electrode and depth electrode technology. If we fail to complete the development of our cortical strip,
grid electrode and depth electrode technology, or any other product candidate we may pursue in the future, in a timely manner,
or fail to obtain regulatory approval, we may never be able to generate any revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administrative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly
associated with research and development activities. Other significant costs include legal fees relating to corporate matters,
intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial
matters and product costs. We anticipate that our general and administrative expenses will significantly increase in the future
to support our continued research and development activities, potential commercialization of our cortical strip, grid electrode
and depth electrode technology, if approved, and the increased costs of operating as a public company. These increases will include
increased costs related to the hiring of additional personnel and fees for legal and professional services, as well as other public-company
related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses consist of expenses incurred in performing research and development activities in developing our cortical strip, grid
electrode and depth electrode technology. Research and development expenses include compensation and benefits for research and
development employees including stock-based compensation, overhead expenses, cost of laboratory supplies, clinical trial and related
clinical manufacturing expenses, costs related to regulatory operations, fees paid to consultants and other outside expenses.
Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work
is performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research
and development expenses to significantly increase over the next several years as we develop our cortical strip, grid electrode
and depth electrode technology and conduct preclinical testing and clinical trials and will depend on the duration, costs and
timing to complete our preclinical programs and clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Interest Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest expense primarily
consists of amortized discount costs and interest costs related to our Series 1 Notes (as defined below), Series 2 Notes (as defined
below) and Series 3 Notes (as defined below). The Series 1 Notes, Series 2 Notes, and Series 3 Notes bear interest at a fixed
rate of 8% per annum, compounding annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net change in fair value for the
warrant liability and premium conversion derivatives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net change in fair
value for the warrant liability and premium conversion derivatives includes the change in the fair value of warrant liability and
the premium conversion derivatives during the particular period while the warrant liability and the premium conversion derivatives
are outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Comparison of the Three Months Ended March 31, 2018 and
2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the results of operations for the three-months ended March 31, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the three months ended</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March 31,</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Period to</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Period</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Change</B></P></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses:</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 64%; padding-left: 10pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">992,435</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">444,016</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">548,419</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,045</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,041</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,004</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097,480</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">516,057</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">581,423</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,097,480</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(516,057</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(581,423</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(193,034</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(213,550</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,516</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change in fair value for the warrant liability and premium conversion derivatives</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,960</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,928</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on short-term notes extinguishment</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(186,220</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(186,220</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,356,774</FONT></TD>
    <TD STYLE="line-height: 107%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(729,575</FONT></TD>
    <TD STYLE="line-height: 107%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(627,199</FONT></TD>
    <TD STYLE="line-height: 107%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and administrative expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were $1.0 million for the three months ended March 31, 2018, compared to $0.4 million for the three months ended March
31, 2017. The increase was primarily due to an increase in stock-based compensation associated with a consulting contract of $0.3
million related to fund raising, and legal and accounting expenses of $0.3 million primarily related to public company related
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and development expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses were $0.1 million for the three months ended March 31, 2018, compared to $72,041 for the three months ended March 31,
2017. The increase was primarily due to an increase in salary-related expenses, stock-based compensation expense of $2,437 related
to a consulting contract, and development materials and supplies to support the increased level of development activities during
the first quarter of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;Interest expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest expense, for
the three months ended March 31, 2018 was $0.2 million consisting of interest expense of $54,116 and amortization of debt discount
costs of $0.1 million related to the Series 1 Notes, Series 2 Notes and Series 3 Notes described further below. Interest expense,
for the three months ended March 31, 2017 was $0.2 million consisting of interest expense and amortization of debt issuance costs
of $0.2 million related to the Series 1 Notes and other interest expense of $1,318.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net change in fair value for the warrant
liability and premium conversion derivatives</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net change
in fair value for the warrant liability and premium conversion derivatives for the three months ended March 31, 2018 and 2017
was income of $0.1 million and $32, respectively. The change is due primarily to fluctuations in our Common Stock fair value and
the number of potential shares of Common Stock issuable upon conversion of the underlying Series 1 Notes, Series 2 Notes and Series
3 Notes.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Loss on short-term notes extinguishment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-cash loss on short-term
notes extinguishment for the three months ended March 31, 2018 was $0.2 million. There were no note extinguishments in the comparable
prior year period. The Series 2 Notes were amended in March 2018. The amendment for the Series 2 Notes added additional embedded
conversion features and warrant coverage. As a result of the modifications made to the Series 2 Notes, we accounted for the amendment
as a note extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Historical Capital Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2018,
our principal source of liquidity consisted of cash deposits of $25,198. We have not generated any revenue, and we anticipate
that we will continue to incur losses for the foreseeable future. We anticipate that our expenses will increase substantially
as we develop our cortical strip, grid electrode and depth electrode technology and pursue pre-clinical testing and clinical trials,
seek regulatory approvals, contract to manufacture any products, establish our own sales, marketing and distribution infrastructure
to commercialize our cortical strip, grid electrode and depth electrode technology under development, if approved, hire additional
staff, add operational, financial and management systems and operate as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our source of cash
to date has been proceeds from the issuances of notes, warrants and unsecured loans, the terms of which are further described
below. See &ldquo;&mdash;Funding Requirements and Outlook&rdquo; below for the outstanding balances on our convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Series 3 Notes and Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From October
2017 to May 2018, the Company issued convertible notes (the &ldquo;Series 3 Notes&rdquo;) in an aggregate principal amount of
$1.5 million that bear interest at a fixed rate of 8% per annum and warrants to purchase shares of the Company&rsquo;s
capital stock (the &ldquo;Series 3 Warrants&rdquo;). The Company initially entered into a subscription agreement with certain
accredited investors and closed an initial private placement of the Series 3 Notes in October 2017. In December 2017, the
Company and holders of a majority in aggregate principal amount of the Series 3 Notes entered into an amended and restated
subscription agreement to amend the terms of the Series 3 Notes and Series 3 Warrants (the &ldquo;Series 3 Amendment&rdquo;).
The Series 3 Notes require us to repay the principal and accrued and unpaid interest thereon at December 31, 2018. If the
Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018
(the &ldquo;Series 3 Qualified Financing&rdquo;), the outstanding principal and accrued and unpaid interest on the Series 3
Notes shall automatically convert into the securities issued by us in the Series 3 Qualified Financing equal to the
outstanding principal and accrued interest on the Series 3 Notes divided by 80% of the price per share of the securities
issued by us in the Series 3 Qualified Financing. If a Change of Control (as defined below) occurs prior to the earlier of a
Series 3 Qualified Financing or December 31, 2018, the Series 3 Notes would, at the election of the holders of a majority of
the outstanding principal amount of the Series 3 Notes, either become payable on demand as of the closing date of the Change
of Control or become convertible into shares of Common Stock immediately prior to the Change of Control at a price per share
equal to the lesser of (i) the per share value of the Common Stock as determined by our Board of Directors (the
&ldquo;Board&rdquo;) as if in connection with the granting of stock based compensation or in a private sale to a third
party in an arms-length transaction or (ii) at the per share consideration to be paid in the Change of Control (the date of
any such conversion of the Series 3 Notes in connection with a Change of Control or Series 3 Qualified Financing, is referred
to herein as the &ldquo;Series 3 Conversion Date&rdquo;). Change of Control means a merger or consolidation with another
entity in which our stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the
disposition of all or substantially all of our assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Series
3 Amendment, if the Company raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal
and accrued and unpaid interest on the Series 3 Notes would have automatically converted into the securities issued by the Company
in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued
interest on the Series 3 Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the Series 3 Notes multiplied
by 1.25, divided by the price paid per security in such financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series 3 Notes
are unsecured. If we fail to complete a Series 3 Qualified Financing by December 31, 2018, the Series 3 Notes will be immediately
due and payable on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Series 3
Warrant grants the holder the option to purchase shares of our capital stock equal to the number of shares of capital stock
of the Company received by the holder upon conversion of the Series 3 Notes at a per share exercise price equal to (i) the
actual per share price of the securities issued in the Series 3 Qualified Financing if the Series 3 Notes convert in
connection with such a qualified financing or (ii) the price at which the Series 3 Noted converted if they converted in
connection with a Change of Control. The Series 3 Warrants are exercisable commencing on the Series 3 Conversion Date and
expiring on the five year anniversary of that date. The exercise price and number of the shares of our capital stock issuable
upon exercising the &nbsp;Series 3 Warrants will be subject to adjustment in the event of any stock dividends and splits,
reverse stock split, recapitalization, reorganization, business combination or similar transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Series 2 Notes and Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2017, the
Company entered into a subscription agreement and issued interest free promissory notes in an aggregate principal amount of $253,000
to certain accredited investors. In November 2017, the Company and each subscriber amended the notes. In March 2018, the Company
and each subscriber entered into a written consent to amend and restate the promissory notes (as amended, the &ldquo;Series 2
Notes&rdquo;) and to amend the subscription agreement to replace the form of warrant agreement annexed to the subscription agreement
(the &ldquo;Replacement Warrant&rdquo;) and to provide for the issuance of an additional warrant (the &ldquo;Additional Warrant&rdquo;).
In March 2018 the Company issued and delivered the Series 2 Notes, the Replacement Warrants and the Additional Warrants to the
subscribers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series 2 Notes,
as amended in March 2018, are now convertible promissory notes that bear interest at a fixed rate of 8% per annum and require
the Company to repay the principal and accrued and unpaid interest thereon on the maturity date of July 31, 2018. If the Company
raises more than $3,000,000 in an equity or equity-linked financing before July 31, 2018 (the &ldquo;Series 2 Qualified Financing&rdquo;),
the outstanding principal and accrued and unpaid interest (the &ldquo;Outstanding Balance&rdquo;) on the Series 2 Notes shall
automatically convert into the securities issued by us in the Series 2 Qualified Financing (the &ldquo;New Round Stock&rdquo;)
based on the greater number of such securities resulting from either (i) the Outstanding Balance divided by $1.80 or (ii) the
Outstanding Balance multiplied by 1.25, divided by the price paid per security in the Series 2 Qualified Financing. If a Change
of Control occurs prior to the earlier of a Series 2 Qualified Financing or July 31, 2018, the Series 2 Notes would, at the election
of the holders of a majority of the outstanding principal of the Series 2 Notes, either become payable on demand as of the closing
date of such transaction or become convertible into shares of Common Stock immediately prior to such transaction at a price per
share equal to the lesser of (i) the per share value of the Common Stock as determined by the Board as if in connection
with the granting of stock based compensation or in a private sale to a third party in an arms-length transaction or (ii) at the
per share consideration to be paid in such transaction (the date of any such conversion of the Series 2 Notes in connection with
a Change of Control or Series 2 Qualified Financing, is referred to herein as the &ldquo;Series 2 Conversion Date&rdquo;). The
Series 2 Notes are unsecured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Replacement Warrant
grants the holder the option to purchase up to the number of shares of capital stock of the Company equal to the New Round Stock
issued or issuable upon the conversion of the Series 2 Note&nbsp;held by such holder at a per share exercise price equal to either
(i) the actual per share price of New Round Stock if the Series 2 Note &nbsp;converted in connection with a Series 2 Qualified
Financing or (ii) the price at which the Series 2&nbsp;Note&nbsp;converted in connection with a Change of Control. The Replacement
Warrants are exercisable commencing on the Series 2 Conversion Date and expire on November 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Additional Warrant
grants the holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained
by multiplying (i) the outstanding principal amount of the Series 2 Note&nbsp;held by such holder and (ii) 0.75; at a per share
exercise price of $1.80. The Additional Warrants are exercisable commencing on the Series 2 Conversion Date and expire on November
21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price
and number of the shares issuable upon exercising the Replacement Warrants and Additional Warrants are subject to adjustment in
the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as
described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to amending
the Series 2 Notes in November 2017 and March 2018, the notes were interest free and matured on February 18, 2018. Upon the maturity
of the notes, the holder was entitled to receive a warrant exercisable for up to such number of shares of Common Stock equal to
the quotient obtained by dividing the outstanding principal amount by two, at an exercise price of $1.80 per share. In connection
with the November 2017 amendment, the maturity date was extended to July 31, 2018 and the number of shares of Common Stock issuable
to the subscribers upon exercise of the warrants was increased (with each subscriber entitled to receive a warrant to purchase
up to such number of shares of Common Stock equal to the amount of such subscriber&rsquo;s note multiplied by 0.75), at an exercise
price of $1.80 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Series 1 Notes and Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From November 2016
to June 2017, the Company issued convertible promissory notes in an aggregate principal amount of $1.6 million that bear interest
at a fixed rate of 8% per annum and warrants to purchase shares of the Company&rsquo;s capital stock. In June 2017 and November
2017, the terms of such notes (as amended, the &ldquo;Series 1 Notes&rdquo;) and warrants (as amended, the &ldquo;Series 1 Warrants&rdquo;)
were amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series 1
Notes require us to repay the principal and accrued and unpaid interest thereon at the earlier of July 31, 2018, or the
consummation of the next equity or equity-linked round of financing resulting in more than $3 million in gross proceeds (the
&ldquo;Series 1 Qualified Financing&rdquo;). If a Series 1 Qualified Financing occurs before July 31, 2018, the outstanding
principal and accrued and unpaid interest on the Series 1 Notes shall automatically convert into the securities issued by us
in the Series 1 Qualified Financing based on the greater number of such securities resulting from either (i) the outstanding
principal and accrued interest on the Series 1 Notes divided by $1.80 or (ii) the outstanding principal and accrued interest
on the Series 1 Notes multiplied by 1.25, divided by the price paid per security in such financing. If a Change of Control or
initial public offering occurs prior to the Series 1 Qualified Financing, the Series 1 Notes would, at the election of the
holders of a majority of the outstanding principal of the Series 1 Notes, either become payable on demand as of the closing
date of such transaction or become convertible into shares of Common Stock immediately prior to such transaction at a price
per share equal to the lesser of (i) the per share value as determined by  the Board as if in connection with
the granting of stock based compensation or in a private sale to a third party in an arms-length transaction or (ii) at the
per share consideration to be paid in such transaction (the date of any such conversion of the Series 1 Notes in connection
with a Change of Control, initial public offering or Series 1 Qualified Financing, is referred to herein as the &ldquo;Series
1 Conversion Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series 1 Notes
are unsecured. If we fail to complete a Series 1 Qualified Financing by July 31, 2018, the Series 1 Notes will be immediately
due and payable on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Series 1 Warrant
grants the holder the option to purchase up to the number of shares of capital stock of the Company equal to the shares of capital
stock received by the holder upon the conversion of the Series 1 Note at a per share exercise price equal to either (i) the actual
per share price of the securities issued in the Series 1 Qualified Financing if the Series 1 Note converted in connection with
the Series 1 Qualified Financing or (ii) the price at which the Series 1 Note converted in connection with a Change of Control
or initial public offering. The Series 1 Warrants (other than the placement agent warrant) are exercisable commencing on the Series
1 Conversion Date and expire on November 21, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price
and number of the shares of our capital stock issuable upon exercising the Series 1 Warrants will be subject to adjustment in
the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization, business combination or similar
transaction, as described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
an engagement letter with the placement agent for the Series 1 Notes and Series 1 Warrants, the placement agent was entitled to
receive a warrant to purchase shares of Common Stock in an amount equal to 8% of the Common Stock purchased by investors in the
Series 1 Notes and Series 1 Warrants private placement, which warrants have an exercise price of $2.00 per share. The placement
agent warrant is immediately exercisable and expires five years from the date of issuance. We also paid the placement agent a
cash fee of $113,610 (8% of the gross proceeds received from the Series 1 Note and Series 1 Warrant investors) and are obligated
to issue to the placement agent a warrant to purchase shares of Common Stock in an amount equal to 8% of the Common Stock purchased
by certain investors in the Series 1 Note and Series 1 Warrant transaction upon fulfillment of the maximum aggregate subscription
amount, which warrant is expected to have an exercise price of $2.00 per share of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Unsecured Loans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We received cash gross
proceeds from an unsecured loan from a stockholder owning over 5% of the Company&rsquo;s Common Stock, represented by a promissory
note for $115,000 in March 2018. The loan is interest free and requires that we repay the principal in full on the earlier of
the closing of an equity round of financing of the Company resulting in more than $3 million in gross proceeds or March 20, 2019.
We also received cash proceeds from an unsecured loan for $50,000 in November 2016. We incurred no fees or interest costs
related to the unsecured loan and repaid it in full in February 2017.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Funding Requirements and Outlook</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no current
source of revenue to sustain our present activities, and we do not expect to generate revenue until, and unless, the FDA or other
regulatory authorities approve our cortical strip, grid electrode and depth electrode technology under development and we successfully
commercialize our cortical strip, grid electrode and depth electrode technology. Until such time, if ever, as we can generate
substantial product revenue, we expect to finance our cash needs through a combination of equity and debt financings as well as
collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the
extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our
stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If
we raise additional funds through collaborations, strategic alliances or licensing arrangements with third-party partners, we
may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be
favorable to us. If we are unable to raise additional funds through equity or debt financings or through collaborations, strategic
alliances or licensing arrangements when needed, we may be required to delay, limit, reduce or terminate our product development,
future commercialization efforts, or grant rights to develop and market our cortical strip, grid electrode and depth electrode
technology that we would otherwise prefer to develop and market ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our independent registered
public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the years ended
December 31, 2017 and 2016, noting the existence of substantial doubt about our ability to continue as a going concern. This uncertainty
arose from management&rsquo;s review of our results of operations and financial condition and its conclusion that, based on our
operating plans, we did not have sufficient existing working capital to fund our operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2018,
the outstanding principal and accrued and unpaid interest on the Series 1 Notes, Series 2 Notes and Series 3 Notes was $1,770,839,
$254,124 and $1,167,494, respectively. If we fail to complete the Series 1 Qualified Financing and the Series 2 Qualified Financing
by July 31, 2018, the Series 1 Notes and Series 2 Notes will be immediately due and payable on such date and we will not have
sufficient cash to pay the principal and accrued and unpaid interest thereon. In addition, the Series 3 Notes mature on December
31, 2018 and we may not have sufficient cash to pay the principal thereon if we fail to complete the Series 3 Qualified Financing
by such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreements
with the Wisconsin Alumni Research Foundation (&ldquo;WARF&rdquo;) and the Mayo Foundation for Medical Education and Research
(&ldquo;Mayo&rdquo;) that require us to make certain milestone and royalty payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under a License Agreement
with WARF, as amended in February 2017 (the &ldquo;WARF License&rdquo;), we agreed to pay WARF $55,000 (representing a license
fee) upon the earliest to occur of the date we cumulatively raise at least $3 million in financing, which threshold was just met,
the date of a change of control, or our revenue reaching a specified threshold amount, and to pay $65,000 (representing reimbursement
for costs incurred by WARF in maintaining the licensed patents) upon the earliest to occur of the date we cumulatively raise at
least $5 million in financing, the date of a change of control, or our revenue reaching a specified threshold amount. The initial
$55,000 payment was due on May 3, 2018 and was paid on April 22, 2018. We have also agreed to pay WARF a royalty equal to a single-digit
percentage of our product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2019, $100,000
for 2020 and $150,000 for 2021 and each calendar year thereafter that the WARF License is in effect. If we or any of our sublicenses
contest the validity of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the
contested patent is found to be valid and would be infringed by us if not for the WARF License, the royalty rate will be tripled
for the remaining term of the WARF License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under an Amended
and Restated exclusive license and development agreement between Mayo and NeuroOne, dated May 25, 2017 (the &ldquo;Mayo Development
Agreement&rdquo;), NeuroOne issued Mayo NeuroOne Shares pursuant to a subscription agreement (which were converted into 859,976
shares of Common Stock in the Acquisition), and NeuroOne agreed to pay Mayo a cash payment of $91,708.80. Following the Acquisition,
the rights and obligations under the Mayo Development Agreement transferred to the Company. In November 2017, the Company and
Mayo amended the Mayo Development Agreement to extend the deadline of the cash payment to December 31, 2017, which the Company
paid in December 2017. Additionally, we have agreed to pay Mayo a royalty equal to a single-digit percentage of our product sales
pursuant to the Mayo Development Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our existing cash
and cash equivalents will not be sufficient to fund our operating expenses throughout fiscal 2018. To continue to fund operations,
we will need to secure additional funding. We may obtain additional financing in the future through the issuance of our Common
Stock, through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able
to raise additional capital on terms acceptable to us, or at all. Further, we may not be able to modify terms of some of our existing
debt that may come due, and any failure to raise capital or to amend existing debt that may be due as and when needed could compromise
our ability to execute on our business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development of
our cortical strip, grid electrode and depth electrode technology is subject to numerous uncertainties, and we have based these
estimates on assumptions that may prove to be substantially different than we currently anticipate and could use our cash resources
sooner than we expect. Additionally, the process of developing medical devices is costly, and the timing of progress in pre-clinical
tests and clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving
FDA approval and then a level of product sales adequate to support our cost structure. We cannot assure you that we will ever
be profitable or generate positive cash flow from operating activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of cash flows
for each of the periods set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For&nbsp;the&nbsp;Three Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2018</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(591,269</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(350,919</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">590,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">315,120</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net decrease in cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,269</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(35,799</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net cash used in operating activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in
operating activities was $0.6 million for the three months ended March 31, 2018, which consisted of a net loss of $1.4 million
partially offset primarily by non-cash interest, stock-based compensation for non-employee services, note discount amortization,
revaluation of premium debt conversion derivative and warrant liabilities and short-term notes extinguishment, totaling $0.5 million
in the aggregate, and an increase in accrued expenses of $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $0.4 million for the three months ended March 31, 2017, which consisted of a net loss of $0.7 million partially
offset by non-cash interest, discount amortization, and warrant issuance costs on the Series 1 Notes of $0.2 million, an increase
in accrued expenses of $0.1 million, and an increase in prepaid expenses of $53,823.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net cash provided by financing activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided
by financing activities was $0.6 million for the three months ended March 31, 2018, which consisted of net proceeds received upon
the issuance of the Series 3 Notes and Warrants of $0.5 million and proceeds from an unsecured loan in the amount of $0.1 million
during the three month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash
provided by financing activities was $0.3 million for the three months ended March 31, 2017, which consisted of $0.4 million
in net proceeds received upon the issuance of the Series 1 Notes and Series 1 Warrants during the quarter partially offset by
the $50,000 repayment of a short-term unsecured loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Critical Accounting Policies</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our financial statements are prepared in
accordance with U.S. generally accepted accounting principles. These accounting principles require us to make estimates and judgments that can affect the reported amounts
of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during
the periods presented. We believe that the estimates and judgments upon which we rely are reasonably based upon information available
to us at the time that we make these estimates and judgments. To the extent that there are material differences between these
estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant
estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial
results are described in Note 3 &mdash; &ldquo;Summary of Significant Accounting Policies&rdquo; to our condensed consolidated
financial statements included in &ldquo;Part 1, Item 1 &ndash; Financial Statements&rdquo; in this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">During the three months ended March 31,
2018, there were no material changes to our critical accounting policies or estimates disclosed in &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; included in our Annual Report on Form 10-K for the year ended
December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Refer to Note 3&mdash; &ldquo;Summary of
Significant Accounting Policies&rdquo; to our condensed financial statements included in &ldquo;Part 1, Item 1 &ndash; Financial
Statements&rdquo; in this Report for a discussion of recently issued accounting pronouncements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Off Balance Sheet Arrangements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3. Quantitative and Qualitative Disclosures About Market
Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable for
smaller reporting companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 4. Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months
ended March 31, 2018, there were no changes in our internal controls over financial reporting (as defined in Rule 13a- 15(f) and
15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Evaluation of Disclosure Controls and
Procedures</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision
and with the participation of our management, including our chief executive officer and principal financial officer, we conducted
an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated
under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), as of&nbsp;March 31, 2018. Based on this
evaluation, our chief executive officer and principal financial officer have concluded such controls and procedures to be ineffective
as of March 31, 2018&nbsp;to ensure that information required to be disclosed by the issuer in the reports that it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms and to ensure that information required to be disclosed by an issuer in the reports that it files or submits under
the Exchange Act is accumulated and communicated to the issuer&rsquo;s management, including its principal executive and principal
financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of March 31, 2018, disclosure controls and procedures were not effective due to previously identified material weaknesses. The
material weaknesses related to our small size and include the inability to (i) maintain effective controls over accounting for
non-routine and/or complex debt and equity transactions and (ii) maintain effective controls over the financial statement close
and reporting process, accounting for routine transactions and segregation of duties.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to recruit
additional professionals to address these material weaknesses, as our business conditions warrant. However, we do not currently
have adequate cash resources to invest in these additional resources. Accordingly, our remediation plans may be delayed. Although
we believe that these corrective steps, when taken, will enable management to conclude that the internal controls over our financial
reporting are effective when the staff is in place and trained, we cannot provide assurance that these steps will be sufficient.
We may be required to expend additional resources to identify, assess and correct any additional weaknesses in internal control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II &ndash;  OTHER
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1. Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time,
we are subject to litigation and claims arising in the ordinary course of business.&nbsp; In May 2017, NeuroOne received a letter
from PMT, the former employer of Mark Christianson and Wade Fredrickson.&nbsp; PMT claimed that these officers had breached their
restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer&rsquo;s prior work during employment
with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal
and state law by misappropriating confidential and trade secret information, and that NeuroOne is responsible for tortious interference
with the contracts.&nbsp; The letter demanded that Mr. Fredrickson (who is no longer with NeuroOne), Mr. Christianson and NeuroOne
cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne
provide the former employer access to NeuroOne&rsquo;s systems to demonstrate that it is not using trade secrets or proprietary
information nor competing with the former employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 29, 2018,
we were served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against
Mr. Fredrickson.&nbsp; In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation
and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition,
engaged in a civil conspiracy, tortiously interfered with PMT&rsquo;s contracts and prospective economic advantage, and breached
a covenant of good faith and fair dealing.&nbsp; Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently
spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law,
and committed the tort of conversion and statutory civil theft. Against the Company and NeuroOne, PMT alleges that the Company
and NeuroOne were unjustly enriched and engaged in unfair competition.&nbsp; PMT asks the Court to impose a constructive trust
over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages,
attorneys&rsquo; fees, costs and interest. The Company, NeuroOne and Mr. Christianson (who has not worked for PMT since 2012)
intend to defend themselves vigorously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no insurance
coverage to protect against any losses we may experience due to this claim. Furthermore, Mr. Christianson is a key officer and
the loss of his services would be detrimental to our operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1A. &nbsp;Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In addition to the other information set
forth elsewhere in this Report, you should carefully consider the factors discussed in Part I, Item 1A &ldquo;Risk Factors&rdquo;
of the Company&rsquo;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017. Those factors, if they were
to occur, could cause our actual results to differ materially from those expressed in our forward-looking statements in this Report,
and materially adversely affect our financial condition or future results. Although we are not aware of any other factors that
we currently anticipate will cause our forward-looking statements to differ materially from our future actual results, or materially
affect the Company&rsquo;s financial condition or future results, additional risks and uncertainties not currently known to us
or that we currently deem to be immaterial might materially adversely affect our actual business, financial condition and/or operating
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2. Unregistered Sales of Equity
Securities and Use of Proceeds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3. &nbsp;Defaults Upon Senior Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 4. &nbsp;Mine Safety Disclosures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable to our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5. &nbsp;Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6. &nbsp;Exhibits </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-indent: 0; padding: 0; text-align: left; vertical-align: top">Exhibit 10.1</TD>
    <TD STYLE="width: 86%; text-align: justify; padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-1_neuroone.htm">Form of Amended and Restated Note issued pursuant to August 2017 Subscription Agreement, as amended (incorporated by reference to Exhibit 4.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 16, 2018).</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0; padding: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0; padding: 0; text-align: left; vertical-align: top">Exhibit 10.2</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-2_neuroone.htm">Form of Replacement Warrant issued pursuant to August 2017 Subscription Agreement, as amended (incorporated by reference to Exhibit 4.2 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 16, 2018).</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0; padding: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0; padding: 0; text-align: left; vertical-align: top">Exhibit 10.3</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-3_neuroone.htm">Form of Additional Warrant issued pursuant to August 2017 Subscription Agreement, as amended (incorporated by reference to Exhibit 4.3 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 16, 2018).</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0; padding: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0; padding: 0; text-align: left; vertical-align: top">Exhibit 10.4</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018004509/f10k2017ex10-40_neuroone.htm">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.40 on the Registrant&rsquo;s Annual Report on Form 10-K filed on April 16, 2018).</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0; padding: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0; padding: 0; text-align: left; vertical-align: top">Exhibit 10.5</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018004509/f10k2017ex10-41_neuroone.htm">Lock-up Agreement, effective as of March 1, 2018 by and between Wade Fredrickson and the Company (incorporated by reference to Exhibit 10.41 on the Registrant&rsquo;s Annual Report on Form 10-K filed on April 16, 2018).</A></TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit 31</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="f10q0318ex31_neuroonemedical.htm"><FONT STYLE="font-size: 10pt">Certifications
    pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit 32</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="f10q0318ex32_neuroonemedical.htm"><FONT STYLE="font-size: 10pt">Certifications
    pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit 101.INS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Instance Document.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit 101.SCH</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Schema Document.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit 101.CAL</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Calculation
    Linkbase Document.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit 101.DEF</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase
    Document.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit 101.LAB</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase
    Document.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit 101.PRE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Presentation
    Linkbase Document.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NeuroOne Medical
Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 10-Q</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: May 15, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NeuroOne Medical Technologies Corporation&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Dave Rosa</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Dave Rosa</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">33</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>f10q0318ex31_neuroonemedical.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a)
OR 15d-14(a) OF THE SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT
TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Dave Rosa, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. I have reviewed
this Quarterly Report on Form 10-Q of NeuroOne Medical Technologies Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. I am responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">a)&nbsp;Designed such
disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">b)&nbsp;Designed such
internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">c)&nbsp;Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report, my conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">d)&nbsp;Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. I have disclosed,
based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit
committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">a) all significant
deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">b) any fraud, whether
or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 15, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Dave Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Dave Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>f10q0318ex32_neuroonemedical.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report
of NeuroOne Medical Technologies Corporation. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarter ended March 31, 2018 as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Dave Rosa, Chief Executive
Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 15, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Dave Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Dave Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nmtc-20180331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Wednesday, May 16, 2018 06:33:32 AM -->
<schema targetNamespace="http://www.originalsourcemusic.com/20180331" elementFormDefault="qualified" xmlns:nmtc="http://www.originalsourcemusic.com/20180331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" id="CondensedConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Organizationandnatureofoperations" id="Organizationandnatureofoperations">
<link:definition>006 - Disclosure - Organization and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/GoingConcern" id="GoingConcern">
<link:definition>007 - Disclosure - Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>009 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Intangibles" id="Intangibles">
<link:definition>010 - Disclosure - Intangibles</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>011 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan" id="ShortTermPromissoryNotesAndUnsecuredLoan">
<link:definition>012 - Disclosure - Short-Term Promissory Notes and Unsecured Loan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements" id="ConvertiblePromissoryNotesAndWarrantAgreements">
<link:definition>013 - Disclosure - Convertible Promissory Notes and Warrant Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/InvestmentBankerFee" id="InvestmentBankerFee">
<link:definition>014 - Disclosure - Investment Banker Fee</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>015 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>016 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficit" id="StockholdersDeficit">
<link:definition>017 - Disclosure - Stockholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>018 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Summaryofsignificantaccountingpoliciespolicies" id="Summaryofsignificantaccountingpoliciespolicies">
<link:definition>019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables" id="SummaryofSignificantAccountingPoliciesTables">
<link:definition>020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesTables" id="IntangiblesTables">
<link:definition>021 - Disclosure - Intangibles (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>022 - Disclosure - Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables" id="ConvertiblePromissoryNotesandWarrantAgreementsTables">
<link:definition>023 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>024 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Organizationandbasisofpresentationdetails" id="Organizationandbasisofpresentationdetails">
<link:definition>025 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/GoingConcernDetails" id="GoingConcernDetails">
<link:definition>026 - Disclosure - Going Concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails" id="SummaryofSignificantAccountingPoliciesDetails">
<link:definition>027 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1" id="SummaryofSignificantAccountingPoliciesDetails1">
<link:definition>028 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2" id="SummaryofSignificantAccountingPoliciesDetails2">
<link:definition>029 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3" id="SummaryofSignificantAccountingPoliciesDetails3">
<link:definition>030 - Disclosure - Summary of Significant Accounting Policies (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails" id="IntangiblesDetails">
<link:definition>031 - Disclosure - Intangibles (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual" id="IntangiblesDetailsTextual">
<link:definition>032 - Disclosure - Intangibles (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
<link:definition>033 - Disclosure - Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails1" id="AccruedExpensesDetails1">
<link:definition>034 - Disclosure - Accrued Expenses (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails" id="ShortTermPromissoryNotesAndUnsecuredLoanDetails">
<link:definition>035 - Disclosure - Short-Term Promissory Notes and Unsecured Loan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails" id="ConvertiblePromissoryNotesAndWarrantAgreementsDetails">
<link:definition>036 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual" id="ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual">
<link:definition>037 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/InvestmentBankerFeeDetails" id="InvestmentBankerFeeDetails">
<link:definition>038 - Disclosure - Investment Banker Fee (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails" id="Stockbasedcompensationdetails">
<link:definition>039 - Disclosure - Stock-Based Compensation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails1" id="Stockbasedcompensationdetails1">
<link:definition>040 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetailsTextual" id="StockBasedCompensationDetailsTextual">
<link:definition>041 - Disclosure - Stock-Based Compensation (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Incometaxesdetails" id="Incometaxesdetails">
<link:definition>042 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Stockholdersdeficitdetails" id="Stockholdersdeficitdetails">
<link:definition>043 - Disclosure - Stockholders' Deficit (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>044 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="nmtc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertiblePromissoryNotesNetAndAccruedInterest" id="nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" id="nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NonCashInterestOnPrincipal" id="nmtc_NonCashInterestOnPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RevaluationOfPremiumDebtConversionDerivative" id="nmtc_RevaluationOfPremiumDebtConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RevaluationOfWarrantLiability" id="nmtc_RevaluationOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" id="nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromRepaymentsOfShortTermUnsecuredLoan" id="nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionDerivativeRelatedToConvertiblePromissoryNotes" id="nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" id="nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedIssuanceCostsAttributedToWarrantLiability" id="nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernAbstract" id="nmtc_GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestmentBankerFeeAbstract" id="nmtc_InvestmentBankerFeeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestmentBankerFeeTextBlock" id="nmtc_InvestmentBankerFeeTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IntellectualPropertyPolicyTextBlock" id="nmtc_IntellectualPropertyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantLiabilityPolicyTextBlock" id="nmtc_WarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumDebtConversionDerivativePolicyTextBlock" id="nmtc_PremiumDebtConversionDerivativePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OrganizationAndBasisOfPresentationTextualAbstract" id="nmtc_OrganizationAndBasisOfPresentationTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernTextualAbstract" id="nmtc_GoingConcernTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertibleNotesPayableOne" id="nmtc_ConvertibleNotesPayableOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubscriptionAmountToConvertiblePromissoryNote" id="nmtc_SubscriptionAmountToConvertiblePromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubscriptionAmountToConvertiblePromissoryNoteOne" id="nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantLiability" id="nmtc_WarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumConversionDerivative" id="nmtc_PremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfWarrantLiabilityAbstract" id="nmtc_ScheduleOfWarrantLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsAndValueAssignedToWarrants" id="nmtc_ProceedsAndValueAssignedToWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtConversionDerivativeMember" id="nmtc_DebtConversionDerivativeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfPremiumConversionDerivativeAbstract" id="nmtc_ScheduleOfPremiumConversionDerivativeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" id="nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" id="nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoodwilAndIntangibleAssetsTextualAbstract" id="nmtc_GoodwilAndIntangibleAssetsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedLicenseFees" id="nmtc_AccruedLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedIssuanceCosts" id="nmtc_AccruedIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedPayroll" id="nmtc_AccruedPayroll" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedExpensesAdvances" id="nmtc_AccruedExpensesAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedExpensesTextualAbstract" id="nmtc_AccruedExpensesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumConversionDerivativeMember" id="nmtc_PremiumConversionDerivativeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" id="nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockPurchaseOfWarrants" id="nmtc_CommonStockPurchaseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsMaturityTerm" id="nmtc_WarrantsMaturityTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueOfPremiumConversionDerivative" id="nmtc_ValueOfPremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalWarrantsAllocated" id="nmtc_AdditionalWarrantsAllocated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsExpirationDate" id="nmtc_WarrantsExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LossOnShortTermNotesExtinguishment" id="nmtc_LossOnShortTermNotesExtinguishment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueAdjustmentOfShortTermNotesAndWarrants" id="nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShortTermNoteQualifiedFinancingDescription" id="nmtc_ShortTermNoteQualifiedFinancingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertiblePromissoryNoteMember" id="nmtc_ConvertiblePromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubscriptionAgreementMember" id="nmtc_SubscriptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NovemberTwoThousandSeventeenMember" id="nmtc_NovemberTwoThousandSeventeenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoZeroOneSevenConvertibleNoteAmendmentMember" id="nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertibleDebtOneMember" id="nmtc_ConvertibleDebtOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NewWarrantsMember" id="nmtc_NewWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" id="nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfMaximumVotingPowerOfSurvivingEntity" id="nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountOfConvertibleNoteHeldByWarrantHolder" id="nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertiblePromissoryNoteProceedsAssignedToWarrants" id="nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertibleNotesOfConversionPremiumAmortizationExpense" id="nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumDebtConversionDerivativeInterestExpense" id="nmtc_PremiumDebtConversionDerivativeInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsToPurchaseSharesOfCommonStock" id="nmtc_WarrantsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfCommonStockPurchaseWarrants" id="nmtc_PercentageOfCommonStockPurchaseWarrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceCostsAttributedToCommonStockPurchaseWarrants" id="nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertibleNotesMaximumExtensionLimit" id="nmtc_ConvertibleNotesMaximumExtensionLimit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueAdjustmentOfPremiumConversionDerivative" id="nmtc_FairValueAdjustmentOfPremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueChangesOfWarrantLiability" id="nmtc_FairValueChangesOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestmentBankerFeeTextualAbstract" id="nmtc_InvestmentBankerFeeTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NonRefundableFeeToInvestmentBanker" id="nmtc_NonRefundableFeeToInvestmentBanker" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandSixteenPlanMember" id="nmtc_TwoThousandSixteenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandSixteenAndSeventeenPlanMember" id="nmtc_TwoThousandSixteenAndSeventeenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeesDirectorsAndConsultantsMember" id="nmtc_EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockBasedCompensationTextualAbstract" id="nmtc_StockBasedCompensationTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" id="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfCommonStockPricePerShare" id="nmtc_FairValueOfCommonStockPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MonthlyCompensationAmount" id="nmtc_MonthlyCompensationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncomeTaxesTextualAbstract" id="nmtc_IncomeTaxesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockholdersMemberDeficitTextualAbstract" id="nmtc_StockholdersMemberDeficitTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentMember" id="nmtc_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmendedAndRestatedShortTermNotesMember" id="nmtc_AmendedAndRestatedShortTermNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReplacementWarrantsMember" id="nmtc_ReplacementWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalWarrantsMember" id="nmtc_AdditionalWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalTwoThousandSeventeenConvertibleNotesMember" id="nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubsequentEventsTextualAbstract" id="nmtc_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>nmtc-20180331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 8.0.1.0 [05/16/2018 05:12:04 AM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Wednesday, May 16, 2018 06:33:32 AM -->
<xbrli:xbrl xmlns:nmtc="http://www.originalsourcemusic.com/20180331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="nmtc-20180331.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_30_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-07-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:SubscriptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-10-04
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:SubscriptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-01
</xbrli:startDate>
<xbrli:endDate>
2017-10-04
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:TwoZeroOneSevenConvertibleNoteAmendmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:NewWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:TwoZeroOneSevenConvertibleNoteAmendmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertiblePromissoryNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_AccruedLiabilitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_Mar_2018T00_00_00_TO_20_Mar_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-03-15
</xbrli:startDate>
<xbrli:endDate>
2018-03-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:TwoZeroOneSevenConvertibleNoteAmendmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:NewWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_PremiumConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">nmtc:PremiumConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:SubscriptionAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nmtc:TwoZeroOneSevenConvertibleNoteAmendmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertiblePromissoryNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_AccruedLiabilitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:ConvertibleDebtOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandSixteenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_10_Apr_2018T00_00_00_TO_26_Apr_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-04-10
</xbrli:startDate>
<xbrli:endDate>
2018-04-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28_Apr_2018T00_00_00_TO_07_May_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-04-28
</xbrli:startDate>
<xbrli:endDate>
2018-05-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Apr_2018T00_00_00_TO_08_May_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_AdditionalTwoThousandSeventeenConvertibleNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmtc:AdditionalTwoThousandSeventeenConvertibleNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-04-13
</xbrli:startDate>
<xbrli:endDate>
2018-05-08
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_14-May-2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-05-14</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevE645<1Y7c444c555cT{h><H:G6F4<1IH;F18:IF1<::G1HI4E4:==JIJF -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">NEUROONE MEDICAL TECHNOLOGIES Corp</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">0001500198</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">false</dei:AmendmentFlag>
<dei:TradingSymbol contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">NMTC</dei:TradingSymbol>
<dei:CurrentFiscalYearEndDate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">2018-03-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">2018</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">Q1</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_14-May-2018T00_00_00" unitRef="shares" decimals="INF">8014994</dei:EntityCommonStockSharesOutstanding>
<us-gaap:Cash contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">522217</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">486418</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">26467</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">25198</us-gaap:Cash>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">7146</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">7146</us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">33613</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">32344</us-gaap:AssetsCurrent>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">216372</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">211420</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">249985</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">243764</us-gaap:Assets>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1021617</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1522874</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:ShortTermBorrowings contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">253000</us-gaap:ShortTermBorrowings>
<us-gaap:ShortTermBorrowings contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">369124</us-gaap:ShortTermBorrowings>
<nmtc:ConvertiblePromissoryNotesNetAndAccruedInterest contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">2168340</nmtc:ConvertiblePromissoryNotesNetAndAccruedInterest>
<nmtc:ConvertiblePromissoryNotesNetAndAccruedInterest contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2505089</nmtc:ConvertiblePromissoryNotesNetAndAccruedInterest>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">137650</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">210565</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">462174</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">462174</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">607173</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">607173</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">3905131</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">5004260</us-gaap:LiabilitiesCurrent>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">345960</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">528438</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1381465</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1381465</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1634059</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1634059</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">5286596</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">6638319</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">7865</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">7865</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">280320</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">279150</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-5324796</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-6681570</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-5036611</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-6394555</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">249985</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">243764</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">7864994</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">7864994</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">7864994</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">7864994</us-gaap:CommonStockSharesOutstanding>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">444016</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">992435</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">72041</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">105045</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">516057</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1097480</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-516057</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-1097480</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-213550</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-193034</us-gaap:InterestIncomeExpenseNet>
<nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">32</nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative>
<nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">119960</nmtc:NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">303560</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-186220</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-729575</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-1356774</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="2">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="0">5216565</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="0">7864994</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:AdjustmentForAmortization contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">5007</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4952</us-gaap:AdjustmentForAmortization>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">254437</us-gaap:ShareBasedCompensation>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">47318</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">118862</us-gaap:AmortizationOfFinancingCosts>

<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">6432</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">70505</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">27021</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">178541</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">16645</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">72732</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">27371</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">138918</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">375</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">15803</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:RevaluationOfPremiumDebtConversionDerivative contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">183</nmtc:RevaluationOfPremiumDebtConversionDerivative>
<nmtc:RevaluationOfPremiumDebtConversionDerivative contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4032</nmtc:RevaluationOfPremiumDebtConversionDerivative>
<nmtc:RevaluationOfWarrantLiability contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-215</nmtc:RevaluationOfWarrantLiability>
<nmtc:RevaluationOfWarrantLiability contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-123992</nmtc:RevaluationOfWarrantLiability>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-53823</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">107627</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">246822</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-350919</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-591269</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">253000</us-gaap:ProceedsFromShortTermDebt>
<nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">182693</nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes>
<nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">238864</nmtc:ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes>
<us-gaap:PaymentsOfLoanCosts contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">5130</us-gaap:PaymentsOfLoanCosts>
<us-gaap:PaymentsOfLoanCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">4870</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">315120</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">590000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-35799</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-1269</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">72732</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">91298</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">16645</nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes>
<nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<nmtc:AccruedIssuanceCostsAttributedToWarrantLiability contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">15803</nmtc:AccruedIssuanceCostsAttributedToWarrantLiability>
<nmtc:AccruedIssuanceCostsAttributedToWarrantLiability contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 1 &amp;#8211; Organization and Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;NeuroOne Medical Technologies Corporation (the &amp;#8220;Company&amp;#8221;), a Delaware Corporation, was originally incorporated as Original Source Entertainment, Inc. under the laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition (as defined below), the Company completed a series of steps contemplated by a Plan of Conversion pursuant to which the Company, among other things, changed its name to NeuroOne Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware. On July 20, 2017, the Company, through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&amp;#8220;NeuroOne&amp;#8221;) in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &amp;#8220;Acquisition&amp;#8221;). The Acquisition was accounted for as a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in this transaction. As such, the historical financial statements of NeuroOne reflect operations of the Company for all periods presented prior to the date of the Acquisition. The accompanying condensed consolidated financial statements subsequent to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Subsequent to the Acquisition, the Company&amp;#8217;s operating activities became the same as those of NeuroOne, an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&amp;#8217;s disease, essential tremors, and other brain related disorders.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;To date, the Company has recorded no product sales and has a limited expense history. The Company is a development stage company and its activities to date have included raising capital to fund the development of its proprietary technology and seek regulatory clearances required to initiate commercial activities.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company is based in Eden Prairie, Minnesota.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Acquisition of NeuroOne, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent:
 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Acquisition was consummated on July 20, 2017 (the &amp;#8220;Closing&amp;#8221;) and, pursuant to the terms of the merger agreement, (i) all outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the &amp;#8220;NeuroOne Shares&amp;#8221;), were exchanged for shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Company Shares&amp;#8221;), based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the &amp;#8220;Exchange Ratio&amp;#8221;), resulting in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options, (iii) all warrants of NeuroOne were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible promissory notes of NeuroOne. NeuroOne options had been issued pursuant to the NeuroOne 2016 Equity Incentive Plan. Pursuant to the merger agreement, the Company assumed the NeuroOne 2016 Equity Incentive Plan upon the Closing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pursuant to the Acquisition, the Company acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became the Company&amp;#8217;s wholly-owned subsidiary. Also at the Closing, Mr. Samad (the majority owner of the Company prior to the Acquisition) tendered for cancellation 3,500,000 Company Shares held by him as part of the conditions to Closing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;All issued and outstanding common stock share amounts, options for common stock and per share amounts contained in the consolidated financial statements were retroactively adjusted to reflect the Exchange Ratio for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Basis of presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The accompanying condensed consolidated financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements may not include all disclosures required by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto for the fiscal year ended December 31, 2017 included in the Annual Report on Form 10-K for the year ended December 31, 2017. The condensed balance sheet at December 31, 2017 was derived from the audited financial statements of the Company.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Certain prior period balances have been reclassified to conform to the current period presentation. Specifically, the Company reclassified all fair market valuation adjustments related to the warrant liability and to the premium conversion derivative from interest expense to a separate line item on the condensed consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 2 &amp;#8211; Going Concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception and had an accumulated deficit of $6,681,570 as of March 31, 2018. The Company does not have adequate liquidity to fund its operations throughout fiscal 2018 without raising additional funds. These factors raise substantial doubt about its ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this condition. Management intends to continue to seek additional financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Through March 31, 2018, the Company has completed a $115,000 unsecured loan financing, a $253,000 short-term promissory note financing (which notes were amended and restated to become convertible promissory notes as described below), a $1,625,120 convertible promissory note financing of a planned $2.5 million subscription and a second $1,140,000 convertible promissory note financing of a planned $2 million subscription. See Note 13 &amp;#8211; Subsequent Events for financings that have closed after March 31, 2018. The Company does not have adequate liquidity to fund its operations throughout fiscal 2018 without raising additional funds. Management intends to continue to seek additional debt and/or equity financing to fund operations. However, if the Company is unable to raise additional funds, or the Company&amp;#8217;s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company&amp;#8217;s operations. If management is unable to obtain the necessary capital, it may have to cease operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 3 &amp;#8211; Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Management&amp;#8217;s Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&amp;#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2018, the Company did not have any deposits in excess of federally insured amounts.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of March 31, 2018 and December 31, 2017, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the short-term and convertible promissory notes of the Company were based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level&amp;#160;3 inputs. There were no transfers between fair value hierarchy levels during the three months ended March 31, 2018 and 2017.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of March 31,&amp;#160;2018&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;Liabilities:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;1,634,059&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;1,634,059&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;607,173&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;607,173&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,241,232&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,241,232&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2017&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;Liabilities:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;1,381,465&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level&amp;#160;3 inputs for the three month periods ended March 31, 2018 and 2017:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;"&gt;Warrant liability&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Value assigned to warrants in connection with convertible promissory and short-term notes&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;376,586&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;182,693&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of warrant liability&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(123,992&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(215&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,634,059&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;528,438&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;"&gt;Premium debt conversion derivatives&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;462,174&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;140,967&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;72,732&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of premium debt conversion derivatives&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,032&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;183&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;607,173&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;210,565&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates its long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through March 31, 2018, the Company has not impaired any long-lived assets.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Debt Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the short term notes and convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company issued warrants to purchase equity securities in connection with the issuance or amendment of short-term and convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&amp;#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Premium Debt Conversion Derivatives&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&amp;#160; The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed consolidated statements of operations. The Company determined that the redemption features under the amended short-term promissory notes and convertible promissory notes qualified as embedded derivatives and were separated from their debt hosts.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&amp;#8217;s short-term notes, convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the short-term notes and convertible promissory notes utilizing the if-converted method was not applicable during the three month periods ended March 31, 2018 and 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three month periods ended March 31, 2018 and 2017.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three month periods ended March 31, 2018 and 2017:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1191px;"&gt;Warrants&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;189,750&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;(1)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;597,283&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Stock options&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;365,716&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 24px;"&gt;&lt;font style="font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2017, the FASB issued ASU 2017-09,&amp;#160;&lt;i&gt;Compensation - Stock Compensation (Topic 718):&amp;#160;Scope of Modification Accounting (ASU 2016-09)&lt;/i&gt;,&amp;#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company has adopted this standard for the three months ended March 31, 2018. The adoption of this standard did not have any impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2017, the FASB issued ASU No. 2017-11,&amp;#160;&lt;i&gt;Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging&lt;/i&gt;, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&amp;#160;15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 4 &amp;#8211; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Legal&lt;/b&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;From time to time, the Company is subject to litigation and claims arising in the ordinary course of business.&amp;#160; In May 2017, NeuroOne received a letter from PMT, the former employer of Mark Christianson and Wade Fredrickson.&amp;#160; PMT claimed that these officers had breached their restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer&amp;#8217;s prior work during employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference with the contracts.&amp;#160; The letter demanded that Mr. Fredrickson (who is no longer with the Company), Mr. Christianson and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne provide the former employer access to NeuroOne&amp;#8217;s systems to demonstrate that it is not using trade secrets or proprietary information nor competing with the former employer.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On March 29, 2018, we were served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson.&amp;#160; In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT&amp;#8217;s contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing.&amp;#160; Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft.&amp;#160; Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne were unjustly enriched and engaged in unfair competition.&amp;#160; PMT asks the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&amp;#8217; fees, costs and interest.&amp;#160; The Company, NeuroOne and Mr. Christianson (who has not worked for PMT since 2012) intend to defend themselves vigorously.&amp;#160;&amp;#160;The outcome and potential loss related to this matter is unknown as of March 31, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has no insurance coverage to protect against any losses that the Company may experience due to this claim. Furthermore, Mr. Christianson is a key officer and the loss of his services would be detrimental to the Company&amp;#8217;s operations and prospects.&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 5 &amp;#8211; Intangibles&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Intangible assets consisted of the following at March 31, 2018:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Useful Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1129px; text-align: justify;"&gt;Net Intangibles, December 31, 2017&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; text-align: center;"&gt;12-13 Years&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 188px; text-align: right;"&gt;216,372&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Less: amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(4,952&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Net Intangibles, March 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;211,420&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Amortization expense was $4,952 and $5,007 for the three months ended March 31, 2018 and 2017, respectively.&lt;/p&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 6 &amp;#8211; Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Accrued expenses consisted of the following at March 31, 2018 and December 31, 2017:&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued&amp;#160;license fees&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;120,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;120,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued services&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;868,811&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;600,339&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued issuance costs&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;28,083&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;28,083&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued payroll&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;251,543&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;223,195&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Advances&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;50,000&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Other (1)&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;254,437&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,522,874&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,021,617&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;table style="font: 11pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in;"&gt;&lt;font style="font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Accrued expenses include an obligation to issue stock awards and stock options to consultants that have met vesting requirements as of March 31, 2018 in the amount of $254,437. See Note 10 &amp;#8211; Stock-Based Compensation for further detail.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:ShortTermDebtTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 7 &amp;#8211; Short-Term Promissory Notes and Unsecured Loan&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Short-Term Promissory Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In August 2017, the Company&amp;#8217;s Board of Directors (the &amp;#8220;Board&amp;#8221;) authorized, and the Company issued short-term unsecured and interest-free promissory notes (the &amp;#8220;Short-Term Notes&amp;#8221;) for aggregate gross proceeds of $253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and were amortized ratably to interest expense over the original term of the Short-Term Notes up though November 2017. On November 30, 2017, the Short-Term Notes were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase warrants (&amp;#8220;Original Warrants&amp;#8221;). The Original Warrants had a term of 5 years and an exercise price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the amendment described below. The November 30, 2017 amendment resulted in a substantial modification to the Short-Term Notes and was accounted for under the provisions of extinguishment accounting.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Short-Term Notes were subsequently amended and restated on March 12, 2018 (the &amp;#8220;Amended and Restated Short-Term Notes&amp;#8221;). The Amended and Restated Short-Term Notes became convertible promissory notes that bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the maturity date of July 31, 2018 (the &amp;#8220;Short-Term Note Maturity Date&amp;#8221;). Pursuant to the terms of each Amended and Restated Short-Term Note and a consent signed by the Company and each holder, the Original Warrants under the Short-Term Notes were modified whereby each subscriber received a replacement warrant (the &amp;#8220;Replacement Warrant&amp;#8221;) upon the issuance of the Amended and Restated Short-Term Note, in lieu of the Original Warrant. In addition, each holder was issued an additional warrant (the &amp;#8220;Additional Warrant&amp;#8221;).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;If the Company raises more than $3,000,000 in an equity or equity-linked financing before July 31, 2018 (the &amp;#8220;Short-Term Note Qualified Financing&amp;#8221;), the outstanding principal and accrued interest (the &amp;#8220;Outstanding Balance&amp;#8221;) on the Amended and Restated Short-Term Notes shall automatically convert into the securities issued by the Company in the Short-Term Note Qualified Financing (the &amp;#8220;New Round Stock&amp;#8221;) based on the greater number of such securities resulting from either (i) the Outstanding Balance divided by $1.80 or (ii) the Outstanding Balance multiplied by 1.25, divided by the price paid per security in the Short-Term Note Qualified Financing. If a change of control transaction occurs prior to the earlier of a Short-Term Note Qualified Financing or the Short-Term Note Maturity Date, the Amended and Restated Short-Term Notes would, at the election of the holders of a majority of the outstanding principal of the Amended and Restated Short-Term Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by the Board as if in connection with the granting of stock-based compensation or in a private sale to a third party in an arms&amp;#8217; length transaction or (ii) at the per share consideration to be paid in such
 transaction. The date of a conversion under a Short-Term Note Qualified Financing or a change of control transaction under the terms of the Amended and Restated Short-Term Notes is referred to herein as the &amp;#8220;Conversion Date&amp;#8221;.&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Replacement Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Each Replacement Warrant grants the holder the option to purchase up to the number of shares of capital stock of the Company equal to the New Round Stock issued or issuable upon the conversion of the Amended and Restated Short-Term Note held by such holder at a per share exercise price equal to either (i) the actual per share price of New Round Stock if the Amended and Restated Short-Term Notes converted in connection with a Short-Term Note Qualified Financing or (ii) the price at which the Amended and Restated Short-Term Notes converted in connection with a change of control transaction. The Replacement Warrants are exercisable commencing on the Conversion Date and expire on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Replacement Warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Replacement Warrants were deemed to be a free-standing instrument and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. The Company recorded an initial liability of $137,722 upon issuance with an offset to extinguishment loss described further below. The fair value changes of the warrant liability associated with the Short-Term Notes are recorded at each reporting date in the condensed consolidated statements of operations which amounted to a benefit of $(2,371) for the three months ended March 31, 2018. A Monte Carlo simulation model was used to estimate the aggregate fair value of the Replacement Warrants as of March 31, 2018. Input assumptions used were as follows: risk-free interest rate of 2.45 percent; expected volatility of 50 percent; expected life of 3.64 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to a separate independent third-party valuation analysis since there was no active trading market for the Company&amp;#8217;s common stock&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Additional Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Each Additional Warrant grants the holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share exercise price of $1.80. The Additional Warrants are exercisable commencing on the Conversion Date and expire on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Additional Warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Additional Warrants were deemed to be a free-standing instrument and were accounted for as equity as there were no variable terms. The Additional Warrants amounted to 189,750 shares as of both the March 12, 2018 amendment date and as of March 31, 2018 with terms that largely parallel the provisions of the Original Warrants except that the Additional Warrants are exercisable on the Conversion Date as opposed to the Short-Term Note Maturity Date and the expiration date was moved up to November 21, 2021 from July 31, 2023. The fair value differential between the Original Warrants and the Additional Warrants was a reduction of $22,624. The fair value change was recorded as a reduction to additional paid-in capital in the accompanying condensed balance sheets and was included as part of the extinguishment loss discussed further below.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Premium Conversion Derivative&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Upon the March 2018 amendment, the Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Short-Term Notes qualified as an embedded derivative and was reflected as a liability in the amount of $49,668 at the time of the March 12, 2018 amendment with a corresponding offset to extinguishment loss which is described further below. Subsequent to the amendment, the embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Short-Term Notes in the condensed consolidated statements of operations for an expense of $43 for the three months ended March 31, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Other&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The March 2018 amendment resulted in a substantial modification to the Short-Term Notes whereby additional conversion features and warrant coverage were added. The Company recorded the Short-Term Note amendment under the provisions of extinguishment accounting. A loss on Short-Term Notes extinguishment in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2018 was recorded in the amount of $186,220, which represented the difference between the carrying value of the Short-Term Notes over the combined fair values of the Short-Term Notes, premium conversion derivative, Replacement Warrant and Additional Warrants on the date of the amendment. The fair value decrease of the Short-Term Notes (inclusive of principal and interest, non-bifurcated embedded conversion feature and the Additional Warrants) relative to its adjusted carrying value at the time of the amendment was $1,170 which was recorded as a reduction to additional paid-in
 capital on the accompanying condensed balance sheets.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pursuant to the Short-Term Note subscription agreement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the Short-Term Notes and associated warrants, and the right to purchase the Short-Term Notes and associated warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the Short-Term Note subscription agreement.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Unsecured Loans&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On March 20, 2018, the Company received cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from an existing stockholder. The loan is interest free and requires that the Company repay the principal in full on the earlier to occur of (i) March 20, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan includes customary events of default.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Additionally, NeuroOne received a $50,000 short-term unsecured loan in November 2016 from the placement agent for its convertible promissory note financing (see Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). NeuroOne incurred no fees or interest costs for this temporary loan and it was repaid in full in February 2017.&lt;/p&gt;&lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;March 31,&lt;br /&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December 31,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;2016 convertible promissory notes, net of discounts&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,578,239&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,543,652&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;2017 convertible promissory notes, net of discounts&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;753,637&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;504,465&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;173,213&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;120,223&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: -9pt; padding-bottom: 4pt; padding-left: 0.25in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,505,089&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,168,340&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;2016 Convertible Promissory Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In November 2016 and as amended in June 2017, the Board authorized the Company to issue convertible promissory notes (the &amp;#8220;Convertible Notes&amp;#8221;) and common stock purchase warrants (the &amp;#8220;Warrants&amp;#8221;) for aggregate gross proceeds of up to $2.5 million and entered into subscription agreements with subscribers (the &amp;#8220;2016 Private Placement&amp;#8221;). The Company amended the Convertible Notes and Warrants again on November 20, 2017 to extend the maturity date of the Convertible Notes from November 21, 2017 to July 31, 2018 and to change the terms of the underlying
 Warrants that include the removal of down-round pricing protection provisions as described more fully below.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of March 31, 2018, the Company issued a total of $1,625,120 of Convertible Notes and Warrants to investors. The Convertible Notes are unsecured. The Convertible Notes bear interest at a fixed rate of 8 percent per annum and require the Company to repay the principal and accrued and unpaid interest thereon at the earlier of July 31, 2018 or the consummation of the next equity or equity-linked round of financing resulting in more than $3.0 million in gross proceeds (a &amp;#8220;Qualified Financing&amp;#8221;). If a Qualified Financing occurs before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by July 31, 2018, the Convertible Notes will be immediately due and payable on such date.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;If a change of control transaction or initial public offering occurs prior to a Qualified Financing, the Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the Convertible Notes, either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of the per share value as determined by the Board as if in connection with the granting of stock based compensation, or in a private sale to a third party in an arms-length transaction, or at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&amp;#8217;s stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Prior to the June 2017 amendment, the Warrants granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number of shares equal to the number of shares received by the holders upon the conversion of the Convertible Notes, or (ii) if exercised prior to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued interest on the Convertible Note held by such warrant holder divided by $1.80. The Warrants were immediately exercisable on the date of issuance and expired on November 21, 2021. In June 2017, however, the Company amended the terms of the Warrants under the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the related Convertible Notes. The amount of warrant shares to be issued are now contingent and are based on the number of shares of common stock received by the holder of the Convertible Notes upon conversion of such holder&amp;#8217;s Convertible Notes, and at an exercise price equal to the same price per share of the securities issued in the Qualified Financing. The Warrants expire on November 21, 2021 in the event of a Qualified Financing or expire unissued if the notes have not been converted.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Warrants were deemed to be a free-standing instrument and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the Warrants. Input assumptions used were as follows: risk-free interest rate of 2.45 and 2.08 percent as of March 31, 2018 and December 31, 2017, respectively; expected volatility of 50
 percent as of March 31, 2018 and December 31, 2017; expected life of 3.64 and 3.89 years as of March 31, 2018 and December 31, 2017, respectively; and expected dividend yield of 0 percent as of March 31, 2018 and December 31, 2017. The underlying stock price used in the analysis was on a non-marketable basis and was according to a separate independent third-party valuation analysis since there was no active trading market for the Company&amp;#8217;s common stock.&amp;#160;The Convertible Note proceeds assigned to the Warrants were zero and $182,693 during the three months ended March 31, 2018 and 2017, respectively, which represented their fair value at issuance, and were discounted from the Convertible Notes and reflected as a warrant liability. The discount was amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was zero and $118,862 for the three months ended March 31, 2018 and 2017, respectively. The Company also recorded the fair value changes of the warrant liability associated with the Convertible Notes in the condensed consolidated statements of operations which amounted to a benefit of $(130,976) and $(215) for the three months ended March 31, 2018 and 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The November 2017 amendment resulted in a substantial modification to the original Convertible Notes whereby the maturity date was extended, and the terms associated with the Warrants were revised. The fair value of the underlying convertible notes was $97,223 lower than the carrying value of the Convertible Notes on the date of the modification. The $97,223 difference was recorded as a discount to the debt and is being amortized over the amended term of the Convertible Notes. The amortization recorded during the three months ended March 31, 2018 and 2017 was $34,585 and zero, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;At the time of their issuance, the Convertible Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes in the amount of zero and $72,732 during the three months ended March 31, 2018 and 2017, respectively. The discount was being amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was zero and $47,318 for the three months ended March 31, 2018 and 2017, respectively. The embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Convertible Notes in the condensed consolidated statements of operations for an expense of $2,666 and $183 for the three months ended March 31, 2018 and 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &amp;#8220;placement agent warrant&amp;#8221;) which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855 on date of Convertible Note issuance, and (iii) legal expenses of $33,450. The placement agent warrant is issuable at the time the private placement transaction closes which has not occurred as of March 31, 2018. The placement agent warrant will be immediately exercisable on the date of issuance and will expire five years following the date of issuance. The placement agent is to receive a placement agent warrant to purchase shares of common stock in an amount equal to 8% of the common stock (or common stock equivalents) purchased by investors in the private placement transaction. As of March 31, 2018 and December 31, 2017, the Company has an obligation to issue a placement agent warrant for the purchase of approximately 63,000 shares of common stock. The Company recorded an issuance cost discount to the Convertible Notes in the amount of zero and $16,645 during the three months ended March 31, 2018 and 2017, respectively, of which zero and $12,361 was amortized to interest expense during the three months ended March 31, 2018 and 2017, respectively. The balance of the issuance costs in the amount of zero and $15,803 was attributed to the Warrants and was immediately recorded as interest expense upon issuance
 during the three months ended March 31, 2018 and 2017, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;2017 Convertible Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 4, 2017, the Company initially entered into a subscription agreement (with certain investors (the &amp;#8220;Subscribers&amp;#8221;), pursuant to which the Company, in a private placement (the &amp;#8220;Private Placement&amp;#8221;), agreed to issue and sell to the Subscribers 8% convertible promissory notes (each, a &amp;#8220;Note&amp;#8221; and collectively, the &amp;#8220;2017 Convertible Notes&amp;#8221;) and warrants (the &amp;#8220;New Warrants&amp;#8221;) to purchase shares of the Company&amp;#8217;s capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering conversion event. In November 2017, the Board approved an increase in the authorized subscription from $1,000,000 to $1,500,000. The subscription agreement and the 2017 Convertible Notes were amended on December 14, 2017 to move up the maturity date from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision in the event of a qualified financing as described more fully below. In May 2018, the Board approved an increase in the authorized subscription from $1,500,000 to $2,000,000 and extended the offering period from five months to eight months.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The initial closing of the Private Placement was consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible Notes in an aggregate principal amount of $1,140,000 to the Subscribers through March 31, 2018. The Company may conduct any number of additional closings so long as the final closing occurs on or before the eight-month anniversary of the initial closing date and the amount does not exceed $2,000,000 or a higher amount determined by the Board. See Note 13 &amp;#8211; Subsequent Events for closings that occurred after March 31, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The 2017 Convertible Notes bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on December 31, 2018 (the &amp;#8220;2017 Convertible Notes Maturity Date&amp;#8221;). If the Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the &amp;#8220;2017 Convertible Notes Qualified Financing&amp;#8221;), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The New Warrants also become exercisable upon a 2017 Convertible Notes Qualified Financing for an amount of shares equal to the number of shares received by the holder in the 2017 Convertible Notes Qualified Financing at the same price per share of the securities issued in the 2017 Convertible Notes Qualified Financing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Prior to the December 2017 amendment, if the Company had raised more than $3,000,000 in an equity financing before October 4,
 2022, the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable in conjunction with the 2017 Convertible Notes Qualified Financing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Lastly, if a change of control transaction occurs prior to the earlier of a 2017 Convertible Notes Qualified Financing or the 2017 Convertible Notes Maturity Date, the 2017 Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by the Board as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms-length transaction or (ii) at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&amp;#8217;s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&amp;#8217;s assets. The New Warrants also become exercisable upon a change of control transaction for an amount of shares equal to the number of shares received by the holder upon conversion in connection with such transaction at the same price per share that the 2017 Convertible Notes converted in the change of control transaction.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The December 2017 amendment resulted in a substantial modification to the original 2017 Convertible Notes whereby the maturity date was moved up to December 2018 from October 2022 and the terms associated with the embedded features were revised as described previously. The fair value of the underlying Convertible Notes was $27,371 lower than the face amount of the 2017 Convertible Notes. The $27,371 difference was recorded as a discount to the debt and is being amortized over the amended term of the 2017 Convertible Notes. The amortization recorded during the three months ended March 31, 2018 was $6,432.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The 2017 Convertible Notes contain a conversion discount in the event of a 2017 Convertible Notes Qualified Financing to equal the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The embedded feature qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the 2017 Convertible Notes in the amount of $91,298 for the convertible debt issued during the three months ended March 31, 2018. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $27,021 for the three months ended March 31, 2018. The embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with all of the 2017 Convertible Notes in the condensed consolidated statements of operations which amounted to an expense of $1,323 for the three months ended March 31, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The New Warrants were deemed to be a free-standing instrument and were accounted for as a liability given the variable number of shares issuable in connection with a change of control conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the New Warrants. Input assumptions used were as follows: risk-free interest rate of 2.57 and 2.22 percent as of March 31, 2018 and December 31, 2017, respectively; expected volatility of 50 percent as of March 31, 2018 and December 31, 2017; expected life of 5.21 and 5.38 years as of March 31, 2018 and December 31, 2017, respectively; and expected dividend yield of 0 percent as of March 31, 2018 and December 31, 2017. The underlying stock price used in the analysis was on a non-marketable basis and was according to a separate independent third-party valuation analysis as there has been very limited trading with the Company&amp;#8217;s common stock since the Acquisition on July 20, 2017. The 2017 Convertible Note proceeds assigned to the New Warrants were $238,864 during the three month period ended March 31, 2018, which represented their fair value at issuance and were discounted from the 2017 Convertible Notes and reflected as a warrant liability. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $70,505 for the three month period ended March 31, 2018. The Company also recorded the fair value changes of the warrant liability associated with &amp;#160;all of the 2017 Convertible Notes in the condensed consolidated statements of operations which amounted to an expense of $9,355 for the three months ended March 31, 2018.&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In connection with the 2017 Convertible Notes, the Company incurred original cost of issuance in the amount of $5,283 which consisted of legal costs and was recorded as an issuance cost discount to the 2017 Convertible Notes, of which $375 was amortized to interest expense during the three months ended March 31, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;2016 and 2017 Convertible Note Subscription Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pursuant to the subscription agreements entered into in connection with the 2016 Private Placement and the Private Placement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the Convertible Notes and associated Warrants or any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right to purchase the Convertible Notes and associated Warrants or the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the respective subscription agreements.&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<nmtc:InvestmentBankerFeeTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify; border-top: 1.5pt solid black; border-bottom: 1.5pt solid black;"&gt;&lt;b&gt;NOTE 9 &amp;#8211; Investment Banker Fee&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Investment Banker Fee&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;NeuroOne paid a $50,000 non-refundable fee to an investment banker in December 2016 to raise equity financing. NeuroOne subsequently concluded that the investment banker was not expected to raise any equity and therefore expensed the fee in March 2017.&lt;/p&gt;</nmtc:InvestmentBankerFeeTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 10 &amp;#8211; Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;NeuroOne formally adopted an equity incentive plan (&amp;#8220;the 2016 Plan&amp;#8221;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition. In addition, the Company adopted a 2017 Equity Incentive Plan (the &amp;#8220;2017 Plan&amp;#8221;) on April 17, 2017. The 2016 and 2017 Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards in the second quarter of 2017, under the 2016 Plan. During the three month periods ended March 31, 2018 and 2017, no stock options or restricted stock award grants were formally issued. See stock-based award liability section below for stock-based award grants committed, but not formally issued as of March 31, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During the three months ended March 31, 2018 and 2017, there was no vesting of formally issued stock options or restricted stock awards. No stock options were forfeited during the three months ended March 31, 2018 and 2017. As of March 31, 2018, 1,711,096 shares were available for future issuance on a combined basis under the 2016 and 2017 Plans.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;There was no unrecognized stock-based compensation cost for stock options and restricted common stock as of March 31, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Award Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of March 31, 2018, the Company had a formal obligation to issue future restricted common stock and common stock options relating to two consulting agreements. The estimated liability associated with the vested portions of these awards was recorded in accrued expenses in the accompanying condensed consolidated balance sheets as of March 31, 2018. The corresponding stock-based services expense related to the stock-based award liability was included in general and administrative and research and development costs as follows in the accompanying condensed statements of operations:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2;
 font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; font-weight: bold;" colspan="2"&gt;Three Months&amp;#160;&lt;br /&gt;Ended&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;March 31,&lt;br /&gt;2018&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;252,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,437&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;254,437&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;A total of up to 250,000 shares of common stock was committed as a result of one consulting agreement for investor relation services executed in February 2018, but none of the underlying shares of common stock were issued as of March 31, 2018. The portion of the stock award that had met performance vesting conditions as of March 31, 2018 amounted to 100,000 common shares and were issued on April 26, 2018. The amount of compensation expense totaling $252,000 related to the vested common shares was based on the fair value of the underlying common stock at point of vesting which was $2.52 per share on a non-marketable basis. The common stock fair value was according to a separate independent third-party valuation analysis since there was no active trading market for the Company&amp;#8217;s common stock. The remaining 150,000 shares of the stock award will vest and be issued in 50,000 share quarterly tranches beginning in May 2018. The first 50,000 tranche of shares was issued on May 7, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Additionally, the Company recorded stock-based services expense related to unissued stock options associated with a second consulting agreement whereby the number of option shares and pricing will not be set until the occurrence of the award date which is defined as the earlier to occur of a public offering, qualified financing, or June 30, 2018. The number of option shares under the agreement is based on a $3,000 monthly compensation amount divided by the fair value of the underlying common stock on the award date. The exercise price will also be set at the fair value of the underlying common stock on the award date. The liability associated with the unissued options was based on an option share equivalent estimate that reflects the portion of the award where performance vesting conditions have been met as of March 31, 2018 and was based on the fair value of the Company&amp;#8217;s common stock on March 31, 2018 as the award date has not occurred. The common stock fair value on March 31, 2018 was $2.30 per share and was determined based on a separate independent third-party valuation analysis since there was no active trading market for the Company&amp;#8217;s common stock.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock- option liability during the three month periods ended March 31, 2018:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47.8&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.6&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Upon the issuance of all of the unissued options associated with the stock-based award liabilities, the estimated number of shares available for future issuance as of March 31, 2018 would be reduced from 1,711,096 shares to 1,704,574 as a result of the potential stock option issuance under the second consulting agreement. The 250,000 shares of common stock issuable under the February 2018 consulting agreement were not eligible for issuance under either of the 2016 or 2017 Plans as the consulting contract was not with an individual. See Note 12 - Stockholders&amp;#8217; Deficit for additional information.&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 11 &amp;#8211; Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The effective tax rate for the three months ended March 31, 2018 and 2017 was zero percent. As a result of the analysis of all available evidence as of&amp;#160;March 31, 2018&amp;#160;and&amp;#160;December&amp;#160;31, 2017, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported&amp;#160;no&amp;#160;income tax benefit during the&amp;#160;three months ended&amp;#160;March 31, 2018 and 2017. If the Company&amp;#8217;s assumptions change and the Company believes that it will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be recognized as a reduction of future income tax expense.&amp;#160;&amp;#160;If the assumptions do not change, each period the Company could record an additional valuation allowance on any increases in the deferred tax assets.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&amp;#8217;s consolidated financial statements include, but are not limited to, a U.S. federal corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and the valuation allowance recorded to reflect the new federal corporate tax rates.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;NOTE 12 &amp;#8211; Stockholders&amp;#8217; Deficit&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has 100,000,000 shares of common stock authorized, par value $0.001 per share, of which 7,864,994 shares were issued and outstanding at March 31, 2018 and December 31, 2017. In connection with the February 2018 consulting contract discussed in Note 10 &amp;#8211; Stock-based Compensation, up to 250,000 shares of common stock are issuable under the contract. Upon issuance, these shares are subject to restrictions pursuant to the provisions of Rule&amp;#160;144. On April 26, 2018 and May 7, 2018, 100,000 and 50,000 shares of common stock were issued under the contract, respectively, and subject to the restrictions under the provisions of Rule 144.&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify; border-top: 1.5pt solid black; border-bottom: 1.5pt solid black;"&gt;&lt;b&gt;NOTE 13 &amp;#8211; Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;i&gt;2017 Convertible Notes&lt;/i&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;The Company issued additional 2017 Convertible Notes and New Warrants to investors for aggregate gross proceeds of $350,000 from April 13, 2018 to May 8, 2018. &amp;#160;The additional convertible notes and warrants issued have identical terms to the 2017 Convertible Notes and New Warrants disclosed in Note 8 - Convertible Promissory Notes and Warrant Agreements.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;Additionally, on May 8, 2018, the Board approved an increase in the maximum amount of aggregate 2017 Convertible Notes offered from $1,500,000 to $2,000,000.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&lt;i&gt;Issuance of Common Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"&gt;Between April 26, 2018 and May 7, 2018, the Company issued 150,000 shares of common stock to an investor relations firm in consideration for consulting services.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Management&amp;#8217;s Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:ConcentrationRiskCreditRisk contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&amp;#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2018, the Company did not have any deposits in excess of federally insured amounts.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 48px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of March 31, 2018 and December 31, 2017, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the short-term and convertible promissory notes of the Company were based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected
 returns by market participants for similar instruments and are based on Level&amp;#160;3 inputs. There were no transfers between fair value hierarchy levels during the three months ended March 31, 2018 and 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of March 31,&amp;#160;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,634,059&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,634,059&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;607,173&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;607,173&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,241,232&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:
 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,241,232&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:
 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level&amp;#160;3 inputs for the three month periods ended March 31, 2018 and 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Value assigned to warrants in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;376,586&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;182,693&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(123,992&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(215&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,634,059&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;528,438&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Premium debt conversion derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;462,174&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;140,967&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;72,732&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of premium debt conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,032&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;183&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;607,173&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;210,565&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<nmtc:IntellectualPropertyPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.&lt;/p&gt;&lt;/div&gt;</nmtc:IntellectualPropertyPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates its long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through March 31, 2018, the Company has not impaired any long-lived assets.&lt;/p&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:DebtPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Debt Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the short term notes and convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<nmtc:WarrantLiabilityPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company issued warrants to purchase equity securities in connection with the issuance or amendment of short-term and convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&amp;#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;</nmtc:WarrantLiabilityPolicyTextBlock>
<nmtc:PremiumDebtConversionDerivativePolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Premium Debt Conversion Derivatives&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&amp;#160; The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed consolidated statements of operations. The Company determined that the redemption features under the amended short-term promissory notes and convertible promissory notes qualified as embedded derivatives and were separated from their debt hosts.&lt;/p&gt;&lt;/div&gt;</nmtc:PremiumDebtConversionDerivativePolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&amp;#8217;s short-term notes, convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the short-term notes and convertible promissory notes utilizing the if-converted method was not applicable during the three month periods ended March 31, 2018 and 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three month periods ended March 31, 2018 and 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three month periods ended March 31, 2018 and 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;(1)&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;597,283&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;365,716&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;font style="font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2017, the FASB issued ASU 2017-09,&amp;#160;&lt;i&gt;Compensation - Stock Compensation (Topic 718):&amp;#160;Scope of Modification Accounting (ASU 2016-09)&lt;/i&gt;,&amp;#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company has adopted this standard for the three months ended March 31, 2018. The adoption of this standard did not have any impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2017, the FASB issued ASU No. 2017-11,&amp;#160;&lt;i&gt;Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging&lt;/i&gt;, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&amp;#160;15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of March 31,&amp;#160;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,634,059&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,634,059&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;607,173&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;607,173&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,241,232&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,241,232&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new
 roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;462,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,843,639&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,381,465&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Value assigned to warrants in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;376,586&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;182,693&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(123,992&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(215&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,634,059&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;528,438&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Premium debt conversion derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;462,174&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;140,967&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 right;"&gt;72,732&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of premium debt conversion derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,032&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;183&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;607,173&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;210,565&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;189,750&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;(1)&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;597,283&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;365,716&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;font style="font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Useful Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1129px; text-align: justify;"&gt;Net Intangibles, December 31, 2017&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; text-align: center;"&gt;12-13 Years&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 188px; text-align: right;"&gt;216,372&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Less: amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(4,952&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;Net Intangibles, March 31, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;211,420&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued&amp;#160;license fees&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;120,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;120,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued services&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;868,811&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;600,339&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued issuance costs&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;28,083&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;28,083&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued payroll&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;251,543&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;223,195&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Advances&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;50,000&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="line-height: 14.26px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Other (1)&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;254,437&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td
 style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,522,874&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,021,617&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 14.26px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;table style="font: 11pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in;"&gt;&lt;font style="font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Accrued expenses include an obligation to issue stock awards and stock options to consultants that have met vesting requirements as of March 31, 2018 in the amount of $254,437. See Note 10 &amp;#8211; Stock-Based Compensation for further detail.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:ConvertibleDebtTableTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;March 31,&lt;br /&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December 31,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;2016 convertible promissory notes, net of discounts&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,578,239&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,543,652&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt;"&gt;2017 convertible promissory notes, net of discounts&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;753,637&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;504,465&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;173,213&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;120,223&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: -9pt; padding-bottom: 4pt; padding-left: 0.25in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,505,089&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,168,340&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; font-weight: bold;" colspan="2"&gt;Three Months&amp;#160;&lt;br /&gt;Ended&lt;/td&gt;&lt;td nowrap="nowrap" style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;March 31,&lt;br /&gt;2018&lt;/td&gt;&lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;252,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,437&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;254,437&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47.8&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.6&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="pure" decimals="2">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
<us-gaap:ConversionOfStockDescription contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">NeuroOne Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware.</us-gaap:ConversionOfStockDescription>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:SharesIssuedPricePerShare>
<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="pure" decimals="7">17.0103706</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">6291994</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">992265</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">2292265</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandSixteenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">1704574</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember" unitRef="shares" decimals="INF">1711096</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">3500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">115000</us-gaap:UnsecuredDebt>
<us-gaap:ShortTermBankLoansAndNotesPayable contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">253000</us-gaap:ShortTermBankLoansAndNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">665000</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">717040</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">128525</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1625120</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">1625120</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="-3">97223000</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">1140000</us-gaap:ConvertibleNotesPayable>
<nmtc:ConvertibleNotesPayableOne contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1140000</nmtc:ConvertibleNotesPayableOne>
<nmtc:SubscriptionAmountToConvertiblePromissoryNote contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="-5">2500000</nmtc:SubscriptionAmountToConvertiblePromissoryNote>
<nmtc:SubscriptionAmountToConvertiblePromissoryNoteOne contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="-6">2000000</nmtc:SubscriptionAmountToConvertiblePromissoryNoteOne>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1381465</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">1381465</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1634059</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">1634059</nmtc:WarrantLiability>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<nmtc:WarrantLiability contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">462174</nmtc:PremiumConversionDerivative>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">462174</nmtc:PremiumConversionDerivative>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">607173</nmtc:PremiumConversionDerivative>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">607173</nmtc:PremiumConversionDerivative>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<nmtc:PremiumConversionDerivative contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1843639</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">1843639</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2241232</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2241232</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">-215</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">-215</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">-123992</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">-130976</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">9355</us-gaap:FairValueAdjustmentOfWarrants>
<nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">72732</nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes>
<nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">140967</nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes>
<nmtc:ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">183</nmtc:ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition>
<nmtc:ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">4032</nmtc:ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">597283</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0" id="Footnote-1_1">189750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">365716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember_RangeAxis_MinimumMember">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember_RangeAxis_MaximumMember">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">216372</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">211420</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">5007</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4952</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">-4952</us-gaap:AmortizationOfIntangibleAssets>
<nmtc:AccruedLicenseFees contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">120000</nmtc:AccruedLicenseFees>
<nmtc:AccruedLicenseFees contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">120000</nmtc:AccruedLicenseFees>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">600339</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">868811</us-gaap:AccruedProfessionalFeesCurrent>
<nmtc:AccruedIssuanceCosts contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">28083</nmtc:AccruedIssuanceCosts>
<nmtc:AccruedIssuanceCosts contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">28083</nmtc:AccruedIssuanceCosts>
<nmtc:AccruedPayroll contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">223195</nmtc:AccruedPayroll>
<nmtc:AccruedPayroll contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">251543</nmtc:AccruedPayroll>
<nmtc:AccruedExpensesAdvances contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">50000</nmtc:AccruedExpensesAdvances>
<nmtc:AccruedExpensesAdvances contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true" id="Footnote-2_1"/>
<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0" id="Footnote-2_2">254437</us-gaap:OtherAccruedLiabilitiesNoncurrent>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">3030</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">2017-02-17</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">2018-07-31</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_15_Mar_2018T00_00_00_TO_20_Mar_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember">2019-03-20</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">2018-07-31</us-gaap:DebtInstrumentMaturityDate>
<nmtc:CommonStockPurchaseOfWarrants contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="shares" decimals="INF">189750</nmtc:CommonStockPurchaseOfWarrants>
<nmtc:WarrantsMaturityTerm contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">P5Y</nmtc:WarrantsMaturityTerm>
<nmtc:WarrantsMaturityTerm contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">P5Y</nmtc:WarrantsMaturityTerm>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD_per_Share" decimals="2">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">137722</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="4">0.0208</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="pure" decimals="4">0.0222</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="4">0.0222</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="5">0.00002</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="4">0.0245</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="4">0.0257</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="pure" decimals="2">0.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="2">0.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="2">0.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="2">0.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">P3Y10M21D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">P5Y4M17D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember">P5Y4M17D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">P3Y7M21D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">P3Y7M21D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember">P5Y2M16D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:UnsecuredDebtCurrent contextRef="Context_As_Of_30_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">50000</us-gaap:UnsecuredDebtCurrent>
<nmtc:AdditionalWarrantsAllocated contextRef="Context_As_Of_12_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="INF">189750</nmtc:AdditionalWarrantsAllocated>
<nmtc:AdditionalWarrantsAllocated contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="INF">189750</nmtc:AdditionalWarrantsAllocated>
<nmtc:WarrantsExpirationDate contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">2023-07-31</nmtc:WarrantsExpirationDate>
<nmtc:LossOnShortTermNotesExtinguishment contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">186220</nmtc:LossOnShortTermNotesExtinguishment>
<nmtc:FairValueAdjustmentOfShortTermNotesAndWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">1170</nmtc:FairValueAdjustmentOfShortTermNotesAndWarrants>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_12_Mar_2018T00_00_00_TO_12_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">3000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
<nmtc:ShortTermNoteQualifiedFinancingDescription contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">The Short-Term Note Qualified Financing (the "New Round Stock") based on the greater number of such securities resulting from either (i) the Outstanding Balance divided by $1.80 or (ii) the Outstanding Balance multiplied by 1.25, divided by the price paid per security in the Short-Term Note Qualified Financing.</nmtc:ShortTermNoteQualifiedFinancingDescription>
<us-gaap:DebtConversionDescription contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_PremiumConversionDerivativeMember">The Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurs at a price under $2.25 per common share.</us-gaap:DebtConversionDescription>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="USD" decimals="-6">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_Custom_15_Mar_2018T00_00_00_TO_20_Mar_2018T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="USD" decimals="0">115000</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">2168340</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="0">1543652</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertiblePromissoryNoteMember" unitRef="USD" decimals="0">504465</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_AccruedLiabilitiesMember" unitRef="USD" decimals="0">120223</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2505089</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="0">1578239</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertiblePromissoryNoteMember" unitRef="USD" decimals="0">753637</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_AccruedLiabilitiesMember" unitRef="USD" decimals="0">173213</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">192427</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">236136</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:ConvertibleDebt contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="-5">2500000</us-gaap:ConvertibleDebt>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="pure" decimals="2">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">665000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">Pursuant to which the Company, in a private placement (the "Private Placement"), agreed to issue and sell to the Subscribers 8% convertible promissory notes (each, a "Note" and collectively, the "2017 Convertible Notes") and warrants (the "New Warrants") to purchase shares of the Company's capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering conversion event. In November 2017, the Board approved an increase in the authorized subscription from $1,000,000 to $1,500,000. The subscription agreement and the 2017 Convertible Notes were amended on December 14, 2017 to move up the maturity date from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision in the event of a qualified financing as described more fully below. In May 2018, the Board approved an increase in the authorized subscription from $1,500,000 to $2,000,000 and extended the offering period from five months to eight months.</us-gaap:DebtInstrumentMaturityDateDescription>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">Convertible Notes whereby the maturity date was moved up to December 2018 from October 2022 and the terms associated embedded features were revised as described previously.</us-gaap:DebtInstrumentMaturityDateDescription>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">The Company to repay the principal and accrued and unpaid interest thereon on December 31, 2018 (the "2017 Convertible Notes Maturity Date"). If the Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the "2017 Convertible Notes Qualified Financing"), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing.</us-gaap:DebtInstrumentMaturityDateDescription>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="-6">3000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">336571</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="-5">3000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:DebtInstrumentInterestRateTerms contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">If a Qualified Financing occurs before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by July 31, 2018, the Convertible Notes will be immediately due and payable on such date.</us-gaap:DebtInstrumentInterestRateTerms>
<us-gaap:DebtInstrumentInterestRateTerms contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">The Company may conduct any number of additional closings so long as the final closing occurs on or before the eight-month anniversary of the initial closing date and the amount does not exceed $2,000,000 or a higher amount determined by the Board. See Note 13 - Subsequent Events for closings that occurred after March 31, 2018.</us-gaap:DebtInstrumentInterestRateTerms>
<nmtc:DescriptionOfMaximumVotingPowerOfSurvivingEntity contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.</nmtc:DescriptionOfMaximumVotingPowerOfSurvivingEntity>
<nmtc:AmountOfConvertibleNoteHeldByWarrantHolder contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="2">1.80</nmtc:AmountOfConvertibleNoteHeldByWarrantHolder>
<us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">2021-11-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
<nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">182693</nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants>
<nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">0</nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">12361</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">0</us-gaap:InterestExpense>
<us-gaap:DebtConversionConvertedInstrumentRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="pure" decimals="2">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
<us-gaap:DebtConversionConvertedInstrumentRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">1.25</us-gaap:DebtConversionConvertedInstrumentRate>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD_per_Share" decimals="2">2.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:DebtInstrumentFee contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember">Prior to the December 2017 amendment, if the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable in conjunction with the 2017 Convertible Notes Qualified Financing.</us-gaap:DebtInstrumentFee>
<us-gaap:DebtInstrumentFee contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the "placement agent warrant") which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855 on date of Convertible Note issuance, and (iii) legal expenses of $33,450.</us-gaap:DebtInstrumentFee>
<us-gaap:DebtInstrumentFee contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember">Pursuant to the subscription agreements entered into in connection with the 2016 Private Placement and the Private Placement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the Convertible Notes and associated Warrants or any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right to purchase the Convertible Notes and associated Warrants or the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the respective subscription agreements.</us-gaap:DebtInstrumentFee>
<nmtc:WarrantsToPurchaseSharesOfCommonStock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="shares" decimals="0">63000</nmtc:WarrantsToPurchaseSharesOfCommonStock>
<nmtc:PercentageOfCommonStockPurchaseWarrants contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_FinancialInstrumentAxis_SubscriptionAgreementMember_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="pure" decimals="2">0.80</nmtc:PercentageOfCommonStockPurchaseWarrants>
<nmtc:PercentageOfCommonStockPurchaseWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="pure" decimals="2">0.08</nmtc:PercentageOfCommonStockPurchaseWarrants>
<nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">15803</nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants>
<nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">0</nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_NovemberTwoThousandSeventeenMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">97223</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">87769</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">5283</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember" unitRef="USD" decimals="0">1286</us-gaap:DebtInstrumentUnamortizedDiscount>
<nmtc:ConvertibleNotesMaximumExtensionLimit contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">1500000</nmtc:ConvertibleNotesMaximumExtensionLimit>
<us-gaap:LegalFees contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">294615</us-gaap:LegalFees>
<us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_TwoZeroOneSevenConvertibleNoteAmendmentMember">Substantial modification to the original 2017 Convertible Notes whereby the maturity date was moved up to December 2018 from October 2022 and the terms associated with the embedded features were revised as described previously. The fair value of the underlying Convertible Notes was $27,371 lower than the face amount of the 2017 Convertible Notes. The $27,371 difference was recorded as a discount to the debt and is being amortized over the amended term of the 2017.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
<nmtc:NonRefundableFeeToInvestmentBanker contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">50000</nmtc:NonRefundableFeeToInvestmentBanker>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">254437</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">252000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">2437</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="3">0.478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">P5Y0M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="3">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="2">2.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<nmtc:FairValueOfCommonStockPricePerShare contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="2">2.52</nmtc:FairValueOfCommonStockPricePerShare>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">The remaining 150,000 shares of the stock award will vest and be issued in 50,000 share quarterly tranches beginning in May 2018. The first 50,000 tranche of shares was issued on May 7, 2018.</us-gaap:SaleOfStockDescriptionOfTransaction>
<nmtc:MonthlyCompensationAmount contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3000</nmtc:MonthlyCompensationAmount>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">252000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_10_Apr_2018T00_00_00_TO_26_Apr_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_28_Apr_2018T00_00_00_TO_07_May_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_13_Apr_2018T00_00_00_TO_08_May_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_AdditionalTwoThousandSeventeenConvertibleNotesMember" unitRef="USD" decimals="0">350000</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:DebtInstrumentDescription contextRef="Context_Custom_13_Apr_2018T00_00_00_TO_08_May_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_AdditionalTwoThousandSeventeenConvertibleNotesMember">Additionally, on May 8, 2018, the Board approved an increase in the maximum amount of aggregate 2017 Convertible Notes offered from $1,500,000 to $2,000,000.</us-gaap:DebtInstrumentDescription>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_28_Apr_2018T00_00_00_TO_07_May_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<nmtc:NonCashInterestOnPrincipal contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">17887</nmtc:NonCashInterestOnPrincipal>
<nmtc:NonCashInterestOnPrincipal contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">54116</nmtc:NonCashInterestOnPrincipal>
<nmtc:VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="0">100000</nmtc:VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance>
<nmtc:ProceedsFromRepaymentsOfShortTermUnsecuredLoan contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-50000</nmtc:ProceedsFromRepaymentsOfShortTermUnsecuredLoan>
<nmtc:ProceedsFromRepaymentsOfShortTermUnsecuredLoan contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">115000</nmtc:ProceedsFromRepaymentsOfShortTermUnsecuredLoan>
<nmtc:ProceedsAndValueAssignedToWarrants contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">182693</nmtc:ProceedsAndValueAssignedToWarrants>
<nmtc:ProceedsAndValueAssignedToWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">376586</nmtc:ProceedsAndValueAssignedToWarrants>
<nmtc:FairValueAdjustmentOfPremiumConversionDerivative contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">183</nmtc:FairValueAdjustmentOfPremiumConversionDerivative>
<nmtc:FairValueAdjustmentOfPremiumConversionDerivative contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">466</nmtc:FairValueAdjustmentOfPremiumConversionDerivative>
<nmtc:FairValueAdjustmentOfPremiumConversionDerivative contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember" unitRef="USD" decimals="0">2666</nmtc:FairValueAdjustmentOfPremiumConversionDerivative>
<nmtc:FairValueAdjustmentOfPremiumConversionDerivative contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtOneMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">1323</nmtc:FairValueAdjustmentOfPremiumConversionDerivative>
<us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_NewWarrantsMember" unitRef="USD" decimals="0">5283</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
<nmtc:ValueOfPremiumConversionDerivative contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ExtinguishmentOfDebtAxis_PremiumConversionDerivativeMember" unitRef="USD" decimals="0">49668</nmtc:ValueOfPremiumConversionDerivative>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_2"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">Accrued expenses include an obligation to issue stock awards and stock options to consultants that have met vesting requirements as of March 31, 2018 in the amount of $254,437. See Note 10 Stock-Based Compensation for further detail.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nmtc-20180331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Wednesday, May 16, 2018 06:33:32 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ShortTermBorrowings" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" xlink:label="loc_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="30" use="optional" weight="1"/></calculationLink>





<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InterestIncomeExpenseNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xlink:label="loc_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="40" use="optional" weight="1"/></calculationLink>

<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentForAmortization" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NonCashInterestOnPrincipal" xlink:label="loc_nmtc_NonCashInterestOnPrincipal"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_NonCashInterestOnPrincipal" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_nmtc_RevaluationOfWarrantLiability"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_RevaluationOfWarrantLiability" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="100" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xlink:label="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" xlink:label="loc_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_us-gaap_PaymentsOfLoanCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfLoanCosts" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="50" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="20" use="optional" weight="1"/></calculationLink>


<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#AccruedExpensesDetails" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_nmtc_AccruedLicenseFees"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedLicenseFees" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_nmtc_AccruedIssuanceCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedIssuanceCosts" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedPayroll" xlink:label="loc_nmtc_AccruedPayroll"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedPayroll" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedExpensesAdvances" xlink:label="loc_nmtc_AccruedExpensesAdvances"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedExpensesAdvances" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent" order="60" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>nmtc-20180331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Wednesday, May 16, 2018 06:33:32 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_DocumentAndEntityInformationAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_DocumentAndEntityInformationAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_3I1H7G53JI2G91JG311H_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_dei_EntityRegistrantName" xlink:to="lab_5K3J9I75LK4I13LI533J_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_IJ5F5144KJKG_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_dei_EntityCentralIndexKey" xlink:to="lab_KL7H7366MLMI_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_3I1H7G53JI2G91JG311H_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_dei_AmendmentFlag" xlink:to="lab_5K3J9I75LK4I13LI533J_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_IJ5F5144KJKG_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_dei_TradingSymbol" xlink:to="lab_KL7H7366MLMI_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_3I1H7G53JI2G91JG311H_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_dei_CurrentFiscalYearEndDate" xlink:to="lab_5K3J9I75LK4I13LI533J_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_IJ5F5144KJKG_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_dei_DocumentType" xlink:to="lab_KL7H7366MLMI_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_3I1H7G53JI2G91JG311H_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_dei_DocumentPeriodEndDate" xlink:to="lab_5K3J9I75LK4I13LI533J_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_IJ5F5144KJKG_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_dei_DocumentFiscalYearFocus" xlink:to="lab_KL7H7366MLMI_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_3I1H7G53JI2G91JG311H_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_dei_DocumentFiscalPeriodFocus" xlink:to="lab_5K3J9I75LK4I13LI533J_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_IJ5F5144KJKG_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_dei_EntityFilerCategory" xlink:to="lab_KL7H7366MLMI_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_3I1H7G53JI2G91JG311H_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_5K3J9I75LK4I13LI533J_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Balance Sheets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AssetsAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AssetsCurrentAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_Cash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_Cash" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_Cash" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_Cash" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_Cash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_IJ5F5144KJKG_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_KL7H7366MLMI_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AssetsCurrent" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_IJ5F5144KJKG_us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_KL7H7366MLMI_us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_Assets" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_IJ5F5144KJKG_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_KL7H7366MLMI_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ShortTermBorrowings"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term promissory notes and unsecured loan, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ShortTermBorrowings" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ShortTermBorrowings"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" xlink:label="loc_IJ5F5144KJKG_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" xml:lang="en-US">Convertible Promissory Notes Net And Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" xml:lang="en-US">Convertible promissory notes, net and accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" xml:lang="en-US">Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable and accrued interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" xlink:to="lab_KL7H7366MLMI_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentUnamortizedPremiumCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Balance as of end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium conversion derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedPremiumCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_IJ5F5144KJKG_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_LiabilitiesCurrent" xlink:to="lab_KL7H7366MLMI_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_WarrantsAndRightsOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Balance as of end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantsAndRightsOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_IJ5F5144KJKG_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_Liabilities" xlink:to="lab_KL7H7366MLMI_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 4)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_CommitmentsAndContingencies" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_StockholdersEquityAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2018 and December 31, 2017; no shares issued or outstanding as of March 31, 2018 and December 31, 2017.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_PreferredStockValue" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_IJ5F5144KJKG_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2018 and December 31, 2017; and 7,864,994 shares issued and outstanding as of March 31, 2018 and December 31, 2017.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_CommonStockValue" xlink:to="lab_KL7H7366MLMI_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AdditionalPaidInCapital" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_IJ5F5144KJKG_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_KL7H7366MLMI_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_StockholdersEquity" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_IJ5F5144KJKG_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_KL7H7366MLMI_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_IJ5F5144KJKG_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_KL7H7366MLMI_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_PreferredStockSharesIssued" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_IJ5F5144KJKG_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_KL7H7366MLMI_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_IJ5F5144KJKG_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_KL7H7366MLMI_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_CommonStockSharesIssued" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_IJ5F5144KJKG_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balances (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balances (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_KL7H7366MLMI_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Statements of Operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_IncomeStatementAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_OperatingExpensesAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_IJ5F5144KJKG_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_KL7H7366MLMI_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_OperatingExpenses" xml:lang="en-US">Operations expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_OperatingExpenses" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_IJ5F5144KJKG_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income (Loss) from Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_OperatingIncomeLoss" xlink:to="lab_KL7H7366MLMI_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_InterestIncomeExpenseNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_InterestIncomeExpenseNet"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xlink:label="loc_IJ5F5144KJKG_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xml:lang="en-US">Net Change In Fair Value Of Warrant Liability And Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xml:lang="en-US">Net change in fair value for the warrant liability and premium conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xml:lang="en-US">Net change in fair value for the warrant liability and premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xlink:to="lab_KL7H7366MLMI_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on convertible note extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on convertible note extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on short-term notes extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Recognition of gain on convertible note extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on convertible notes extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on convertibles notes extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on short-term notes extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on convertible notes extinguishment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_IJ5F5144KJKG_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KL7H7366MLMI_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_NetIncomeLoss" xlink:to="lab_KL7H7366MLMI_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net loss per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_IJ5F5144KJKG_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_KL7H7366MLMI_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Number of shares used in per share calculations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_IJ5F5144KJKG_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_KL7H7366MLMI_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Cash Flows:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_IJ5F5144KJKG_us-gaap_AdjustmentForAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AdjustmentForAmortization" xlink:to="lab_KL7H7366MLMI_us-gaap_AdjustmentForAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based services expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensation" xml:lang="en-US">Obligation to issue stock awards and stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensation" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NonCashInterestOnPrincipal" xlink:label="loc_IJ5F5144KJKG_nmtc_NonCashInterestOnPrincipal"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_NonCashInterestOnPrincipal" xml:lang="en-US">Non Cash Interest On Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_NonCashInterestOnPrincipal" xml:lang="en-US">Non-cash interest or non-cash interest on principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_NonCashInterestOnPrincipal" xml:lang="en-US">Non cash interest or non cash interest on principal.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_NonCashInterestOnPrincipal" xlink:to="lab_KL7H7366MLMI_nmtc_NonCashInterestOnPrincipal"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AmortizationOfDebtDiscountPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Discount to convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Non-cash discount amortization on convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Non-cash discount amortization on short-term promissory notes and convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_IJ5F5144KJKG_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Note issuance costs attributed to warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_KL7H7366MLMI_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_RevaluationOfPremiumDebtConversionDerivative"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation Of Premium Debt Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation of premium conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation of premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation of premium debt conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_RevaluationOfPremiumDebtConversionDerivative"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_IJ5F5144KJKG_nmtc_RevaluationOfWarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Gain on convertible note extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_KL7H7366MLMI_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation of warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_RevaluationOfWarrantLiability" xlink:to="lab_KL7H7366MLMI_nmtc_RevaluationOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Change in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_IJ5F5144KJKG_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_KL7H7366MLMI_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_IJ5F5144KJKG_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_KL7H7366MLMI_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_IJ5F5144KJKG_us-gaap_ProceedsFromConvertibleDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of warrants associated with convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_KL7H7366MLMI_us-gaap_ProceedsFromConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xml:lang="en-US">Proceeds From Issuance Of Warrants Associated With Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xml:lang="en-US">Proceeds from issuance of warrants associated with short-term and convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xml:lang="en-US">The cash inflow from issuance of warrants associated with convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" xlink:label="loc_IJ5F5144KJKG_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" xml:lang="en-US">Proceeds From Repayments Of Short Term Unsecured Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" xml:lang="en-US">(Repayment) proceeds from short term unsecured loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" xml:lang="en-US">Proceeds from repayments of short term unsecured loan.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" xml:lang="en-US">(Repayment) proceeds from short term unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" xlink:to="lab_KL7H7366MLMI_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_PaymentsOfLoanCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PaymentsOfLoanCosts" xml:lang="en-US">Payments of Loan Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PaymentsOfLoanCosts" xml:lang="en-US">Issuance costs related to convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_PaymentsOfLoanCosts" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_PaymentsOfLoanCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_IJ5F5144KJKG_us-gaap_PaymentsOfStockIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Issuance costs related to warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Issuance costs related to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_KL7H7366MLMI_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_IJ5F5144KJKG_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net decrease in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_KL7H7366MLMI_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental non-cash financing and investing transactions:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_IJ5F5144KJKG_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Conversion Derivative Related To Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Bifurcation of premium conversion derivative related to convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Bifurcation of premium conversion derivative related to convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:to="lab_KL7H7366MLMI_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued Issuance Costs Attributed To Short Term Promissory Notes And Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued issuance costs attributed to convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued issuance costs attributed to short term promissory notes and convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:label="loc_IJ5F5144KJKG_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued Issuance Costs Attributed To Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued issuance costs attributed to warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued issuance costs attributed to warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:to="lab_KL7H7366MLMI_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization and Basis of Presentation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Operations and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_GoingConcernAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_GoingConcernAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_GoingConcernAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Intangibles [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_IntangibleAssetsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_IntangibleAssetsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_PayablesAndAccrualsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Accrued Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_PayablesAndAccrualsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loan\Convertible Promissory Notes and Warrant Agreements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Description of convertible notes issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtDisclosureAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_ShortTermDebtTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ShortTermDebtTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_ShortTermDebtTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_InvestmentBankerFeeAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_InvestmentBankerFeeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_InvestmentBankerFeeAbstract" xml:lang="en-US">Investment Banker Fee [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_InvestmentBankerFeeAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_InvestmentBankerFeeAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_InvestmentBankerFeeTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_InvestmentBankerFeeTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_InvestmentBankerFeeTextBlock" xml:lang="en-US">Investment Banker Fee [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_InvestmentBankerFeeTextBlock" xml:lang="en-US">Investment Banker Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_InvestmentBankerFeeTextBlock" xml:lang="en-US">The entire disclosure for investment banker fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_InvestmentBankerFeeTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_InvestmentBankerFeeTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Stock-Based Compensation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_StockholdersEquityNoteAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Deficit [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_IJ5F5144KJKG_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_SubsequentEventsAbstract" xlink:to="lab_KL7H7366MLMI_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_IJ5F5144KJKG_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_UseOfEstimates" xml:lang="en-US">Management's Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_UseOfEstimates" xlink:to="lab_KL7H7366MLMI_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ConcentrationRiskCreditRisk"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ConcentrationRiskCreditRisk"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_IntellectualPropertyPolicyTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_IntellectualPropertyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Intellectual Property [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Intellectual Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy fori ntellectual property.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_IntellectualPropertyPolicyTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_IntellectualPropertyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtPolicyTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_IJ5F5144KJKG_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_KL7H7366MLMI_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantLiabilityPolicyTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_WarrantLiabilityPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Warrant Liability [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_WarrantLiabilityPolicyTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_WarrantLiabilityPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:label="loc_IJ5F5144KJKG_nmtc_PremiumDebtConversionDerivativePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Premium Debt Conversion Derivative [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Premium Debt Conversion Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for premium debt conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:to="lab_KL7H7366MLMI_nmtc_PremiumDebtConversionDerivativePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_IJ5F5144KJKG_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_KL7H7366MLMI_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueInputsLevel3Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_IJ5F5144KJKG_us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DefinedBenefitPlanDisclosureLineItems" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_KL7H7366MLMI_us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of fair value of financial instruments measured on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of warrant liability and premium conversion derivative measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of computation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_ConvertibleDebtTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Schedule of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_IJ5F5144KJKG_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of weighted-average assumptions used Black-Scholes option-pricing model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_KL7H7366MLMI_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_IJ5F5144KJKG_us-gaap_ConsolidatedEntitiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ConsolidatedEntitiesAxis" xlink:to="lab_KL7H7366MLMI_us-gaap_ConsolidatedEntitiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ConsolidatedEntitiesDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ConsolidatedEntitiesDomain" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ConsolidatedEntitiesDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_SubsidiariesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_SubsidiariesMember" xml:lang="en-US">Subsidiaries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_SubsidiariesMember" xml:lang="en-US">NeuroOne, Inc. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_SubsidiariesMember" xml:lang="en-US">NeuroOne, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_SubsidiariesMember" xlink:to="lab_KL7H7366MLMI_us-gaap_SubsidiariesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_BusinessAcquisitionLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_OrganizationAndBasisOfPresentationTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xml:lang="en-US">Organization And Basis Of Presentation Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xml:lang="en-US">Organization and Basis of Presentation (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_OrganizationAndBasisOfPresentationTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Common stock, ownership percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Common stock, ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_IJ5F5144KJKG_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xml:lang="en-US">Business Acquisition, Description of Acquired Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xml:lang="en-US">Description of acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="lab_KL7H7366MLMI_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ConversionOfStockDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConversionOfStockDescription" xml:lang="en-US">Conversion of Stock, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConversionOfStockDescription" xml:lang="en-US">Conversation of stock, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ConversionOfStockDescription" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ConversionOfStockDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_IJ5F5144KJKG_us-gaap_BusinessAcquisitionSharePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Par value of outstanding shares of common stock of NeuroOne</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_KL7H7366MLMI_us-gaap_BusinessAcquisitionSharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_SharesIssuedPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Par value of company's common stock issued in lieu of exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_IJ5F5144KJKG_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Common shares exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_KL7H7366MLMI_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Aggregate shares issued of the then-outstanding NeuroOne shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Aggregate of outstanding NeuroOne shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_IJ5F5144KJKG_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Reserved shares of common stock for issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Reserved for future issuance shares exercise of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Restricted common stock not yet issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_KL7H7366MLMI_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Tendered for cancellation of shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Tendered for cancellation of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_GoingConcernTextualAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_GoingConcernTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_GoingConcernTextualAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_GoingConcernTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_UnsecuredDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_UnsecuredDebt" xml:lang="en-US">Unsecured Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_UnsecuredDebt" xml:lang="en-US">Unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_UnsecuredDebt" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_UnsecuredDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_IJ5F5144KJKG_us-gaap_ShortTermBankLoansAndNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ShortTermBankLoansAndNotesPayable" xml:lang="en-US">Short-term Bank Loans and Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ShortTermBankLoansAndNotesPayable" xml:lang="en-US">Short-term promissory note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="lab_KL7H7366MLMI_us-gaap_ShortTermBankLoansAndNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ConvertibleNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible promissory note financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible notes and common stock purchase warrants to investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Balance as of end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Aggregate principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ConvertibleNotesPayable" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayable"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleNotesPayableOne" xlink:label="loc_IJ5F5144KJKG_nmtc_ConvertibleNotesPayableOne"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertibleNotesPayableOne" xml:lang="en-US">Convertible Notes Payable One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertibleNotesPayableOne" xml:lang="en-US">Second convertible promissory note financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertibleNotesPayableOne" xml:lang="en-US">Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ConvertibleNotesPayableOne" xlink:to="lab_KL7H7366MLMI_nmtc_ConvertibleNotesPayableOne"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNote" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_SubscriptionAmountToConvertiblePromissoryNote"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_SubscriptionAmountToConvertiblePromissoryNote" xml:lang="en-US">Subscription Amount To Convertible Promissory Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_SubscriptionAmountToConvertiblePromissoryNote" xml:lang="en-US">Subscription Agreement Limit 2016 Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_SubscriptionAmountToConvertiblePromissoryNote" xml:lang="en-US">Amount of subscription to convertible promissory note.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_SubscriptionAmountToConvertiblePromissoryNote" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_SubscriptionAmountToConvertiblePromissoryNote"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xlink:label="loc_IJ5F5144KJKG_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xml:lang="en-US">Subscription Amount To Convertible Promissory Note One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xml:lang="en-US">Subscription Agreement Limit 2017 Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xml:lang="en-US">Amount of subscription to convertible promissory note one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xlink:to="lab_KL7H7366MLMI_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueInputsLevel1Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueInputsLevel2Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantLiability" xlink:label="loc_IJ5F5144KJKG_nmtc_WarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantLiability" xml:lang="en-US">Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantLiability" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantLiability" xml:lang="en-US">Warant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_WarrantLiability" xlink:to="lab_KL7H7366MLMI_nmtc_WarrantLiability"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumConversionDerivative" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_PremiumConversionDerivative"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_PremiumConversionDerivative" xml:lang="en-US">Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_PremiumConversionDerivative" xml:lang="en-US">Premium conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_PremiumConversionDerivative" xml:lang="en-US">Premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_PremiumConversionDerivative" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_PremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_IJ5F5144KJKG_us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_KL7H7366MLMI_us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_IJ5F5144KJKG_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_EquityComponentDomain" xlink:to="lab_KL7H7366MLMI_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_WarrantMember" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_ScheduleOfWarrantLiabilityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ScheduleOfWarrantLiabilityAbstract" xml:lang="en-US">Schedule Of Warrant Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ScheduleOfWarrantLiabilityAbstract" xml:lang="en-US">Schedule of warrant liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_ScheduleOfWarrantLiabilityAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsAndValueAssignedToWarrants" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ProceedsAndValueAssignedToWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Proceeds And Value Assigned To Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Value assigned to warrants in connection with convertible promissory and short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Proceeds and value assigned to warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Value assigned to warrants in connection with convertible promissory and short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsAndValueAssignedToWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ProceedsAndValueAssignedToWarrants" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ProceedsAndValueAssignedToWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueAdjustmentOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value changes of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability and derecognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Aggregate fair value attributed to the warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value changes of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentNameDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_DebtConversionDerivativeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Debt Conversion Derivative [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Premium debt conversion derivative [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Debt Conversion Derivative [Member].</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Premium debt conversion derivative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_DebtConversionDerivativeMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_DebtConversionDerivativeMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_ScheduleOfPremiumConversionDerivativeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xml:lang="en-US">Schedule Of Premium Conversion Derivative [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xml:lang="en-US">Schedule of Premium debt conversion derivative [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_ScheduleOfPremiumConversionDerivativeAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value Assigned To Underlying Derivative In Connection With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value assigned to the underlying derivative in connection with convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xlink:label="loc_IJ5F5144KJKG_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xml:lang="en-US">Change In Fair Value Of Premium Debt Conversion Derivative And Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xml:lang="en-US">Change in fair value of premium debt conversion derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xml:lang="en-US">Change in fair value of premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xlink:to="lab_KL7H7366MLMI_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_IJ5F5144KJKG_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_KL7H7366MLMI_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_EmployeeStockOptionMember" xlink:to="lab_KL7H7366MLMI_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_IJ5F5144KJKG_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Anti-dilutive computation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_KL7H7366MLMI_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueByAssetClassAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueByAssetClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_FiniteLivedIntangibleAssetsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsMember" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsMember" xml:lang="en-US">Intangible Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_RangeAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_RangeMember" xlink:to="lab_KL7H7366MLMI_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_MinimumMember" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_MaximumMember" xlink:to="lab_KL7H7366MLMI_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_IJ5F5144KJKG_us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsRollForward" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsRollForward" xml:lang="en-US">Schedule of Intangible Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">License agreement Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_IJ5F5144KJKG_us-gaap_FiniteLivedIntangibleAssetsNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net Intangibles, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net Intangibles, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_KL7H7366MLMI_us-gaap_FiniteLivedIntangibleAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AmortizationOfIntangibleAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Less: amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_GoodwilAndIntangibleAssetsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Goodwil And Intangible Assets Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Intangibles (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Goodwil And Intangible Assets Textual [Abstract].</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_GoodwilAndIntangibleAssetsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedLicenseFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued license fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued License Fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedLicenseFees" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedLicenseFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_IJ5F5144KJKG_us-gaap_AccruedProfessionalFeesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_KL7H7366MLMI_us-gaap_AccruedProfessionalFeesCurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued Issuance Costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedIssuanceCosts" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedPayroll" xlink:label="loc_IJ5F5144KJKG_nmtc_AccruedPayroll"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_AccruedPayroll" xml:lang="en-US">Accrued Payroll</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_AccruedPayroll" xml:lang="en-US">Accrued payroll</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_AccruedPayroll" xml:lang="en-US">Accrued compensation and payroll related costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_AccruedPayroll" xml:lang="en-US">Accrued payroll.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_AccruedPayroll" xlink:to="lab_KL7H7366MLMI_nmtc_AccruedPayroll"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedExpensesAdvances" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedExpensesAdvances"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedExpensesAdvances" xml:lang="en-US">Accrued Expenses Advances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedExpensesAdvances" xml:lang="en-US">Advances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedExpensesAdvances" xml:lang="en-US">Accrued Expenses Advances.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedExpensesAdvances" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedExpensesAdvances"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_IJ5F5144KJKG_us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_OtherAccruedLiabilitiesNoncurrent" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_OtherAccruedLiabilitiesNoncurrent" xml:lang="en-US">Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KL7H7366MLMI_us-gaap_OtherAccruedLiabilitiesNoncurrent" xml:lang="en-US">Accrued expenses include an obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="lab_KL7H7366MLMI_us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedExpensesTextualAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedExpensesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedExpensesTextualAbstract" xml:lang="en-US">Accrued Expenses Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedExpensesTextualAbstract" xml:lang="en-US">Accrued Expenses (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AccruedExpensesTextualAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AccruedExpensesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_IJ5F5144KJKG_us-gaap_ScheduleOfShortTermDebtTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_KL7H7366MLMI_us-gaap_ScheduleOfShortTermDebtTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ExtinguishmentOfDebtAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ExtinguishmentOfDebtAxis" xml:lang="en-US">Extinguishment of Debt [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ExtinguishmentOfDebtAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ExtinguishmentOfDebtAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_IJ5F5144KJKG_us-gaap_ExtinguishmentOfDebtTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ExtinguishmentOfDebtTypeDomain" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="lab_KL7H7366MLMI_us-gaap_ExtinguishmentOfDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ShortTermDebtMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShortTermDebtMember" xml:lang="en-US">Short-term Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShortTermDebtMember" xml:lang="en-US">Short-Term Promissory Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ShortTermDebtMember" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ShortTermDebtMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumConversionDerivativeMember" xlink:label="loc_IJ5F5144KJKG_nmtc_PremiumConversionDerivativeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_PremiumConversionDerivativeMember" xml:lang="en-US">Premium Conversion Derivative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_PremiumConversionDerivativeMember" xlink:to="lab_KL7H7366MLMI_nmtc_PremiumConversionDerivativeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_LongtermDebtTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_LongtermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_IJ5F5144KJKG_us-gaap_LongtermDebtTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_KL7H7366MLMI_us-gaap_LongtermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_UnsecuredDebtMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_UnsecuredDebtMember" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_UnsecuredDebtMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_IJ5F5144KJKG_us-gaap_ShortTermDebtLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ShortTermDebtLineItems" xlink:to="lab_KL7H7366MLMI_us-gaap_ShortTermDebtLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xml:lang="en-US">Short Term Promissory Notes And Unsecured Loan Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loan (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_IJ5F5144KJKG_us-gaap_ProceedsFromShortTermDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Aggregate gross proceeds of short-term unsecured promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from issuance of short-term promissory notes and convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_KL7H7366MLMI_us-gaap_ProceedsFromShortTermDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Issuance costs discounted of short-term unsecured promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentMaturityDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Short-term unsecured promissory notes maturity date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Repay principal and accrued and unpaid interest earlier</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentMaturityDate"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_CommonStockPurchaseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common Stock Purchase Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common stock purchase of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_CommonStockPurchaseOfWarrants" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_CommonStockPurchaseOfWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_IJ5F5144KJKG_nmtc_WarrantsMaturityTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants Maturity Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants maturity term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrant term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants maturity term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_WarrantsMaturityTerm" xlink:to="lab_KL7H7366MLMI_nmtc_WarrantsMaturityTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_IJ5F5144KJKG_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Initial warrant liability changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KL7H7366MLMI_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Aggregate fair value to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_KL7H7366MLMI_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ValueOfPremiumConversionDerivative" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ValueOfPremiumConversionDerivative"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ValueOfPremiumConversionDerivative" xml:lang="en-US">Value Of Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ValueOfPremiumConversionDerivative" xml:lang="en-US">Value of premium conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ValueOfPremiumConversionDerivative" xml:lang="en-US">Value of premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ValueOfPremiumConversionDerivative" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ValueOfPremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair value of warrants risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair value of warrants expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_IJ5F5144KJKG_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair value of warrants expected life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_KL7H7366MLMI_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair value of warrants expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_IJ5F5144KJKG_us-gaap_UnsecuredDebtCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_UnsecuredDebtCurrent" xml:lang="en-US">Unsecured Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_UnsecuredDebtCurrent" xml:lang="en-US">Short-term unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_UnsecuredDebtCurrent" xlink:to="lab_KL7H7366MLMI_us-gaap_UnsecuredDebtCurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalWarrantsAllocated" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AdditionalWarrantsAllocated"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AdditionalWarrantsAllocated" xml:lang="en-US">Additional Warrants Allocated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AdditionalWarrantsAllocated" xml:lang="en-US">Additional warrants allocated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AdditionalWarrantsAllocated" xml:lang="en-US">Additional warrants allocated additional coverage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AdditionalWarrantsAllocated" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AdditionalWarrantsAllocated"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsExpirationDate" xlink:label="loc_IJ5F5144KJKG_nmtc_WarrantsExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantsExpirationDate" xml:lang="en-US">Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantsExpirationDate" xml:lang="en-US">Warrants expiration date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_WarrantsExpirationDate" xml:lang="en-US">Warrants expiration date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_WarrantsExpirationDate" xlink:to="lab_KL7H7366MLMI_nmtc_WarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_LossOnShortTermNotesExtinguishment" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_LossOnShortTermNotesExtinguishment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_LossOnShortTermNotesExtinguishment" xml:lang="en-US">Loss On Short Term Notes Extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_LossOnShortTermNotesExtinguishment" xml:lang="en-US">Loss on short-term notes extinguishment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_LossOnShortTermNotesExtinguishment" xml:lang="en-US">Difference between the face value of the short-term notes over the combined carrying values of the short-term notes and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_LossOnShortTermNotesExtinguishment" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_LossOnShortTermNotesExtinguishment"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xlink:label="loc_IJ5F5144KJKG_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xml:lang="en-US">Fair Value Adjustment Of Short Term Notes And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xml:lang="en-US">Fair value decrease of short-term notes and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of short term notes and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xlink:to="lab_KL7H7366MLMI_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Convertible notes bear interest at fixed rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Percentage of convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Outstanding principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ShortTermNoteQualifiedFinancingDescription" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ShortTermNoteQualifiedFinancingDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ShortTermNoteQualifiedFinancingDescription" xml:lang="en-US">Short Term Note Qualified Financing, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ShortTermNoteQualifiedFinancingDescription" xml:lang="en-US">Shor-term note qualified financing, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ShortTermNoteQualifiedFinancingDescription" xml:lang="en-US">Description of short-term note qualified financing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ShortTermNoteQualifiedFinancingDescription" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ShortTermNoteQualifiedFinancingDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtConversionDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtConversionDescription" xml:lang="en-US">Debt Conversion, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtConversionDescription" xml:lang="en-US">Short-term notes conversion, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtConversionDescription" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtConversionDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ProceedsFromIssuanceOfDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Cash gross proceeds from an unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_IJ5F5144KJKG_us-gaap_ShortTermDebtTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_KL7H7366MLMI_us-gaap_ShortTermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ShortTermDebtTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ShortTermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_ConvertibleDebtMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtMember" xml:lang="en-US">2016 convertible promissory notes, net of discounts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ConvertibleDebtMember" xlink:to="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNoteMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertiblePromissoryNoteMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNoteMember" xml:lang="en-US">Convertible Promissory Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNoteMember" xml:lang="en-US">2017 convertible promissory notes, net of discounts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertiblePromissoryNoteMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNoteMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_IJ5F5144KJKG_us-gaap_FinancialInstrumentAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_FinancialInstrumentAxis" xlink:to="lab_KL7H7366MLMI_us-gaap_FinancialInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_AccruedLiabilitiesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AccruedLiabilitiesMember" xml:lang="en-US">Accrued Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AccruedLiabilitiesMember" xml:lang="en-US">Accrued interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_KL7H7366MLMI_us-gaap_AccruedLiabilitiesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ConvertibleNotesPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes and warrant agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ConvertibleNotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentTable" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentTable"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubscriptionAgreementMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_SubscriptionAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_SubscriptionAgreementMember" xml:lang="en-US">Subscription Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_SubscriptionAgreementMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_SubscriptionAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NovemberTwoThousandSeventeenMember" xlink:label="loc_IJ5F5144KJKG_nmtc_NovemberTwoThousandSeventeenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_NovemberTwoThousandSeventeenMember" xml:lang="en-US">November Two Thousand Seventeen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_NovemberTwoThousandSeventeenMember" xml:lang="en-US">November 2017 amendment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_NovemberTwoThousandSeventeenMember" xlink:to="lab_KL7H7366MLMI_nmtc_NovemberTwoThousandSeventeenMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xml:lang="en-US">Two Zero One Seven Convertible Note Amendment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xml:lang="en-US">2017 Convertible Note amendment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_ConvertibleNotesPayableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">2016 Convertible Promissory Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Promissory Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_KL7H7366MLMI_us-gaap_ConvertibleNotesPayableMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleDebtOneMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertibleDebtOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleDebtOneMember" xml:lang="en-US">Convertible Debt One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleDebtOneMember" xml:lang="en-US">2017 Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleDebtOneMember" xml:lang="en-US">2017 Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleDebtOneMember" xml:lang="en-US">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertibleDebtOneMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleDebtOneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_IJ5F5144KJKG_us-gaap_SubsidiarySaleOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_KL7H7366MLMI_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_PrivatePlacementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private placement agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_PrivatePlacementMember" xlink:to="lab_KL7H7366MLMI_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NewWarrantsMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_NewWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_NewWarrantsMember" xml:lang="en-US">New Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_NewWarrantsMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_NewWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentLineItems" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xml:lang="en-US">Convertible Promissory Notes And Warrant Agreements Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_IJ5F5144KJKG_us-gaap_ConvertibleDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleDebt" xml:lang="en-US">Subscription Agreement Limit 2016 Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ConvertibleDebt" xlink:to="lab_KL7H7366MLMI_us-gaap_ConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Exchange for the issuance of company shares acquisition percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of outstanding voting power</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentFaceAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Issuance of Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Qualified financing that tirggers note conversion amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentMaturityDateDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Maturity date, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentMaturityDateDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_IJ5F5144KJKG_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Gross proceeds of equity qualified financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_KL7H7366MLMI_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentInterestRateTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Debt Instrument, Interest Rate Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Description of outstanding principal and accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentInterestRateTerms" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentInterestRateTerms"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_IJ5F5144KJKG_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description Of Maximum Voting Power Of Surviving Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description of maximum voting power of surviving entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description of maximum voting power of surviving entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:to="lab_KL7H7366MLMI_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount Of Convertible Note Held By Warrant Holder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount of convertible note held by warrant holder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount of convertible note held by warrant holder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_IJ5F5144KJKG_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Warrants exercisable date of issuance and expire</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="lab_KL7H7366MLMI_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible Promissory Note Proceeds Assigned To Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible promissory note proceeds assigned to warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible promissory note proceeds assigned to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_IJ5F5144KJKG_us-gaap_AmortizationOfFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Non-cash interest or non-cash interest on principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_KL7H7366MLMI_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_InterestExpense" xml:lang="en-US">Convertible notes to interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_InterestExpense" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtConversionConvertedInstrumentRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtConversionConvertedInstrumentRate" xml:lang="en-US">Debt Conversion, Converted Instrument, Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtConversionConvertedInstrumentRate" xml:lang="en-US">Convertible notes conversion premium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtConversionConvertedInstrumentRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Convertible notes conversion price per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Cost of issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible Notes Of Conversion Premium Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible notes of conversion premium amortization expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible notes of conversion premium amortization expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_IJ5F5144KJKG_nmtc_PremiumDebtConversionDerivativeInterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium Debt Conversion Derivative Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium debt conversion derivative interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium debt conversion derivative interest expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:to="lab_KL7H7366MLMI_nmtc_PremiumDebtConversionDerivativeInterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DeferredFinanceCostsNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Convertible notes incurred issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DeferredFinanceCostsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentFee" xml:lang="en-US">Debt Instrument, Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentFee" xml:lang="en-US">Description of convertible notes issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentFee" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentFee"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsToPurchaseSharesOfCommonStock" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_WarrantsToPurchaseSharesOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_WarrantsToPurchaseSharesOfCommonStock" xml:lang="en-US">Warrants To Purchase Shares Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_WarrantsToPurchaseSharesOfCommonStock" xml:lang="en-US">Common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_WarrantsToPurchaseSharesOfCommonStock" xml:lang="en-US">Warrants to purchase shares of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_WarrantsToPurchaseSharesOfCommonStock" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_WarrantsToPurchaseSharesOfCommonStock"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_IJ5F5144KJKG_nmtc_PercentageOfCommonStockPurchaseWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage Of Common Stock Purchase Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage of common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage of common stock purchase warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:to="lab_KL7H7366MLMI_nmtc_PercentageOfCommonStockPurchaseWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance Costs Attributed To Common Stock Purchase Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance costs attributed to common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance costs attributed to common stock purchase warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_IJ5F5144KJKG_us-gaap_ConvertibleDebtFairValueDisclosures"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Fair value of the amended convertible notes carrying value at time of the amendment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_KL7H7366MLMI_us-gaap_ConvertibleDebtFairValueDisclosures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt issuance cost discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleNotesMaximumExtensionLimit" xlink:label="loc_IJ5F5144KJKG_nmtc_ConvertibleNotesMaximumExtensionLimit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertibleNotesMaximumExtensionLimit" xml:lang="en-US">Convertible Notes Maximum Extension Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertibleNotesMaximumExtensionLimit" xml:lang="en-US">Convertible notes maximum extension limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertibleNotesMaximumExtensionLimit" xml:lang="en-US">Convertible notes maximum extension limit.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_KL7H7366MLMI_nmtc_ConvertibleNotesMaximumExtensionLimit" xml:lang="en-US">Subscription Agreement Limit 2017 Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ConvertibleNotesMaximumExtensionLimit" xlink:to="lab_KL7H7366MLMI_nmtc_ConvertibleNotesMaximumExtensionLimit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_LegalFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_LegalFees" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_LegalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Terms of Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xml:lang="en-US">Fair value of underlying Convertible Notes, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_FairValueAdjustmentOfPremiumConversionDerivative"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xml:lang="en-US">Fair Value Adjustment Of Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xml:lang="en-US">Fair value changes on premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xml:lang="en-US">Fair value adjustment of premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_FairValueAdjustmentOfPremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueChangesOfWarrantLiability" xlink:label="loc_IJ5F5144KJKG_nmtc_FairValueChangesOfWarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_FairValueChangesOfWarrantLiability" xml:lang="en-US">Fair Value Changes Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_FairValueChangesOfWarrantLiability" xml:lang="en-US">Fair value changes of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_FairValueChangesOfWarrantLiability" xml:lang="en-US">Fair value changes of warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_FairValueChangesOfWarrantLiability" xlink:to="lab_KL7H7366MLMI_nmtc_FairValueChangesOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_InvestmentBankerFeeTextualAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_InvestmentBankerFeeTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_InvestmentBankerFeeTextualAbstract" xml:lang="en-US">Investment Banker Fee Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_InvestmentBankerFeeTextualAbstract" xml:lang="en-US">Investment Banker Fee (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_InvestmentBankerFeeTextualAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_InvestmentBankerFeeTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NonRefundableFeeToInvestmentBanker" xlink:label="loc_IJ5F5144KJKG_nmtc_NonRefundableFeeToInvestmentBanker"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_NonRefundableFeeToInvestmentBanker" xml:lang="en-US">Non Refundable Fee To Investment Banker</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_NonRefundableFeeToInvestmentBanker" xml:lang="en-US">Non-refundable fee to investment banker</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_NonRefundableFeeToInvestmentBanker" xml:lang="en-US">The amount of non-refundable fee to investment banker.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_NonRefundableFeeToInvestmentBanker" xlink:to="lab_KL7H7366MLMI_nmtc_NonRefundableFeeToInvestmentBanker"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_IJ5F5144KJKG_us-gaap_IncomeStatementLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_KL7H7366MLMI_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_IncomeStatementLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_KL7H7366MLMI_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_IJ5F5144KJKG_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_KL7H7366MLMI_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_IJ5F5144KJKG_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_KL7H7366MLMI_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of options (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_IJ5F5144KJKG_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_KL7H7366MLMI_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_IJ5F5144KJKG_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_KL7H7366MLMI_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_PlanNameAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_IJ5F5144KJKG_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_PlanNameDomain" xlink:to="lab_KL7H7366MLMI_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_TwoThousandSixteenPlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_TwoThousandSixteenPlanMember" xml:lang="en-US">Two Thousand Sixteen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_TwoThousandSixteenPlanMember" xml:lang="en-US">2016 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_TwoThousandSixteenPlanMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_TwoThousandSixteenPlanMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_IJ5F5144KJKG_nmtc_TwoThousandSixteenAndSeventeenPlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xml:lang="en-US">Two Thousand Sixteen And Seventeen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xml:lang="en-US">2016 and 2017 Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:to="lab_KL7H7366MLMI_nmtc_TwoThousandSixteenAndSeventeenPlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_TitleOfIndividualAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_IJ5F5144KJKG_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_KL7H7366MLMI_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_EmployeesDirectorsAndConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees, directors, and consultants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_EmployeesDirectorsAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_IJ5F5144KJKG_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_AwardTypeAxis" xlink:to="lab_KL7H7366MLMI_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_IJ5F5144KJKG_us-gaap_RestrictedStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_RestrictedStockMember" xlink:to="lab_KL7H7366MLMI_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_StockBasedCompensationTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_StockBasedCompensationTextualAbstract" xml:lang="en-US">Stock Based Compensation Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_StockBasedCompensationTextualAbstract" xml:lang="en-US">Stock-Based Compensation (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_StockBasedCompensationTextualAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_StockBasedCompensationTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Stock options weighted average exercise price for shares of common stock granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_IJ5F5144KJKG_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Vested Restricted Common Stock Capital Shares Reserved For Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Restricted common stock not yet issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of vested restricted shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_KL7H7366MLMI_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueOfCommonStockPricePerShare" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_FairValueOfCommonStockPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_FairValueOfCommonStockPricePerShare" xml:lang="en-US">Fair Value Of Common Stock Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_FairValueOfCommonStockPricePerShare" xml:lang="en-US">Fair value of common stock price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_FairValueOfCommonStockPricePerShare" xml:lang="en-US">Fair value of common stock price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_FairValueOfCommonStockPricePerShare" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_FairValueOfCommonStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_IJ5F5144KJKG_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Description of founders' shares subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Stock award vesting and issued, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_KL7H7366MLMI_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_MonthlyCompensationAmount" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_MonthlyCompensationAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_MonthlyCompensationAmount" xml:lang="en-US">Monthly Compensation Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_MonthlyCompensationAmount" xml:lang="en-US">Monthly compensation amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_MonthlyCompensationAmount" xml:lang="en-US">Monthly compensation amount divided by the fair value of the underlying common stock on the award date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_MonthlyCompensationAmount" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_MonthlyCompensationAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_IJ5F5144KJKG_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xml:lang="en-US">Compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_KL7H7366MLMI_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_IncomeTaxesTextualAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_IncomeTaxesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_IncomeTaxesTextualAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_IncomeTaxesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_IJ5F5144KJKG_us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_KL7H7366MLMI_us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">U.S. federal corporate tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_IJ5F5144KJKG_us-gaap_ScheduleOfStockByClassTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_KL7H7366MLMI_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_IJ5F5144KJKG_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_KL7H7366MLMI_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Events [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventMember" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_IJ5F5144KJKG_us-gaap_ClassOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_ClassOfStockLineItems" xlink:to="lab_KL7H7366MLMI_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_StockholdersMemberDeficitTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_StockholdersMemberDeficitTextualAbstract" xml:lang="en-US">Stockholders Member Deficit Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_StockholdersMemberDeficitTextualAbstract" xml:lang="en-US">Stockholders' Deficit (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_StockholdersMemberDeficitTextualAbstract" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_StockholdersMemberDeficitTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_IJ5F5144KJKG_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Shares of restricted common stock vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Issuance of restricted stock award, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_KL7H7366MLMI_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventTable" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PlacementAgentMember" xlink:label="loc_IJ5F5144KJKG_nmtc_PlacementAgentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_PlacementAgentMember" xlink:to="lab_KL7H7366MLMI_nmtc_PlacementAgentMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AmendedAndRestatedShortTermNotesMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AmendedAndRestatedShortTermNotesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AmendedAndRestatedShortTermNotesMember" xml:lang="en-US">Amended And Restated Short Term Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AmendedAndRestatedShortTermNotesMember" xml:lang="en-US">Amended and Restated Short-Term Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AmendedAndRestatedShortTermNotesMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AmendedAndRestatedShortTermNotesMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ReplacementWarrantsMember" xlink:label="loc_IJ5F5144KJKG_nmtc_ReplacementWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_ReplacementWarrantsMember" xml:lang="en-US">Replacement Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_ReplacementWarrantsMember" xlink:to="lab_KL7H7366MLMI_nmtc_ReplacementWarrantsMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalWarrantsMember" xlink:label="loc_3I1H7G53JI2G91JG311H_nmtc_AdditionalWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_nmtc_AdditionalWarrantsMember" xml:lang="en-US">Additional Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_nmtc_AdditionalWarrantsMember" xlink:to="lab_5K3J9I75LK4I13LI533J_nmtc_AdditionalWarrantsMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember" xlink:label="loc_IJ5F5144KJKG_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember" xml:lang="en-US">Additional Two Thousand Seventeen Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember" xml:lang="en-US">Additional 2017 Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_KL7H7366MLMI_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember" xml:lang="en-US">Additional two thousand seventeen convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember" xlink:to="lab_KL7H7366MLMI_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_SubsequentEventLineItems" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_IJ5F5144KJKG_nmtc_SubsequentEventsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_nmtc_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_nmtc_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_nmtc_SubsequentEventsTextualAbstract" xlink:to="lab_KL7H7366MLMI_nmtc_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Common stock purchase warrants for aggregate gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of warrants associated with short-term notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">New warrants to investors for aggregate gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Debt Instrument, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_KL7H7366MLMI_us-gaap_DebtInstrumentDescription" xml:lang="en-US">An increase in maximum amount of aggregate, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_IJ5F5144KJKG_us-gaap_DebtInstrumentDescription" xlink:to="lab_KL7H7366MLMI_us-gaap_DebtInstrumentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_3I1H7G53JI2G91JG311H_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_5K3J9I75LK4I13LI533J_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Shares of common stock to an investor relations firm in consideration for consulting services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_3I1H7G53JI2G91JG311H_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_5K3J9I75LK4I13LI533J_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nmtc-20180331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Wednesday, May 16, 2018 06:33:32 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Organizationandbasisofpresentationdetails" roleURI="http://www.originalsourcemusic.com/role/Organizationandbasisofpresentationdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesDetails1" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesDetails2" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesDetails3" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#IntangiblesDetails" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ShortTermPromissoryNotesAndUnsecuredLoanDetails" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ConvertiblePromissoryNotesAndWarrantAgreementsDetails" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Stockbasedcompensationdetails" roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#StockBasedCompensationDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Stockholdersdeficitdetails" roleURI="http://www.originalsourcemusic.com/role/Stockholdersdeficitdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SubsequentEventsDetails" roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Organizationandbasisofpresentationdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xlink:label="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaap_ConversionOfStockDescription_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_ConversionOfStockDescription_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_11" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_12" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_13" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_14" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantLiability" xlink:label="loc_nmtc_WarrantLiability_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" xlink:to="loc_nmtc_WarrantLiability_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumConversionDerivative" xlink:label="loc_nmtc_PremiumConversionDerivative_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" xlink:to="loc_nmtc_PremiumConversionDerivative_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_10" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsAndValueAssignedToWarrants" xlink:label="loc_nmtc_ProceedsAndValueAssignedToWarrants_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_nmtc_ProceedsAndValueAssignedToWarrants_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_8" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_nmtc_DebtConversionDerivativeMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_nmtc_DebtConversionDerivativeMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xlink:label="loc_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition_8" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_12" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_us-gaap_ShortTermDebtMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumConversionDerivativeMember" xlink:label="loc_nmtc_PremiumConversionDerivativeMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_nmtc_PremiumConversionDerivativeMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7" xlink:to="loc_us-gaap_UnsecuredDebtMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_9" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_9" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_10" xlink:to="loc_us-gaap_SubsidiariesMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_nmtc_CommonStockPurchaseOfWarrants_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_nmtc_CommonStockPurchaseOfWarrants_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_nmtc_WarrantsMaturityTerm_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_19" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ValueOfPremiumConversionDerivative" xlink:label="loc_nmtc_ValueOfPremiumConversionDerivative_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_nmtc_ValueOfPremiumConversionDerivative_20" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_21" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_22" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_23" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_24" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaap_UnsecuredDebtCurrent_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_UnsecuredDebtCurrent_25" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalWarrantsAllocated" xlink:label="loc_nmtc_AdditionalWarrantsAllocated_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_nmtc_AdditionalWarrantsAllocated_26" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_27" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsExpirationDate" xlink:label="loc_nmtc_WarrantsExpirationDate_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_nmtc_WarrantsExpirationDate_28" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_LossOnShortTermNotesExtinguishment" xlink:label="loc_nmtc_LossOnShortTermNotesExtinguishment_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_nmtc_LossOnShortTermNotesExtinguishment_29" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xlink:label="loc_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants_30" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_32" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ShortTermNoteQualifiedFinancingDescription" xlink:label="loc_nmtc_ShortTermNoteQualifiedFinancingDescription_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_nmtc_ShortTermNoteQualifiedFinancingDescription_33" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_DebtConversionDescription_34" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_12" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_35" order="220" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_ConvertibleDebtMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNoteMember" xlink:label="loc_nmtc_ConvertiblePromissoryNoteMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_nmtc_ConvertiblePromissoryNoteMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_9" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubscriptionAgreementMember" xlink:label="loc_nmtc_SubscriptionAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_SubscriptionAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NovemberTwoThousandSeventeenMember" xlink:label="loc_nmtc_NovemberTwoThousandSeventeenMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_NovemberTwoThousandSeventeenMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xlink:label="loc_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleDebtOneMember" xlink:label="loc_nmtc_ConvertibleDebtOneMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_nmtc_ConvertibleDebtOneMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_us-gaap_PrivatePlacementMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NewWarrantsMember" xlink:label="loc_nmtc_NewWarrantsMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_nmtc_NewWarrantsMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ConvertibleDebt_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ConvertibleNotesPayable_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_21" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_22" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_23" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_24" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_25" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_26" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_27" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_28" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_29" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_30" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_31" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_32" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_33" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_34" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_InterestExpense_35" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_36" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_37" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_38" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_39" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_40" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_41" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_42" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_us-gaap_DebtInstrumentFee_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentFee_43" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_WarrantsMaturityTerm_44" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsToPurchaseSharesOfCommonStock" xlink:label="loc_nmtc_WarrantsToPurchaseSharesOfCommonStock_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_WarrantsToPurchaseSharesOfCommonStock_45" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_46" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_47" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_48" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_49" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleNotesMaximumExtensionLimit" xlink:label="loc_nmtc_ConvertibleNotesMaximumExtensionLimit_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_ConvertibleNotesMaximumExtensionLimit_50" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_LegalFees_51" order="350" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52" order="360" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_53" order="370" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_54" order="380" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_55" order="390" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xlink:label="loc_nmtc_FairValueAdjustmentOfPremiumConversionDerivative_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_FairValueAdjustmentOfPremiumConversionDerivative_56" order="400" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueChangesOfWarrantLiability" xlink:label="loc_nmtc_FairValueChangesOfWarrantLiability_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_15" xlink:to="loc_nmtc_FairValueChangesOfWarrantLiability_57" order="410" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenPlanMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenPlanMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_RestrictedStockMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_nmtc_StockBasedCompensationTextualAbstract_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmtc_StockBasedCompensationTextualAbstract_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_13" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_13" xlink:to="loc_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueOfCommonStockPricePerShare" xlink:label="loc_nmtc_FairValueOfCommonStockPricePerShare_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_13" xlink:to="loc_nmtc_FairValueOfCommonStockPricePerShare_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_13" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_MonthlyCompensationAmount" xlink:label="loc_nmtc_MonthlyCompensationAmount_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_13" xlink:to="loc_nmtc_MonthlyCompensationAmount_19" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_13" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_20" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockholdersdeficitdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_nmtc_StockholdersMemberDeficitTextualAbstract_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_nmtc_StockholdersMemberDeficitTextualAbstract_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockSharesIssued_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_13" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_14" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PlacementAgentMember" xlink:label="loc_nmtc_PlacementAgentMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_nmtc_PlacementAgentMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AmendedAndRestatedShortTermNotesMember" xlink:label="loc_nmtc_AmendedAndRestatedShortTermNotesMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_nmtc_AmendedAndRestatedShortTermNotesMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ReplacementWarrantsMember" xlink:label="loc_nmtc_ReplacementWarrantsMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_nmtc_ReplacementWarrantsMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalWarrantsMember" xlink:label="loc_nmtc_AdditionalWarrantsMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_nmtc_AdditionalWarrantsMember_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember" xlink:label="loc_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_16" xlink:to="loc_us-gaap_UnsecuredDebtMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_nmtc_SubsequentEventsTextualAbstract_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_nmtc_SubsequentEventsTextualAbstract_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_18" xlink:to="loc_us-gaap_DebtInstrumentDescription_20" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_21" order="20" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nmtc-20180331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Wednesday, May 16, 2018 06:33:32 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#DocumentAndEntityInformation" roleURI="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Organizationandnatureofoperations" roleURI="http://www.originalsourcemusic.com/role/Organizationandnatureofoperations"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#GoingConcern" roleURI="http://www.originalsourcemusic.com/role/GoingConcern"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#CommitmentsAndContingencies" roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Intangibles" roleURI="http://www.originalsourcemusic.com/role/Intangibles"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#AccruedExpenses" roleURI="http://www.originalsourcemusic.com/role/AccruedExpenses"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ShortTermPromissoryNotesAndUnsecuredLoan" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ConvertiblePromissoryNotesAndWarrantAgreements" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#InvestmentBankerFee" roleURI="http://www.originalsourcemusic.com/role/InvestmentBankerFee"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#StockBasedCompensation" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensation"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#IncomeTaxes" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#StockholdersDeficit" roleURI="http://www.originalsourcemusic.com/role/StockholdersDeficit"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SubsequentEvents" roleURI="http://www.originalsourcemusic.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Summaryofsignificantaccountingpoliciespolicies" roleURI="http://www.originalsourcemusic.com/role/Summaryofsignificantaccountingpoliciespolicies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#IntangiblesTables" roleURI="http://www.originalsourcemusic.com/role/IntangiblesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#AccruedExpensesTables" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ConvertiblePromissoryNotesandWarrantAgreementsTables" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#StockBasedCompensationTables" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Organizationandbasisofpresentationdetails" roleURI="http://www.originalsourcemusic.com/role/Organizationandbasisofpresentationdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#GoingConcernDetails" roleURI="http://www.originalsourcemusic.com/role/GoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesDetails1" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesDetails2" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SummaryofSignificantAccountingPoliciesDetails3" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#IntangiblesDetails" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#IntangiblesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#AccruedExpensesDetails" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#AccruedExpensesDetails1" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ShortTermPromissoryNotesAndUnsecuredLoanDetails" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ConvertiblePromissoryNotesAndWarrantAgreementsDetails" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#InvestmentBankerFeeDetails" roleURI="http://www.originalsourcemusic.com/role/InvestmentBankerFeeDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Stockbasedcompensationdetails" roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Stockbasedcompensationdetails1" roleURI="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#StockBasedCompensationDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Incometaxesdetails" roleURI="http://www.originalsourcemusic.com/role/Incometaxesdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#Stockholdersdeficitdetails" roleURI="http://www.originalsourcemusic.com/role/Stockholdersdeficitdetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20180331.xsd#SubsequentEventsDetails" roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_DocumentAndEntityInformationAbstract" xlink:label="loc_nmtc_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_11" order="100" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_Cash_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_ShortTermBorrowings_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest" xlink:label="loc_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_LiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_Liabilities_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_PreferredStockValue_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommonStockValue_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_AdditionalPaidInCapital_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquity_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative" xlink:label="loc_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_10" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_12" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentForAmortization_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NonCashInterestOnPrincipal" xlink:label="loc_nmtc_NonCashInterestOnPrincipal_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmtc_NonCashInterestOnPrincipal_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_nmtc_RevaluationOfWarrantLiability_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmtc_RevaluationOfWarrantLiability_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes" xlink:label="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan" xlink:label="loc_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_us-gaap_PaymentsOfLoanCosts_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsOfLoanCosts_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_Cash_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_Cash_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26" xlink:to="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:label="loc_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26" xlink:to="loc_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:label="loc_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26" xlink:to="loc_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Organizationandnatureofoperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/GoingConcern">
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_nmtc_GoingConcernAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernAbstract_0" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Intangibles">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ShortTermDebtTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/InvestmentBankerFee">
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_InvestmentBankerFeeAbstract" xlink:label="loc_nmtc_InvestmentBankerFeeAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_InvestmentBankerFeeTextBlock" xlink:label="loc_nmtc_InvestmentBankerFeeTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_InvestmentBankerFeeAbstract_0" xlink:to="loc_nmtc_InvestmentBankerFeeTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Summaryofsignificantaccountingpoliciespolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_IntellectualPropertyPolicyTextBlock" xlink:label="loc_nmtc_IntellectualPropertyPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_IntellectualPropertyPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DebtPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantLiabilityPolicyTextBlock" xlink:label="loc_nmtc_WarrantLiabilityPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_WarrantLiabilityPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:label="loc_nmtc_PremiumDebtConversionDerivativePolicyTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_PremiumDebtConversionDerivativePolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Organizationandbasisofpresentationdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xlink:label="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5" xlink:to="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaap_ConversionOfStockDescription_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_ConversionOfStockDescription_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/GoingConcernDetails">
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_nmtc_GoingConcernAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_GoingConcernTextualAbstract" xlink:label="loc_nmtc_GoingConcernTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernAbstract_0" xlink:to="loc_nmtc_GoingConcernTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaap_UnsecuredDebt_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_UnsecuredDebt_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_ConvertibleNotesPayable_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleNotesPayableOne" xlink:label="loc_nmtc_ConvertibleNotesPayableOne_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_1" xlink:to="loc_nmtc_ConvertibleNotesPayableOne_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNote" xlink:label="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNote_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_1" xlink:to="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNote_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne" xlink:label="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_1" xlink:to="loc_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantLiability" xlink:label="loc_nmtc_WarrantLiability_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" xlink:to="loc_nmtc_WarrantLiability_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumConversionDerivative" xlink:label="loc_nmtc_PremiumConversionDerivative_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" xlink:to="loc_nmtc_PremiumConversionDerivative_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ProceedsAndValueAssignedToWarrants" xlink:label="loc_nmtc_ProceedsAndValueAssignedToWarrants_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_nmtc_ProceedsAndValueAssignedToWarrants_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_nmtc_DebtConversionDerivativeMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_nmtc_DebtConversionDerivativeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition" xlink:label="loc_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:label="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_nmtc_AccruedLicenseFees_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedLicenseFees_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_nmtc_AccruedIssuanceCosts_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedIssuanceCosts_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedPayroll" xlink:label="loc_nmtc_AccruedPayroll_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedPayroll_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedExpensesAdvances" xlink:label="loc_nmtc_AccruedExpensesAdvances_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedExpensesAdvances_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AccruedExpensesTextualAbstract" xlink:label="loc_nmtc_AccruedExpensesTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedExpensesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_AccruedExpensesTextualAbstract_1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_us-gaap_ShortTermDebtMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumConversionDerivativeMember" xlink:label="loc_nmtc_PremiumConversionDerivativeMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_nmtc_PremiumConversionDerivativeMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7" xlink:to="loc_us-gaap_UnsecuredDebtMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_9" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_10" xlink:to="loc_us-gaap_SubsidiariesMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_12" xlink:to="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_nmtc_CommonStockPurchaseOfWarrants_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_nmtc_CommonStockPurchaseOfWarrants_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_nmtc_WarrantsMaturityTerm_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ValueOfPremiumConversionDerivative" xlink:label="loc_nmtc_ValueOfPremiumConversionDerivative_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_nmtc_ValueOfPremiumConversionDerivative_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_24" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_25" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaap_UnsecuredDebtCurrent_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_UnsecuredDebtCurrent_26" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalWarrantsAllocated" xlink:label="loc_nmtc_AdditionalWarrantsAllocated_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_nmtc_AdditionalWarrantsAllocated_27" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_28" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsExpirationDate" xlink:label="loc_nmtc_WarrantsExpirationDate_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_nmtc_WarrantsExpirationDate_29" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_LossOnShortTermNotesExtinguishment" xlink:label="loc_nmtc_LossOnShortTermNotesExtinguishment_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_nmtc_LossOnShortTermNotesExtinguishment_30" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants" xlink:label="loc_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants_31" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_33" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ShortTermNoteQualifiedFinancingDescription" xlink:label="loc_nmtc_ShortTermNoteQualifiedFinancingDescription_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_nmtc_ShortTermNoteQualifiedFinancingDescription_34" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_DebtConversionDescription_35" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_13" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_36" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_ConvertibleDebtMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNoteMember" xlink:label="loc_nmtc_ConvertiblePromissoryNoteMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_nmtc_ConvertiblePromissoryNoteMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_9" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubscriptionAgreementMember" xlink:label="loc_nmtc_SubscriptionAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_SubscriptionAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NovemberTwoThousandSeventeenMember" xlink:label="loc_nmtc_NovemberTwoThousandSeventeenMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_NovemberTwoThousandSeventeenMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember" xlink:label="loc_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleDebtOneMember" xlink:label="loc_nmtc_ConvertibleDebtOneMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_nmtc_ConvertibleDebtOneMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_us-gaap_PrivatePlacementMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NewWarrantsMember" xlink:label="loc_nmtc_NewWarrantsMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_nmtc_NewWarrantsMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ConvertibleDebt_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ConvertibleNotesPayable_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_31" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_33" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_34" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_35" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_InterestExpense_36" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_37" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_39" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_40" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_41" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_42" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_43" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_us-gaap_DebtInstrumentFee_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentFee_44" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_WarrantsMaturityTerm_45" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_WarrantsToPurchaseSharesOfCommonStock" xlink:label="loc_nmtc_WarrantsToPurchaseSharesOfCommonStock_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_WarrantsToPurchaseSharesOfCommonStock_46" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_47" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_48" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_49" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_50" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConvertibleNotesMaximumExtensionLimit" xlink:label="loc_nmtc_ConvertibleNotesMaximumExtensionLimit_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_ConvertibleNotesMaximumExtensionLimit_51" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_LegalFees_52" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_53" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_54" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_55" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_56" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueAdjustmentOfPremiumConversionDerivative" xlink:label="loc_nmtc_FairValueAdjustmentOfPremiumConversionDerivative_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_FairValueAdjustmentOfPremiumConversionDerivative_57" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueChangesOfWarrantLiability" xlink:label="loc_nmtc_FairValueChangesOfWarrantLiability_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_16" xlink:to="loc_nmtc_FairValueChangesOfWarrantLiability_58" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/InvestmentBankerFeeDetails">
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_InvestmentBankerFeeAbstract" xlink:label="loc_nmtc_InvestmentBankerFeeAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_InvestmentBankerFeeTextualAbstract" xlink:label="loc_nmtc_InvestmentBankerFeeTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_InvestmentBankerFeeAbstract_0" xlink:to="loc_nmtc_InvestmentBankerFeeTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_NonRefundableFeeToInvestmentBanker" xlink:label="loc_nmtc_NonRefundableFeeToInvestmentBanker_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_InvestmentBankerFeeTextualAbstract_1" xlink:to="loc_nmtc_NonRefundableFeeToInvestmentBanker_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenPlanMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenPlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_RestrictedStockMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_nmtc_StockBasedCompensationTextualAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13" xlink:to="loc_nmtc_StockBasedCompensationTextualAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_14" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_14" xlink:to="loc_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_FairValueOfCommonStockPricePerShare" xlink:label="loc_nmtc_FairValueOfCommonStockPricePerShare_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_14" xlink:to="loc_nmtc_FairValueOfCommonStockPricePerShare_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_14" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_MonthlyCompensationAmount" xlink:label="loc_nmtc_MonthlyCompensationAmount_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_14" xlink:to="loc_nmtc_MonthlyCompensationAmount_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Incometaxesdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_IncomeTaxesTextualAbstract" xlink:label="loc_nmtc_IncomeTaxesTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_nmtc_IncomeTaxesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Stockholdersdeficitdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_nmtc_StockholdersMemberDeficitTextualAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_nmtc_StockholdersMemberDeficitTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockSharesIssued_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/zeroLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_PlacementAgentMember" xlink:label="loc_nmtc_PlacementAgentMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_nmtc_PlacementAgentMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AmendedAndRestatedShortTermNotesMember" xlink:label="loc_nmtc_AmendedAndRestatedShortTermNotesMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_nmtc_AmendedAndRestatedShortTermNotesMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_ReplacementWarrantsMember" xlink:label="loc_nmtc_ReplacementWarrantsMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_nmtc_ReplacementWarrantsMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalWarrantsMember" xlink:label="loc_nmtc_AdditionalWarrantsMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_nmtc_AdditionalWarrantsMember_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember" xlink:label="loc_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_16" xlink:to="loc_us-gaap_UnsecuredDebtMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmtc-20180331.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_nmtc_SubsequentEventsTextualAbstract_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_nmtc_SubsequentEventsTextualAbstract_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_DebtInstrumentDescription_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757991120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>May 14, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROONE MEDICAL TECHNOLOGIES Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001500198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,014,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758298816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 25,198<span></span>
</td>
<td class="nump">$ 26,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">7,146<span></span>
</td>
<td class="nump">7,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">32,344<span></span>
</td>
<td class="nump">33,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">211,420<span></span>
</td>
<td class="nump">216,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">243,764<span></span>
</td>
<td class="nump">249,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,522,874<span></span>
</td>
<td class="nump">1,021,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term promissory notes and unsecured loan, net of discount</a></td>
<td class="nump">369,124<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest', window );">Convertible promissory notes, net and accrued interest</a></td>
<td class="nump">2,505,089<span></span>
</td>
<td class="nump">2,168,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivatives</a></td>
<td class="nump">607,173<span></span>
</td>
<td class="nump">462,174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,004,260<span></span>
</td>
<td class="nump">3,905,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">1,634,059<span></span>
</td>
<td class="nump">1,381,465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,638,319<span></span>
</td>
<td class="nump">5,286,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2018 and December 31, 2017; no shares issued or outstanding as of March 31, 2018 and December 31, 2017.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2018 and December 31, 2017; and 7,864,994 shares issued and outstanding as of March 31, 2018 and December 31, 2017.</a></td>
<td class="nump">7,865<span></span>
</td>
<td class="nump">7,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">279,150<span></span>
</td>
<td class="nump">280,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(6,681,570)<span></span>
</td>
<td class="num">(5,324,796)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(6,394,555)<span></span>
</td>
<td class="num">(5,036,611)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 243,764<span></span>
</td>
<td class="nump">$ 249,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNotesNetAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt premium to be amortized within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758358096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,864,994<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,864,994<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758286992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 992,435<span></span>
</td>
<td class="nump">$ 444,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">105,045<span></span>
</td>
<td class="nump">72,041<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,097,480<span></span>
</td>
<td class="nump">516,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,097,480)<span></span>
</td>
<td class="num">(516,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="num">(193,034)<span></span>
</td>
<td class="num">(213,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative', window );">Net change in fair value for the warrant liability and premium conversion derivatives</a></td>
<td class="nump">119,960<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on short-term notes extinguishment</a></td>
<td class="num">(186,220)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,356,774)<span></span>
</td>
<td class="num">$ (729,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">7,864,994<span></span>
</td>
<td class="nump">5,216,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net change in fair value for the warrant liability and premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NetChangeInFairValueOfWarrantLiabilityAndPremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758498224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,356,774)<span></span>
</td>
<td class="num">$ (729,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">4,952<span></span>
</td>
<td class="nump">5,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based services expense</a></td>
<td class="nump">254,437<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NonCashInterestOnPrincipal', window );">Non-cash interest or non-cash interest on principal</a></td>
<td class="nump">54,116<span></span>
</td>
<td class="nump">17,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash discount amortization on convertible promissory notes</a></td>
<td class="nump">138,918<span></span>
</td>
<td class="nump">178,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Note issuance costs attributed to warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevaluationOfPremiumDebtConversionDerivative', window );">Revaluation of premium conversion derivatives</a></td>
<td class="nump">4,032<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevaluationOfWarrantLiability', window );">Revaluation of warrant liability</a></td>
<td class="num">(123,992)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on short-term notes extinguishment</a></td>
<td class="nump">186,220<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">53,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">246,822<span></span>
</td>
<td class="nump">107,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(591,269)<span></span>
</td>
<td class="num">(350,919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="nump">236,136<span></span>
</td>
<td class="nump">192,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes', window );">Proceeds from issuance of warrants associated with short-term and convertible promissory notes</a></td>
<td class="nump">238,864<span></span>
</td>
<td class="nump">182,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan', window );">(Repayment) proceeds from short term unsecured loan</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfLoanCosts', window );">Issuance costs related to convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs related to warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,870)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">590,000<span></span>
</td>
<td class="nump">315,120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
<td class="num">(1,269)<span></span>
</td>
<td class="num">(35,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at beginning of period</a></td>
<td class="nump">26,467<span></span>
</td>
<td class="nump">522,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at end of period</a></td>
<td class="nump">25,198<span></span>
</td>
<td class="nump">486,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing and investing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes', window );">Bifurcation of premium conversion derivative related to convertible promissory notes</a></td>
<td class="nump">91,298<span></span>
</td>
<td class="nump">72,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes', window );">Accrued issuance costs attributed to convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability', window );">Accrued issuance costs attributed to warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued issuance costs attributed to short term promissory notes and convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued issuance costs attributed to warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCostsAttributedToWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bifurcation of premium conversion derivative related to convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NonCashInterestOnPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash interest or non cash interest on principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NonCashInterestOnPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of warrants associated with convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromIssuanceOfWarrantsAssociatedWithConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from repayments of short term unsecured loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromRepaymentsOfShortTermUnsecuredLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RevaluationOfPremiumDebtConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of premium debt conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RevaluationOfPremiumDebtConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RevaluationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RevaluationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan origination associated cost which is usually collected through escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754641472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 1 &#8211; Organization and Basis of Presentation</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NeuroOne Medical Technologies Corporation (the &#8220;Company&#8221;), a Delaware Corporation, was originally incorporated as Original Source Entertainment, Inc. under the laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition (as defined below), the Company completed a series of steps contemplated by a Plan of Conversion pursuant to which the Company, among other things, changed its name to NeuroOne Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware. On July 20, 2017, the Company, through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&#8220;NeuroOne&#8221;) in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &#8220;Acquisition&#8221;). The Acquisition was accounted for as a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in this transaction. As such, the historical financial statements of NeuroOne reflect operations of the Company for all periods presented prior to the date of the Acquisition. The accompanying condensed consolidated financial statements subsequent to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Subsequent to the Acquisition, the Company&#8217;s operating activities became the same as those of NeuroOne, an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&#8217;s disease, essential tremors, and other brain related disorders.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">To date, the Company has recorded no product sales and has a limited expense history. The Company is a development stage company and its activities to date have included raising capital to fund the development of its proprietary technology and seek regulatory clearances required to initiate commercial activities.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company is based in Eden Prairie, Minnesota.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Acquisition of NeuroOne, Inc.</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent:
 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Acquisition was consummated on July 20, 2017 (the &#8220;Closing&#8221;) and, pursuant to the terms of the merger agreement, (i) all outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the &#8220;NeuroOne Shares&#8221;), were exchanged for shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Company Shares&#8221;), based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the &#8220;Exchange Ratio&#8221;), resulting in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options, (iii) all warrants of NeuroOne were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible promissory notes of NeuroOne. NeuroOne options had been issued pursuant to the NeuroOne 2016 Equity Incentive Plan. Pursuant to the merger agreement, the Company assumed the NeuroOne 2016 Equity Incentive Plan upon the Closing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pursuant to the Acquisition, the Company acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became the Company&#8217;s wholly-owned subsidiary. Also at the Closing, Mr. Samad (the majority owner of the Company prior to the Acquisition) tendered for cancellation 3,500,000 Company Shares held by him as part of the conditions to Closing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">All issued and outstanding common stock share amounts, options for common stock and per share amounts contained in the consolidated financial statements were retroactively adjusted to reflect the Exchange Ratio for all periods presented.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Basis of presentation</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accompanying condensed consolidated financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements may not include all disclosures required by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto for the fiscal year ended December 31, 2017 included in the Annual Report on Form 10-K for the year ended December 31, 2017. The condensed balance sheet at December 31, 2017 was derived from the audited financial statements of the Company.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Certain prior period balances have been reclassified to conform to the current period presentation. Specifically, the Company reclassified all fair market valuation adjustments related to the warrant liability and to the premium conversion derivative from interest expense to a separate line item on the condensed consolidated statements of operations.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630751824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 2 &#8211; Going Concern</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception and had an accumulated deficit of $6,681,570 as of March 31, 2018. The Company does not have adequate liquidity to fund its operations throughout fiscal 2018 without raising additional funds. These factors raise substantial doubt about its ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this condition. Management intends to continue to seek additional financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Through March 31, 2018, the Company has completed a $115,000 unsecured loan financing, a $253,000 short-term promissory note financing (which notes were amended and restated to become convertible promissory notes as described below), a $1,625,120 convertible promissory note financing of a planned $2.5 million subscription and a second $1,140,000 convertible promissory note financing of a planned $2 million subscription. See Note 13 &#8211; Subsequent Events for financings that have closed after March 31, 2018. The Company does not have adequate liquidity to fund its operations throughout fiscal 2018 without raising additional funds. Management intends to continue to seek additional debt and/or equity financing to fund operations. However, if the Company is unable to raise additional funds, or the Company&#8217;s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company&#8217;s operations. If management is unable to obtain the necessary capital, it may have to cease operations.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754659168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 3 &#8211; Summary of Significant Accounting Policies</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Management&#8217;s Use of Estimates</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Concentration of Credit Risk</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2018, the Company did not have any deposits in excess of federally insured amounts.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Fair Value of Financial Instruments</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 48px;"><font style="font-size: 10pt;">&#9679;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 48px;"><font style="font-size: 10pt;">&#9679;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 48px;"><font style="font-size: 10pt;">&#9679;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2018 and December 31, 2017, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the short-term and convertible promissory notes of the Company were based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level&#160;3 inputs. There were no transfers between fair value hierarchy levels during the three months ended March 31, 2018 and 2017.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of financial instruments measured on a recurring basis is as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of March 31,&#160;2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>Liabilities:</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 815px; text-align: left;">Warrant liability</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">1,634,059</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">&#8212;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">&#8212;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">1,634,059</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">607,173</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">607,173</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,241,232</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,241,232</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>Liabilities:</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 815px; text-align: left;">Warrant liability</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">1,381,465</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">&#8212;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">&#8212;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">1,381,465</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level&#160;3 inputs for the three month periods ended March 31, 2018 and 2017:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold;">Warrant liability</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1191px;">Balance as of beginning of period</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">1,381,465</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">345,960</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Value assigned to warrants in connection with convertible promissory and short-term notes</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">376,586</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">182,693</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of warrant liability</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(123,992</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(215</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,634,059</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">528,438</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-weight: bold;">Premium debt conversion derivatives</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1191px;">Balance as of beginning of period</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">462,174</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">137,650</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">140,967</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">72,732</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of premium debt conversion derivatives</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">4,032</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">183</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">607,173</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">210,565</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Intellectual Property</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Impairment of Long-Lived Assets</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates its long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through March 31, 2018, the Company has not impaired any long-lived assets.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Debt Issuance Costs</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the short term notes and convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;<i>&#160;</i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Research and Development Costs</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Warrant Liability</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company issued warrants to purchase equity securities in connection with the issuance or amendment of short-term and convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Premium Debt Conversion Derivatives</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&#160; The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed consolidated statements of operations. The Company determined that the redemption features under the amended short-term promissory notes and convertible promissory notes qualified as embedded derivatives and were separated from their debt hosts.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Income Taxes</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Net Loss Per Share</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s short-term notes, convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the short-term notes and convertible promissory notes utilizing the if-converted method was not applicable during the three month periods ended March 31, 2018 and 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three month periods ended March 31, 2018 and 2017.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three month periods ended March 31, 2018 and 2017:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1191px;">Warrants</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 142px; text-align: right;">189,750</td>
<td style="width: 16px; text-align: left;">(1)</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 141px; text-align: right;">597,283</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Stock options</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">365,716</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 24px;"><font style="font-size: 10pt;">(1)</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.&#160;</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Recent Accounting Pronouncements</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2017, the FASB issued ASU 2017-09,&#160;<i>Compensation - Stock Compensation (Topic 718):&#160;Scope of Modification Accounting (ASU 2016-09)</i>,&#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company has adopted this standard for the three months ended March 31, 2018. The adoption of this standard did not have any impact on the Company&#8217;s consolidated financial statements.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2017, the FASB issued ASU No. 2017-11,&#160;<i>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</i>, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&#160;15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#8217;s consolidated financial statements.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6921547776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 4 &#8211; Commitments and Contingencies</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Legal</b>&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">From time to time, the Company is subject to litigation and claims arising in the ordinary course of business.&#160; In May 2017, NeuroOne received a letter from PMT, the former employer of Mark Christianson and Wade Fredrickson.&#160; PMT claimed that these officers had breached their restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer&#8217;s prior work during employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference with the contracts.&#160; The letter demanded that Mr. Fredrickson (who is no longer with the Company), Mr. Christianson and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne provide the former employer access to NeuroOne&#8217;s systems to demonstrate that it is not using trade secrets or proprietary information nor competing with the former employer.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On March 29, 2018, we were served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson.&#160; In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT&#8217;s contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing.&#160; Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft.&#160; Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne were unjustly enriched and engaged in unfair competition.&#160; PMT asks the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&#8217; fees, costs and interest.&#160; The Company, NeuroOne and Mr. Christianson (who has not worked for PMT since 2012) intend to defend themselves vigorously.&#160;&#160;The outcome and potential loss related to this matter is unknown as of March 31, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has no insurance coverage to protect against any losses that the Company may experience due to this claim. Furthermore, Mr. Christianson is a key officer and the loss of his services would be detrimental to the Company&#8217;s operations and prospects.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754661600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangibles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 5 &#8211; Intangibles</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Intangible assets consisted of the following at March 31, 2018:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Useful Life</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1129px; text-align: justify;">Net Intangibles, December 31, 2017</td><td style="width: 16px;">&#160;</td><td style="width: 189px; text-align: center;">12-13 Years</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 188px; text-align: right;">216,372</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt;">Less: amortization</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: justify; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(4,952</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 4pt;">Net Intangibles, March 31, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: justify; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">211,420</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Amortization expense was $4,952 and $5,007 for the three months ended March 31, 2018 and 2017, respectively.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633017760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 6 &#8211; Accrued Expenses</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Accrued expenses consisted of the following at March 31, 2018 and December 31, 2017:&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: center; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>March 31,</b></font><br /><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>2018</b></font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: center; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>December 31,</b></font><br /><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>2017</b></font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued&#160;license fees</font></td><td style="width: 16px; line-height: 14.26px;">&#160;</td><td style="width: 16px; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="width: 142px; text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">120,000</font></td><td style="width: 16px; line-height: 14.26px;">&#160;</td><td style="width: 15px; line-height: 14.26px;">&#160;</td><td style="width: 15px; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="width: 141px; text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">120,000</font></td><td style="width: 15px; line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued services</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">868,811</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">600,339</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued issuance costs</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">28,083</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">28,083</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued payroll</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">251,543</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">223,195</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="line-height: 14.26px;"><font
 style="font-family: 'times new roman', times, serif; font-size: 10pt;">Advances</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#8212;</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,000</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Other (1)</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">254,437</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#8212;</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,522,874</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,021,617</font></td><td style="line-height: 14.26px;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><table style="font: 11pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.25in;"></td><td style="width: 0.25in;"><font style="font-size: 10pt;">(1)</font></td><td><font style="font-size: 10pt;">Accrued expenses include an obligation to issue stock awards and stock options to consultants that have met vesting requirements as of March 31, 2018 in the amount of $254,437. See Note 10 &#8211; Stock-Based Compensation for further detail.</font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633106112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Promissory Notes and Unsecured Loan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-Term Promissory Notes and Unsecured Loan</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 7 &#8211; Short-Term Promissory Notes and Unsecured Loan</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Short-Term Promissory Notes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In August 2017, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) authorized, and the Company issued short-term unsecured and interest-free promissory notes (the &#8220;Short-Term Notes&#8221;) for aggregate gross proceeds of $253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and were amortized ratably to interest expense over the original term of the Short-Term Notes up though November 2017. On November 30, 2017, the Short-Term Notes were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase warrants (&#8220;Original Warrants&#8221;). The Original Warrants had a term of 5 years and an exercise price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the amendment described below. The November 30, 2017 amendment resulted in a substantial modification to the Short-Term Notes and was accounted for under the provisions of extinguishment accounting.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Short-Term Notes were subsequently amended and restated on March 12, 2018 (the &#8220;Amended and Restated Short-Term Notes&#8221;). The Amended and Restated Short-Term Notes became convertible promissory notes that bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the maturity date of July 31, 2018 (the &#8220;Short-Term Note Maturity Date&#8221;). Pursuant to the terms of each Amended and Restated Short-Term Note and a consent signed by the Company and each holder, the Original Warrants under the Short-Term Notes were modified whereby each subscriber received a replacement warrant (the &#8220;Replacement Warrant&#8221;) upon the issuance of the Amended and Restated Short-Term Note, in lieu of the Original Warrant. In addition, each holder was issued an additional warrant (the &#8220;Additional Warrant&#8221;).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">If the Company raises more than $3,000,000 in an equity or equity-linked financing before July 31, 2018 (the &#8220;Short-Term Note Qualified Financing&#8221;), the outstanding principal and accrued interest (the &#8220;Outstanding Balance&#8221;) on the Amended and Restated Short-Term Notes shall automatically convert into the securities issued by the Company in the Short-Term Note Qualified Financing (the &#8220;New Round Stock&#8221;) based on the greater number of such securities resulting from either (i) the Outstanding Balance divided by $1.80 or (ii) the Outstanding Balance multiplied by 1.25, divided by the price paid per security in the Short-Term Note Qualified Financing. If a change of control transaction occurs prior to the earlier of a Short-Term Note Qualified Financing or the Short-Term Note Maturity Date, the Amended and Restated Short-Term Notes would, at the election of the holders of a majority of the outstanding principal of the Amended and Restated Short-Term Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by the Board as if in connection with the granting of stock-based compensation or in a private sale to a third party in an arms&#8217; length transaction or (ii) at the per share consideration to be paid in such
 transaction. The date of a conversion under a Short-Term Note Qualified Financing or a change of control transaction under the terms of the Amended and Restated Short-Term Notes is referred to herein as the &#8220;Conversion Date&#8221;.&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Replacement Warrants</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Each Replacement Warrant grants the holder the option to purchase up to the number of shares of capital stock of the Company equal to the New Round Stock issued or issuable upon the conversion of the Amended and Restated Short-Term Note held by such holder at a per share exercise price equal to either (i) the actual per share price of New Round Stock if the Amended and Restated Short-Term Notes converted in connection with a Short-Term Note Qualified Financing or (ii) the price at which the Amended and Restated Short-Term Notes converted in connection with a change of control transaction. The Replacement Warrants are exercisable commencing on the Conversion Date and expire on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Replacement Warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Replacement Warrants were deemed to be a free-standing instrument and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. The Company recorded an initial liability of $137,722 upon issuance with an offset to extinguishment loss described further below. The fair value changes of the warrant liability associated with the Short-Term Notes are recorded at each reporting date in the condensed consolidated statements of operations which amounted to a benefit of $(2,371) for the three months ended March 31, 2018. A Monte Carlo simulation model was used to estimate the aggregate fair value of the Replacement Warrants as of March 31, 2018. Input assumptions used were as follows: risk-free interest rate of 2.45 percent; expected volatility of 50 percent; expected life of 3.64 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to a separate independent third-party valuation analysis since there was no active trading market for the Company&#8217;s common stock</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Additional Warrants</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Each Additional Warrant grants the holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share exercise price of $1.80. The Additional Warrants are exercisable commencing on the Conversion Date and expire on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Additional Warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Additional Warrants were deemed to be a free-standing instrument and were accounted for as equity as there were no variable terms. The Additional Warrants amounted to 189,750 shares as of both the March 12, 2018 amendment date and as of March 31, 2018 with terms that largely parallel the provisions of the Original Warrants except that the Additional Warrants are exercisable on the Conversion Date as opposed to the Short-Term Note Maturity Date and the expiration date was moved up to November 21, 2021 from July 31, 2023. The fair value differential between the Original Warrants and the Additional Warrants was a reduction of $22,624. The fair value change was recorded as a reduction to additional paid-in capital in the accompanying condensed balance sheets and was included as part of the extinguishment loss discussed further below.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Premium Conversion Derivative</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Upon the March 2018 amendment, the Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Short-Term Notes qualified as an embedded derivative and was reflected as a liability in the amount of $49,668 at the time of the March 12, 2018 amendment with a corresponding offset to extinguishment loss which is described further below. Subsequent to the amendment, the embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Short-Term Notes in the condensed consolidated statements of operations for an expense of $43 for the three months ended March 31, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Other</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The March 2018 amendment resulted in a substantial modification to the Short-Term Notes whereby additional conversion features and warrant coverage were added. The Company recorded the Short-Term Note amendment under the provisions of extinguishment accounting. A loss on Short-Term Notes extinguishment in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2018 was recorded in the amount of $186,220, which represented the difference between the carrying value of the Short-Term Notes over the combined fair values of the Short-Term Notes, premium conversion derivative, Replacement Warrant and Additional Warrants on the date of the amendment. The fair value decrease of the Short-Term Notes (inclusive of principal and interest, non-bifurcated embedded conversion feature and the Additional Warrants) relative to its adjusted carrying value at the time of the amendment was $1,170 which was recorded as a reduction to additional paid-in
 capital on the accompanying condensed balance sheets.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pursuant to the Short-Term Note subscription agreement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the Short-Term Notes and associated warrants, and the right to purchase the Short-Term Notes and associated warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the Short-Term Note subscription agreement.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Unsecured Loans</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On March 20, 2018, the Company received cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from an existing stockholder. The loan is interest free and requires that the Company repay the principal in full on the earlier to occur of (i) March 20, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan includes customary events of default.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Additionally, NeuroOne received a $50,000 short-term unsecured loan in November 2016 from the placement agent for its convertible promissory note financing (see Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). NeuroOne incurred no fees or interest costs for this temporary loan and it was repaid in full in February 2017.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754544944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Promissory Notes and Warrant Agreements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 8 &#8211; Convertible Promissory Notes and Warrant Agreements</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />March 31,<br />2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December 31,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;">2016 convertible promissory notes, net of discounts</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,578,239</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,543,652</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9pt; padding-left: 9pt;">2017 convertible promissory notes, net of discounts</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">753,637</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">504,465</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9pt; padding-bottom: 1.5pt; padding-left: 9pt;">Accrued interest</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">173,213</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">120,223</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -9pt; padding-bottom: 4pt; padding-left: 0.25in;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,505,089</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,168,340</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;<b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>2016 Convertible Promissory Notes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In November 2016 and as amended in June 2017, the Board authorized the Company to issue convertible promissory notes (the &#8220;Convertible Notes&#8221;) and common stock purchase warrants (the &#8220;Warrants&#8221;) for aggregate gross proceeds of up to $2.5 million and entered into subscription agreements with subscribers (the &#8220;2016 Private Placement&#8221;). The Company amended the Convertible Notes and Warrants again on November 20, 2017 to extend the maturity date of the Convertible Notes from November 21, 2017 to July 31, 2018 and to change the terms of the underlying
 Warrants that include the removal of down-round pricing protection provisions as described more fully below.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2018, the Company issued a total of $1,625,120 of Convertible Notes and Warrants to investors. The Convertible Notes are unsecured. The Convertible Notes bear interest at a fixed rate of 8 percent per annum and require the Company to repay the principal and accrued and unpaid interest thereon at the earlier of July 31, 2018 or the consummation of the next equity or equity-linked round of financing resulting in more than $3.0 million in gross proceeds (a &#8220;Qualified Financing&#8221;). If a Qualified Financing occurs before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by July 31, 2018, the Convertible Notes will be immediately due and payable on such date.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">If a change of control transaction or initial public offering occurs prior to a Qualified Financing, the Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the Convertible Notes, either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of the per share value as determined by the Board as if in connection with the granting of stock based compensation, or in a private sale to a third party in an arms-length transaction, or at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&#8217;s stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Prior to the June 2017 amendment, the Warrants granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number of shares equal to the number of shares received by the holders upon the conversion of the Convertible Notes, or (ii) if exercised prior to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued interest on the Convertible Note held by such warrant holder divided by $1.80. The Warrants were immediately exercisable on the date of issuance and expired on November 21, 2021. In June 2017, however, the Company amended the terms of the Warrants under the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the related Convertible Notes. The amount of warrant shares to be issued are now contingent and are based on the number of shares of common stock received by the holder of the Convertible Notes upon conversion of such holder&#8217;s Convertible Notes, and at an exercise price equal to the same price per share of the securities issued in the Qualified Financing. The Warrants expire on November 21, 2021 in the event of a Qualified Financing or expire unissued if the notes have not been converted.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Warrants were deemed to be a free-standing instrument and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the Warrants. Input assumptions used were as follows: risk-free interest rate of 2.45 and 2.08 percent as of March 31, 2018 and December 31, 2017, respectively; expected volatility of 50
 percent as of March 31, 2018 and December 31, 2017; expected life of 3.64 and 3.89 years as of March 31, 2018 and December 31, 2017, respectively; and expected dividend yield of 0 percent as of March 31, 2018 and December 31, 2017. The underlying stock price used in the analysis was on a non-marketable basis and was according to a separate independent third-party valuation analysis since there was no active trading market for the Company&#8217;s common stock.&#160;The Convertible Note proceeds assigned to the Warrants were zero and $182,693 during the three months ended March 31, 2018 and 2017, respectively, which represented their fair value at issuance, and were discounted from the Convertible Notes and reflected as a warrant liability. The discount was amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was zero and $118,862 for the three months ended March 31, 2018 and 2017, respectively. The Company also recorded the fair value changes of the warrant liability associated with the Convertible Notes in the condensed consolidated statements of operations which amounted to a benefit of $(130,976) and $(215) for the three months ended March 31, 2018 and 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The November 2017 amendment resulted in a substantial modification to the original Convertible Notes whereby the maturity date was extended, and the terms associated with the Warrants were revised. The fair value of the underlying convertible notes was $97,223 lower than the carrying value of the Convertible Notes on the date of the modification. The $97,223 difference was recorded as a discount to the debt and is being amortized over the amended term of the Convertible Notes. The amortization recorded during the three months ended March 31, 2018 and 2017 was $34,585 and zero, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the time of their issuance, the Convertible Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes in the amount of zero and $72,732 during the three months ended March 31, 2018 and 2017, respectively. The discount was being amortized to interest expense over the original term of the Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was zero and $47,318 for the three months ended March 31, 2018 and 2017, respectively. The embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Convertible Notes in the condensed consolidated statements of operations for an expense of $2,666 and $183 for the three months ended March 31, 2018 and 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &#8220;placement agent warrant&#8221;) which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855 on date of Convertible Note issuance, and (iii) legal expenses of $33,450. The placement agent warrant is issuable at the time the private placement transaction closes which has not occurred as of March 31, 2018. The placement agent warrant will be immediately exercisable on the date of issuance and will expire five years following the date of issuance. The placement agent is to receive a placement agent warrant to purchase shares of common stock in an amount equal to 8% of the common stock (or common stock equivalents) purchased by investors in the private placement transaction. As of March 31, 2018 and December 31, 2017, the Company has an obligation to issue a placement agent warrant for the purchase of approximately 63,000 shares of common stock. The Company recorded an issuance cost discount to the Convertible Notes in the amount of zero and $16,645 during the three months ended March 31, 2018 and 2017, respectively, of which zero and $12,361 was amortized to interest expense during the three months ended March 31, 2018 and 2017, respectively. The balance of the issuance costs in the amount of zero and $15,803 was attributed to the Warrants and was immediately recorded as interest expense upon issuance
 during the three months ended March 31, 2018 and 2017, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>2017 Convertible Notes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 4, 2017, the Company initially entered into a subscription agreement (with certain investors (the &#8220;Subscribers&#8221;), pursuant to which the Company, in a private placement (the &#8220;Private Placement&#8221;), agreed to issue and sell to the Subscribers 8% convertible promissory notes (each, a &#8220;Note&#8221; and collectively, the &#8220;2017 Convertible Notes&#8221;) and warrants (the &#8220;New Warrants&#8221;) to purchase shares of the Company&#8217;s capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering conversion event. In November 2017, the Board approved an increase in the authorized subscription from $1,000,000 to $1,500,000. The subscription agreement and the 2017 Convertible Notes were amended on December 14, 2017 to move up the maturity date from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision in the event of a qualified financing as described more fully below. In May 2018, the Board approved an increase in the authorized subscription from $1,500,000 to $2,000,000 and extended the offering period from five months to eight months.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The initial closing of the Private Placement was consummated on October 4, 2017, and the Company entered into additional subscription agreements and issued 2017 Convertible Notes in an aggregate principal amount of $1,140,000 to the Subscribers through March 31, 2018. The Company may conduct any number of additional closings so long as the final closing occurs on or before the eight-month anniversary of the initial closing date and the amount does not exceed $2,000,000 or a higher amount determined by the Board. See Note 13 &#8211; Subsequent Events for closings that occurred after March 31, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The 2017 Convertible Notes bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on December 31, 2018 (the &#8220;2017 Convertible Notes Maturity Date&#8221;). If the Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the &#8220;2017 Convertible Notes Qualified Financing&#8221;), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The New Warrants also become exercisable upon a 2017 Convertible Notes Qualified Financing for an amount of shares equal to the number of shares received by the holder in the 2017 Convertible Notes Qualified Financing at the same price per share of the securities issued in the 2017 Convertible Notes Qualified Financing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Prior to the December 2017 amendment, if the Company had raised more than $3,000,000 in an equity financing before October 4,
 2022, the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable in conjunction with the 2017 Convertible Notes Qualified Financing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Lastly, if a change of control transaction occurs prior to the earlier of a 2017 Convertible Notes Qualified Financing or the 2017 Convertible Notes Maturity Date, the 2017 Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by the Board as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms-length transaction or (ii) at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&#8217;s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&#8217;s assets. The New Warrants also become exercisable upon a change of control transaction for an amount of shares equal to the number of shares received by the holder upon conversion in connection with such transaction at the same price per share that the 2017 Convertible Notes converted in the change of control transaction.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The December 2017 amendment resulted in a substantial modification to the original 2017 Convertible Notes whereby the maturity date was moved up to December 2018 from October 2022 and the terms associated with the embedded features were revised as described previously. The fair value of the underlying Convertible Notes was $27,371 lower than the face amount of the 2017 Convertible Notes. The $27,371 difference was recorded as a discount to the debt and is being amortized over the amended term of the 2017 Convertible Notes. The amortization recorded during the three months ended March 31, 2018 was $6,432.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The 2017 Convertible Notes contain a conversion discount in the event of a 2017 Convertible Notes Qualified Financing to equal the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The embedded feature qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the 2017 Convertible Notes in the amount of $91,298 for the convertible debt issued during the three months ended March 31, 2018. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $27,021 for the three months ended March 31, 2018. The embedded derivative is accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with all of the 2017 Convertible Notes in the condensed consolidated statements of operations which amounted to an expense of $1,323 for the three months ended March 31, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The New Warrants were deemed to be a free-standing instrument and were accounted for as a liability given the variable number of shares issuable in connection with a change of control conversion event. A Monte Carlo simulation model was used to estimate the aggregate fair value of the New Warrants. Input assumptions used were as follows: risk-free interest rate of 2.57 and 2.22 percent as of March 31, 2018 and December 31, 2017, respectively; expected volatility of 50 percent as of March 31, 2018 and December 31, 2017; expected life of 5.21 and 5.38 years as of March 31, 2018 and December 31, 2017, respectively; and expected dividend yield of 0 percent as of March 31, 2018 and December 31, 2017. The underlying stock price used in the analysis was on a non-marketable basis and was according to a separate independent third-party valuation analysis as there has been very limited trading with the Company&#8217;s common stock since the Acquisition on July 20, 2017. The 2017 Convertible Note proceeds assigned to the New Warrants were $238,864 during the three month period ended March 31, 2018, which represented their fair value at issuance and were discounted from the 2017 Convertible Notes and reflected as a warrant liability. The discount is being amortized to interest expense over the term of the 2017 Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $70,505 for the three month period ended March 31, 2018. The Company also recorded the fair value changes of the warrant liability associated with &#160;all of the 2017 Convertible Notes in the condensed consolidated statements of operations which amounted to an expense of $9,355 for the three months ended March 31, 2018.&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In connection with the 2017 Convertible Notes, the Company incurred original cost of issuance in the amount of $5,283 which consisted of legal costs and was recorded as an issuance cost discount to the 2017 Convertible Notes, of which $375 was amortized to interest expense during the three months ended March 31, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>2016 and 2017 Convertible Note Subscription Agreements</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pursuant to the subscription agreements entered into in connection with the 2016 Private Placement and the Private Placement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the Convertible Notes and associated Warrants or any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right to purchase the Convertible Notes and associated Warrants or the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the respective subscription agreements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6651892416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Banker Fee<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InvestmentBankerFeeAbstract', window );"><strong>Investment Banker Fee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InvestmentBankerFeeTextBlock', window );">Investment Banker Fee</a></td>
<td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify; border-top: 1.5pt solid black; border-bottom: 1.5pt solid black;"><b>NOTE 9 &#8211; Investment Banker Fee</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"><b><i>&#160;</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"><b><i>Investment Banker Fee</i></b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">NeuroOne paid a $50,000 non-refundable fee to an investment banker in December 2016 to raise equity financing. NeuroOne subsequently concluded that the investment banker was not expected to raise any equity and therefore expensed the fee in March 2017.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InvestmentBankerFeeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InvestmentBankerFeeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InvestmentBankerFeeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment banker fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InvestmentBankerFeeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754651824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 10 &#8211; Stock-Based Compensation</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NeuroOne formally adopted an equity incentive plan (&#8220;the 2016 Plan&#8221;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition. In addition, the Company adopted a 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) on April 17, 2017. The 2016 and 2017 Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards in the second quarter of 2017, under the 2016 Plan. During the three month periods ended March 31, 2018 and 2017, no stock options or restricted stock award grants were formally issued. See stock-based award liability section below for stock-based award grants committed, but not formally issued as of March 31, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the three months ended March 31, 2018 and 2017, there was no vesting of formally issued stock options or restricted stock awards. No stock options were forfeited during the three months ended March 31, 2018 and 2017. As of March 31, 2018, 1,711,096 shares were available for future issuance on a combined basis under the 2016 and 2017 Plans.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">There was no unrecognized stock-based compensation cost for stock options and restricted common stock as of March 31, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Stock-Based Award Liabilities</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2018, the Company had a formal obligation to issue future restricted common stock and common stock options relating to two consulting agreements. The estimated liability associated with the vested portions of these awards was recorded in accrued expenses in the accompanying condensed consolidated balance sheets as of March 31, 2018. The corresponding stock-based services expense related to the stock-based award liability was included in general and administrative and research and development costs as follows in the accompanying condensed statements of operations:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2;
 font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="font-weight: bold;">&#160;</td><td nowrap="nowrap" style="text-align: center; font-weight: bold;" colspan="2">Three Months&#160;<br />Ended</td><td nowrap="nowrap" style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td nowrap="nowrap" style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March 31,<br />2018</td><td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">General and administrative</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">252,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Research and development</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,437</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total stock-based compensation</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">254,437</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">A total of up to 250,000 shares of common stock was committed as a result of one consulting agreement for investor relation services executed in February 2018, but none of the underlying shares of common stock were issued as of March 31, 2018. The portion of the stock award that had met performance vesting conditions as of March 31, 2018 amounted to 100,000 common shares and were issued on April 26, 2018. The amount of compensation expense totaling $252,000 related to the vested common shares was based on the fair value of the underlying common stock at point of vesting which was $2.52 per share on a non-marketable basis. The common stock fair value was according to a separate independent third-party valuation analysis since there was no active trading market for the Company&#8217;s common stock. The remaining 150,000 shares of the stock award will vest and be issued in 50,000 share quarterly tranches beginning in May 2018. The first 50,000 tranche of shares was issued on May 7, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Additionally, the Company recorded stock-based services expense related to unissued stock options associated with a second consulting agreement whereby the number of option shares and pricing will not be set until the occurrence of the award date which is defined as the earlier to occur of a public offering, qualified financing, or June 30, 2018. The number of option shares under the agreement is based on a $3,000 monthly compensation amount divided by the fair value of the underlying common stock on the award date. The exercise price will also be set at the fair value of the underlying common stock on the award date. The liability associated with the unissued options was based on an option share equivalent estimate that reflects the portion of the award where performance vesting conditions have been met as of March 31, 2018 and was based on the fair value of the Company&#8217;s common stock on March 31, 2018 as the award date has not occurred. The common stock fair value on March 31, 2018 was $2.30 per share and was determined based on a separate independent third-party valuation analysis since there was no active trading market for the Company&#8217;s common stock.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock- option liability during the three month periods ended March 31, 2018:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">Expected stock price volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">47.8</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life of options (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2.6</td><td style="text-align: left;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Upon the issuance of all of the unissued options associated with the stock-based award liabilities, the estimated number of shares available for future issuance as of March 31, 2018 would be reduced from 1,711,096 shares to 1,704,574 as a result of the potential stock option issuance under the second consulting agreement. The 250,000 shares of common stock issuable under the February 2018 consulting agreement were not eligible for issuance under either of the 2016 or 2017 Plans as the consulting contract was not with an individual. See Note 12 - Stockholders&#8217; Deficit for additional information.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618075328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 11 &#8211; Income Taxes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The effective tax rate for the three months ended March 31, 2018 and 2017 was zero percent. As a result of the analysis of all available evidence as of&#160;March 31, 2018&#160;and&#160;December&#160;31, 2017, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported&#160;no&#160;income tax benefit during the&#160;three months ended&#160;March 31, 2018 and 2017. If the Company&#8217;s assumptions change and the Company believes that it will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be recognized as a reduction of future income tax expense.&#160;&#160;If the assumptions do not change, each period the Company could record an additional valuation allowance on any increases in the deferred tax assets.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law making significant changes to the U.S. tax code. Changes affecting the Company&#8217;s consolidated financial statements include, but are not limited to, a U.S. federal corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. The Company has adjusted the disclosure amounts related to deferred tax assets and the valuation allowance recorded to reflect the new federal corporate tax rates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754617248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Deficit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1.5pt; border-bottom-width: 1.5pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>NOTE 12 &#8211; Stockholders&#8217; Deficit</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Common Stock</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has 100,000,000 shares of common stock authorized, par value $0.001 per share, of which 7,864,994 shares were issued and outstanding at March 31, 2018 and December 31, 2017. In connection with the February 2018 consulting contract discussed in Note 10 &#8211; Stock-based Compensation, up to 250,000 shares of common stock are issuable under the contract. Upon issuance, these shares are subject to restrictions pursuant to the provisions of Rule&#160;144. On April 26, 2018 and May 7, 2018, 100,000 and 50,000 shares of common stock were issued under the contract, respectively, and subject to the restrictions under the provisions of Rule 144.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754658368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify; border-top: 1.5pt solid black; border-bottom: 1.5pt solid black;"><b>NOTE 13 &#8211; Subsequent Events</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"><i>2017 Convertible Notes</i></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">The Company issued additional 2017 Convertible Notes and New Warrants to investors for aggregate gross proceeds of $350,000 from April 13, 2018 to May 8, 2018. &#160;The additional convertible notes and warrants issued have identical terms to the 2017 Convertible Notes and New Warrants disclosed in Note 8 - Convertible Promissory Notes and Warrant Agreements.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">Additionally, on May 8, 2018, the Board approved an increase in the maximum amount of aggregate 2017 Convertible Notes offered from $1,500,000 to $2,000,000.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;"><i>Issuance of Common Stock</i></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0pt 0px; text-align: justify;">Between April 26, 2018 and May 7, 2018, the Company issued 150,000 shares of common stock to an investor relations firm in consideration for consulting services.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762125456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Management's Use of Estimates</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Management&#8217;s Use of Estimates</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2018, the Company did not have any deposits in excess of federally insured amounts.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;"><font style="font-size: 10pt;">&#9679;</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;"><font style="font-size: 10pt;">&#9679;</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;"><font style="font-size: 10pt;">&#9679;</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 41pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2018 and December 31, 2017, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term and convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the short-term and convertible promissory notes of the Company were based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected
 returns by market participants for similar instruments and are based on Level&#160;3 inputs. There were no transfers between fair value hierarchy levels during the three months ended March 31, 2018 and 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of financial instruments measured on a recurring basis is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of March 31,&#160;2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,634,059</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,634,059</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">607,173</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">607,173</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,241,232</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom:
 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,241,232</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,381,465</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom:
 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level&#160;3 inputs for the three month periods ended March 31, 2018 and 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Warrant liability</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Value assigned to warrants in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">376,586</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">182,693</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(123,992</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(215</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,634,059</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">528,438</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Premium debt conversion derivatives</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">462,174</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">137,650</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">140,967</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">72,732</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of premium debt conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">4,032</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">183</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">607,173</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">210,565</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IntellectualPropertyPolicyTextBlock', window );">Intellectual Property</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Intellectual Property</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Impairment of Long-Lived Assets</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates its long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through March 31, 2018, the Company has not impaired any long-lived assets.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Debt Issuance Costs</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the short term notes and convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Research and Development Costs</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Warrant Liability</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company issued warrants to purchase equity securities in connection with the issuance or amendment of short-term and convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumDebtConversionDerivativePolicyTextBlock', window );">Premium Debt Conversion Derivatives</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Premium Debt Conversion Derivatives</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&#160; The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed consolidated statements of operations. The Company determined that the redemption features under the amended short-term promissory notes and convertible promissory notes qualified as embedded derivatives and were separated from their debt hosts.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Income Taxes</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.</p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s short-term notes, convertible promissory notes, warrants and stock options are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants and stock options. Diluted earnings with respect to the short-term notes and convertible promissory notes utilizing the if-converted method was not applicable during the three month periods ended March 31, 2018 and 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three month periods ended March 31, 2018 and 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three month periods ended March 31, 2018 and 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Warrants</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">189,750</td><td style="width: 16px; text-align: left;">(1)</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">597,283</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Stock options</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">365,716</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style:
 initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 24px;"><font style="font-size: 10pt;">(1)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2017, the FASB issued ASU 2017-09,&#160;<i>Compensation - Stock Compensation (Topic 718):&#160;Scope of Modification Accounting (ASU 2016-09)</i>,&#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The Company has adopted this standard for the three months ended March 31, 2018. The adoption of this standard did not have any impact on the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2017, the FASB issued ASU No. 2017-11,&#160;<i>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</i>, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&#160;15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#8217;s consolidated financial statements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IntellectualPropertyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy fori ntellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IntellectualPropertyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PremiumDebtConversionDerivativePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium debt conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PremiumDebtConversionDerivativePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6621289696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of financial instruments measured on a recurring basis</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of March 31,&#160;2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,634,059</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,634,059</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">607,173</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">607,173</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,241,232</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,241,232</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new
 roman', times, serif; margin: 0pt 0px 0pt 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,381,465</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">462,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,843,639</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of warrant liability and premium conversion derivative measured at fair value on a recurring basis</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Warrant liability</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,381,465</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Value assigned to warrants in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">376,586</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">182,693</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(123,992</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(215</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,634,059</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">528,438</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Premium debt conversion derivatives</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">462,174</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">137,650</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">140,967</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align:
 right;">72,732</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of premium debt conversion derivatives</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">4,032</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">183</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">607,173</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">210,565</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of computation of diluted net loss per share</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Warrants</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">189,750</td><td style="width: 16px; text-align: left;">(1)</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">597,283</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Stock options</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">365,716</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 24px;"><font style="font-size: 10pt;">(1)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.</font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6921252016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangibles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Useful Life</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1129px; text-align: justify;">Net Intangibles, December 31, 2017</td><td style="width: 16px;">&#160;</td><td style="width: 189px; text-align: center;">12-13 Years</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 188px; text-align: right;">216,372</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt;">Less: amortization</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: justify; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(4,952</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 4pt;">Net Intangibles, March 31, 2018</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: justify; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">211,420</td><td style="text-align: left; padding-bottom: 4pt;"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6637582656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: center; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>March 31,</b></font><br /><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>2018</b></font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: center; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>December 31,</b></font><br /><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>2017</b></font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued&#160;license fees</font></td><td style="width: 16px; line-height: 14.26px;">&#160;</td><td style="width: 16px; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="width: 142px; text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">120,000</font></td><td style="width: 16px; line-height: 14.26px;">&#160;</td><td style="width: 15px; line-height: 14.26px;">&#160;</td><td style="width: 15px; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="width: 141px; text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">120,000</font></td><td style="width: 15px; line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued services</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">868,811</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">600,339</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued issuance costs</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">28,083</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">28,083</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued payroll</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">251,543</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">223,195</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Advances</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#8212;</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="text-align: right; line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,000</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="line-height: 14.26px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Other (1)</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">254,437</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#8212;</font></td><td style="line-height: 14.26px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td
 style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,522,874</font></td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px;">&#160;</td><td style="line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="text-align: right; line-height: 14.26px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,021,617</font></td><td style="line-height: 14.26px;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><table style="font: 11pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.25in;"></td><td style="width: 0.25in;"><font style="font-size: 10pt;">(1)</font></td><td><font style="font-size: 10pt;">Accrued expenses include an obligation to issue stock awards and stock options to consultants that have met vesting requirements as of March 31, 2018 in the amount of $254,437. See Note 10 &#8211; Stock-Based Compensation for further detail.</font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758011408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible notes</a></td>
<td class="text"><div><br class="apple-interchange-newline" /><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />March 31,<br />2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December 31,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1179px; text-align: left; text-indent: -9pt; padding-left: 9pt;">2016 convertible promissory notes, net of discounts</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,578,239</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1,543,652</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9pt; padding-left: 9pt;">2017 convertible promissory notes, net of discounts</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">753,637</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">504,465</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9pt; padding-bottom: 1.5pt; padding-left: 9pt;">Accrued interest</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">173,213</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">120,223</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -9pt; padding-bottom: 4pt; padding-left: 0.25in;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,505,089</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,168,340</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6652032368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="font-weight: bold;">&#160;</td><td nowrap="nowrap" style="text-align: center; font-weight: bold;" colspan="2">Three Months&#160;<br />Ended</td><td nowrap="nowrap" style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td nowrap="nowrap" style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">March 31,<br />2018</td><td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">General and administrative</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">252,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Research and development</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,437</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total stock-based compensation</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">254,437</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used Black-Scholes option-pricing model</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">Expected stock price volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">47.8</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life of options (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2.6</td><td style="text-align: left;">%</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758484032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 20, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OrganizationAndBasisOfPresentationTextualAbstract', window );"><strong>Organization and Basis of Presentation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Par value of company's common stock issued in lieu of exchange | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance shares exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OrganizationAndBasisOfPresentationTextualAbstract', window );"><strong>Organization and Basis of Presentation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Common stock, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversation of stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">NeuroOne Medical Technologies Corporation, increased its authorized number of shares of common stock from 45,000,000 to 100,000,000, increased its authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Par value of company's common stock issued in lieu of exchange | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common shares exchange ratio</a></td>
<td class="nump">17.0103706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate shares issued of the then-outstanding NeuroOne shares</a></td>
<td class="nump">6,291,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance shares exercise of options</a></td>
<td class="nump">992,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Tendered for cancellation of shares</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OrganizationAndBasisOfPresentationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OrganizationAndBasisOfPresentationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758087280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 6,681,570<span></span>
</td>
<td class="nump">$ 5,324,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term promissory note</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory note financing</a></td>
<td class="nump">1,625,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNotesPayableOne', window );">Second convertible promissory note financing</a></td>
<td class="nump">1,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubscriptionAmountToConvertiblePromissoryNote', window );">Subscription Agreement Limit 2016 Convertible Notes</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne', window );">Subscription Agreement Limit 2017 Convertible Notes</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNotesPayableOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNotesPayableOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoingConcernTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoingConcernTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SubscriptionAmountToConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription to convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SubscriptionAmountToConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription to convertible promissory note one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SubscriptionAmountToConvertiblePromissoryNoteOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764480560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 1,634,059<span></span>
</td>
<td class="nump">$ 1,381,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumConversionDerivative', window );">Premium conversion derivative</a></td>
<td class="nump">607,173<span></span>
</td>
<td class="nump">462,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">2,241,232<span></span>
</td>
<td class="nump">1,843,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumConversionDerivative', window );">Premium conversion derivative</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumConversionDerivative', window );">Premium conversion derivative</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">1,634,059<span></span>
</td>
<td class="nump">1,381,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumConversionDerivative', window );">Premium conversion derivative</a></td>
<td class="nump">607,173<span></span>
</td>
<td class="nump">462,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">$ 2,241,232<span></span>
</td>
<td class="nump">$ 1,843,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764378608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfWarrantLiabilityAbstract', window );"><strong>Schedule of warrant liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 1,381,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of end of period</a></td>
<td class="nump">1,634,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,381,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfWarrantLiabilityAbstract', window );"><strong>Schedule of warrant liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of beginning of period</a></td>
<td class="nump">1,381,465<span></span>
</td>
<td class="nump">$ 345,960<span></span>
</td>
<td class="nump">345,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsAndValueAssignedToWarrants', window );">Value assigned to warrants in connection with convertible promissory and short-term notes</a></td>
<td class="nump">376,586<span></span>
</td>
<td class="nump">182,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(123,992)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of end of period</a></td>
<td class="nump">$ 1,634,059<span></span>
</td>
<td class="nump">$ 528,438<span></span>
</td>
<td class="nump">$ 1,381,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsAndValueAssignedToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds and value assigned to warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsAndValueAssignedToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764353712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract', window );"><strong>Schedule of Premium debt conversion derivative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 462,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Balance as of end of period</a></td>
<td class="nump">607,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember', window );">Premium debt conversion derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract', window );"><strong>Schedule of Premium debt conversion derivative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Balance as of beginning of period</a></td>
<td class="nump">462,174<span></span>
</td>
<td class="nump">$ 137,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes', window );">Value assigned to the underlying derivatives in connection with convertible promissory and short-term notes</a></td>
<td class="nump">140,967<span></span>
</td>
<td class="nump">72,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition', window );">Change in fair value of premium debt conversion derivatives</a></td>
<td class="nump">4,032<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Balance as of end of period</a></td>
<td class="nump">$ 607,173<span></span>
</td>
<td class="nump">$ 210,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ChangeInFairValueOfPremiumDebtConversionDerivativeAndRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfPremiumConversionDerivativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value assigned to the underlying derivative in connection with convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt premium to be amortized within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762156640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive computation of diluted net loss per share</a></td>
<td class="nump">189,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">597,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive computation of diluted net loss per share</a></td>
<td class="nump">365,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">There are additional potential warrants to be included which will be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758386144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Less: amortization</a></td>
<td class="nump">$ 4,952<span></span>
</td>
<td class="nump">$ 5,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangibles, Beginning Balance</a></td>
<td class="nump">216,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Less: amortization</a></td>
<td class="num">(4,952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangibles, Ending Balance</a></td>
<td class="nump">$ 211,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Intangible Assets [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">License agreement Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Intangible Assets [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">License agreement Useful Life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618107600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoodwilAndIntangibleAssetsTextualAbstract', window );"><strong>Intangibles (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 4,952<span></span>
</td>
<td class="nump">$ 5,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoodwilAndIntangibleAssetsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwil And Intangible Assets Textual [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoodwilAndIntangibleAssetsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764266384">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedLicenseFees', window );">Accrued license fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">868,811<span></span>
</td>
<td class="nump">600,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCosts', window );">Accrued issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,083<span></span>
</td>
<td class="nump">28,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedPayroll', window );">Accrued payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">251,543<span></span>
</td>
<td class="nump">223,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedExpensesAdvances', window );">Advances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">254,437<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,522,874<span></span>
</td>
<td class="nump">$ 1,021,617<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accrued expenses include an obligation to issue stock awards and stock options to consultants that have met vesting requirements as of March 31, 2018 in the amount of $254,437. See Note 10 Stock-Based Compensation for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedExpensesAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses Advances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedExpensesAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Issuance Costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609957552">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedExpensesTextualAbstract', window );"><strong>Accrued Expenses (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued expenses include an obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 254,437<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accrued expenses include an obligation to issue stock awards and stock options to consultants that have met vesting requirements as of March 31, 2018 in the amount of $254,437. See Note 10 Stock-Based Compensation for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedExpensesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedExpensesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765427168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Promissory Notes and Unsecured Loan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 20, 2018</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 12, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Short-term unsecured promissory notes maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 17,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Short-term unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Short-term unsecured promissory notes maturity date</a></td>
<td class="text">Mar. 20,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Cash gross proceeds from an unsecured loan</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember', window );">Short-Term Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Aggregate gross proceeds of short-term unsecured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Issuance costs discounted of short-term unsecured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Short-term unsecured promissory notes maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommonStockPurchaseOfWarrants', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsMaturityTerm', window );">Warrants maturity term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Initial warrant liability changes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AdditionalWarrantsAllocated', window );">Additional warrants allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LossOnShortTermNotesExtinguishment', window );">Loss on short-term notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants', window );">Fair value decrease of short-term notes and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermNoteQualifiedFinancingDescription', window );">Shor-term note qualified financing, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Short-Term Note Qualified Financing (the "New Round Stock") based on the greater number of such securities resulting from either (i) the Outstanding Balance divided by $1.80 or (ii) the Outstanding Balance multiplied by 1.25, divided by the price paid per security in the Short-Term Note Qualified Financing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=nmtc_PremiumConversionDerivativeMember', window );">Premium Conversion Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ValueOfPremiumConversionDerivative', window );">Value of premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionDescription', window );">Short-term notes conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurs at a price under $2.25 per common share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AdditionalWarrantsAllocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional warrants allocated additional coverage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AdditionalWarrantsAllocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CommonStockPurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock purchase of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CommonStockPurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of short term notes and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAdjustmentOfShortTermNotesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LossOnShortTermNotesExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the face value of the short-term notes over the combined carrying values of the short-term notes and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LossOnShortTermNotesExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShortTermNoteQualifiedFinancingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of short-term note qualified financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShortTermNoteQualifiedFinancingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ValueOfPremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ValueOfPremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants maturity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=d3e4724-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=nmtc_PremiumConversionDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=nmtc_PremiumConversionDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765426400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes and warrant agreements</a></td>
<td class="nump">$ 2,505,089<span></span>
</td>
<td class="nump">$ 2,168,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes and warrant agreements</a></td>
<td class="nump">173,213<span></span>
</td>
<td class="nump">120,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2016 convertible promissory notes, net of discounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes and warrant agreements</a></td>
<td class="nump">1,578,239<span></span>
</td>
<td class="nump">1,543,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertiblePromissoryNoteMember', window );">2017 convertible promissory notes, net of discounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes and warrant agreements</a></td>
<td class="nump">$ 753,637<span></span>
</td>
<td class="nump">$ 504,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767753504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,136<span></span>
</td>
<td class="nump">$ 192,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,625,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,918<span></span>
</td>
<td class="nump">178,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt issuance cost discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(186,220)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes', window );">Bifurcation of premium conversion derivative related to convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,298<span></span>
</td>
<td class="nump">72,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_NewWarrantsMember', window );">New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Cost of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value changes of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">2016 Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Subscription Agreement Limit 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,625,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Repay principal and accrued and unpaid interest earlier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds of equity qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If a Qualified Financing occurs before July 31, 2018, the outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by July 31, 2018, the Convertible Notes will be immediately due and payable on such date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity', window );">Description of maximum voting power of surviving entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder', window );">Amount of convertible note held by warrant holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date of issuance and expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.002%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants', window );">Convertible promissory note proceeds assigned to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">182,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">118,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Convertible notes conversion premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible notes conversion price per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">72,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value changes of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (215)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">2016 Convertible Promissory Notes [Member] | Private placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Convertible notes to interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFee', window );">Description of convertible notes issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the "placement agent warrant") which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855 on date of Convertible Note issuance, and (iii) legal expenses of $33,450.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsMaturityTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsToPurchaseSharesOfCommonStock', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfCommonStockPurchaseWarrants', window );">Percentage of common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants', window );">Issuance costs attributed to common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">15,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember', window );">2017 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">717,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt issuance cost discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNotesMaximumExtensionLimit', window );">Subscription Agreement Limit 2017 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAdjustmentOfPremiumConversionDerivative', window );">Fair value changes on premium debt conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember', window );">2017 Convertible Notes [Member] | Private placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may conduct any number of additional closings so long as the final closing occurs on or before the eight-month anniversary of the initial closing date and the amount does not exceed $2,000,000 or a higher amount determined by the Board. See Note 13 - Subsequent Events for closings that occurred after March 31, 2018.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAdjustmentOfPremiumConversionDerivative', window );">Fair value changes on premium debt conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nmtc_SubscriptionAgreementMember', window );">Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFee', window );">Description of convertible notes issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the subscription agreements entered into in connection with the 2016 Private Placement and the Private Placement, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the Convertible Notes and associated Warrants or any portion of the 2017 Convertible Notes or New Warrants, as applicable, and the right to purchase the Convertible Notes and associated Warrants or the 2017 Convertible Notes and associated New Warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the respective subscription agreements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nmtc_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | 2017 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Aggregate principal amount</a></td>
<td class="nump">$ 665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of outstanding voting power</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity date, description</a></td>
<td class="text">Pursuant to which the Company, in a private placement (the "Private Placement"), agreed to issue and sell to the Subscribers 8% convertible promissory notes (each, a "Note" and collectively, the "2017 Convertible Notes") and warrants (the "New Warrants") to purchase shares of the Company's capital stock in the event of a conversion event. The number of shares and pricing per share of the New Warrants are based on the underlying conversion event and are exercisable for five years commencing on the triggering conversion event. In November 2017, the Board approved an increase in the authorized subscription from $1,000,000 to $1,500,000. The subscription agreement and the 2017 Convertible Notes were amended on December 14, 2017 to move up the maturity date from October 4, 2022 to December 31, 2018, remove subordination provisions and simplify the conversion provision in the event of a qualified financing as described more fully below. In May 2018, the Board approved an increase in the authorized subscription from $1,500,000 to $2,000,000 and extended the offering period from five months to eight months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds of equity qualified financing</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFee', window );">Description of convertible notes issuance costs</a></td>
<td class="text">Prior to the December 2017 amendment, if the Company had raised more than $3,000,000 in an equity financing before October 4, 2022, the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the 2017 Convertible Notes multiplied by 1.25, divided by the price paid per security in such financing. The New Warrants would have also become exercisable in conjunction with the 2017 Convertible Notes Qualified Financing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfCommonStockPurchaseWarrants', window );">Percentage of common stock purchase warrants</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nmtc_NovemberTwoThousandSeventeenMember', window );">November 2017 amendment [Member] | 2016 Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of the amended convertible notes carrying value at time of the amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember', window );">2017 Convertible Note amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company to repay the principal and accrued and unpaid interest thereon on December 31, 2018 (the "2017 Convertible Notes Maturity Date"). If the Company consummates an equity round of financing resulting in more than $3 million in gross proceeds before December 31, 2018 (the "2017 Convertible Notes Qualified Financing"), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Convertible Notes whereby the maturity date was moved up to December 2018 from October 2022 and the terms associated embedded features were revised as described previously.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds of equity qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Convertible notes conversion premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt issuance cost discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature', window );">Fair value of underlying Convertible Notes, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Substantial modification to the original 2017 Convertible Notes whereby the maturity date was moved up to December 2018 from October 2022 and the terms associated with the embedded features were revised as described previously. The fair value of the underlying Convertible Notes was $27,371 lower than the face amount of the 2017 Convertible Notes. The $27,371 difference was recorded as a discount to the debt and is being amortized over the amended term of the 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible note held by warrant holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AmountOfConvertibleNoteHeldByWarrantHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bifurcation of premium conversion derivative related to convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNotesMaximumExtensionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes maximum extension limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNotesMaximumExtensionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note proceeds assigned to warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of maximum voting power of surviving entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAdjustmentOfPremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAdjustmentOfPremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs attributed to common stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PercentageOfCommonStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock purchase warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PercentageOfCommonStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants maturity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nmtc_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nmtc_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nmtc_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nmtc_NovemberTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nmtc_NovemberTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nmtc_TwoZeroOneSevenConvertibleNoteAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6610259952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Banker Fee (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InvestmentBankerFeeTextualAbstract', window );"><strong>Investment Banker Fee (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NonRefundableFeeToInvestmentBanker', window );">Non-refundable fee to investment banker</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InvestmentBankerFeeTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InvestmentBankerFeeTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NonRefundableFeeToInvestmentBanker">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable fee to investment banker.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NonRefundableFeeToInvestmentBanker</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6644150416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 254,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">252,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6621202128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">47.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923344208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options weighted average exercise price for shares of common stock granted | $ / shares</a></td>
<td class="nump">$ 2.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance', window );">Restricted common stock not yet issued</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueOfCommonStockPricePerShare', window );">Fair value of common stock price per share | $ / shares</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_MonthlyCompensationAmount', window );">Monthly compensation amount | $</a></td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Compensation expense | $</a></td>
<td class="nump">$ 252,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Stock award vesting and issued, description</a></td>
<td class="text">The remaining 150,000 shares of the stock award will vest and be issued in 50,000 share quarterly tranches beginning in May 2018. The first 50,000 tranche of shares was issued on May 7, 2018.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenPlanMember', window );">2016 Plan [Member] | Employees, directors, and consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">1,704,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">1,711,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member] | Employees, directors, and consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">2,292,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueOfCommonStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueOfCommonStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_MonthlyCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly compensation amount divided by the fair value of the underlying common stock on the award date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_MonthlyCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockBasedCompensationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockBasedCompensationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of vested restricted shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4582445-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569655-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized and expensed compensation cost from equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=nmtc_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=nmtc_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618691920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764336576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 07, 2018</div></th>
<th class="th"><div>Apr. 26, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 20, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Restricted common stock not yet issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock award, shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders' Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Restricted common stock not yet issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">992,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockholdersMemberDeficitTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockholdersMemberDeficitTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753975952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Events [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 07, 2018</div></th>
<th class="th"><div>May 08, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock to an investor relations firm in consideration for consulting services</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Additional 2017 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">New warrants to investors for aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">An increase in maximum amount of aggregate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additionally, on May 8, 2018, the Board approved an increase in the maximum amount of aggregate 2017 Convertible Notes offered from $1,500,000 to $2,000,000.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SubsequentEventsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SubsequentEventsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=nmtc_AdditionalTwoThousandSeventeenConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??5=AZ;?;F'QM?!+L6?MU%]P502P,$%     @ !*JO3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M+[UYCZ^,2:+\B9Z4)[5JT?."DJO4TXV:\[%/C0O)^JD'@_F/0/4'4$L#!!0
M   (  2JKTPEP04R;@,  'P.   8    >&PO=V]R:W-H965T<R]S:&5E=#(N
M>&ULA9=O;YLP$,:_"N)]A\]_H4HB+9FF3=JDJM.VUS1Q&E3 &="F^_8SA$;$
M=W1O C;/^9X#^Q=[<7+-4WNPMHM>J[)NE_&AZXZW2=)N#[;*VP_N:&O_9.^:
M*N]\LWE,VF-C\]T05)4)9TPG55[4\6HQ]-TUJX5[[LJBMG=-U#Y75=[\7=O2
MG98QQ&\=]\7CH>L[DM7BF#_:'[;[>;QK?"NYC+(K*ENWA:NCQNZ7\4>XW7#1
M!PR*7X4]M9/[J"_EP;FGOO%UMXQ9[\B6=MOU0^3^\F(WMBS[D;R//^.@\25G
M'SB]?QO]\U"\+^8A;^W&E;^+77=8QFD<[>P^?RZ[>W?Z8L>"5!R-U7^S+[;T
M\MZ)S[%U93O\1MOGMG/5.(JW4N6OYVM1#]?3./Y;&!W QP!^"0#Y;H 8 T00
MD)R=#:5^RKM\M6C<*6K.7^N8]Y,";H5_F=N^<WAWPS-?;>M[7U9<+I*7?IQ1
MLCY+^%1RK=@0"G61)#[_Q00G3? A7DSC-1TOR'@QQ,MIO F*.$O,(*E'BY"E
M02&$2DMM:"^2]"*QER#+^BQ1DRP&I ZL_$=TY4213A1VD@5.%$HBN)#!!-@0
M*J%!T%XTZ44C+X(%7C3*P@$D#V0;2J:%X;0;0[HQV T$;@Q.(X71X:NA9%F6
MSLS^E'23HMDO9JK)R/@,5R.":C)D$Q3GJ0G+(73,OUZ860' :*8P[ A!A>%)
MI3,(X;,A=%P)QMB,HQG* 7:D0D= 9&**I5EHB1""3H6<\T1##SCVI$-/'*72
MS( 1H26LDYK#Y/M>.Z(Q"IBC(N3HJ)EF4HQ)KL-U2@A%QA1,5MJU)QJG@'DJ
M0IX"9J5'@F0*?3E"*%*/U9GU"C18 9-5A&0%#$VM12H ><)"Q5.MLAG6 PU8
MP(25(6$I#81VWM5<.Z'A"@;Q3,[P#&@@0HH]A$2C-*B6=S773FBT F9K^.^X
M!@Q-DVH5>OF/ZGJ71'.58Z[*D&*<X*7)0(7+D]*E3/ 9AG&:JQQS-=S(K#G&
MY8W6*2B#/!%*);@T<VN!SVPG,5EER#&.B7FC12:5"K\<I51,: TS<XG3=.68
MKC(D&2<VH-2V@]01^XYD<@SHSV7?\^:QJ-OHP77^1#'L^_?.==:/R3[X"@_^
M*'AIE';?];?&WS?G\]"YT;GC>-9++@?.U3]02P,$%     @ !*JO3!%E-^4Y
M @  M <  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6R-E6VOFR 8AO^*
M\0<4?+>--5E=EBW9DN8L._M,6UK-07% Z]F_'Z#'*+*V_5#>[OOA>I#P9!UE
M;[S$6#CO-6GXUBV%:#< \&.):\17M,6-7#E35B,AA^P">,LP.FE338 /80QJ
M5#5NGNFY/<LS>A6D:O">.?Q:UXC]W6%"NZWKN1\3+]6E%&H"Y%F++O@G%K_:
M/9,C,$8Y535N>$4;A^'SUOWD;0H/*H-6O%:XXY.^HU(Y4/JF!M].6Q<J(DSP
M4:@02#8W7&!"5"3)\6<(ZHY[*N.T_Q']BTY>)G- '!>4_*Y.HMRZJ>N<\!E=
MB7BAW5<\)!2YSI#]=WS#1,H5B=SC2 G7_\[QR@6MAR@2I4;O?5LUNNWZE3@9
M;':#/QC\T>"%=PW!8 @, ^C)=*J?D4!YQFCGL/YKM4A="F\3R,,\JDE]=GI-
M9LOE["T/UQFXJ3B#9-=+_(G$GRL*BR(:)4#N/T+X5@A?^X.)/X)V?V#U!]H?
M3OV>D40O2;6DT1*X@M!0%8]4,Y;0RA(N68SCVO62:+*+!_N?@?.$<$8468FB
M)5%@$"TEH7DT=R4SBMA*$2\I0H-B*5E0W)7,*!(K1;*DB R*Y*F;\D@U8TFM
M+.F2)398TO]> /.J/*.<,:VM3.LE4V(PK1<[)6D<KM?&URP>ZV8\LA98WR>X
M)$K-!PH^B?2$L&<"D^=3U;,?B%VJACL'*N1+K-_+,Z4"RZ!P)<.5LH2. X+/
M0G43V6=]'>D'@K9#C01CH<[_ 5!+ P04    "  $JJ],94)N<,\"  #Y"0
M&    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;'V6;6_;(!#'OXKE]ZT!\V!7
M2:0FT[1)FU1MVO::)B2Q:AL/DZ3[]@/LNA[@O8F!_._N=V ?M[I)]=*?A=#)
M:U.W_3H]:]T]9%F_/XN&]_>R$ZWYYRA5P[69JE/6=TKP@S-JZ@P!0+.&5VVZ
M6;FU)[59R8NNJU8\J:2_- U7?[:BEK=U"M.WA6_5Z:SM0K99=?PDO@O]HWM2
M9I9-7@Y5(]J^DFVBQ'&=/L*''236P"E^5N+6S\:)3>59RA<[^7Q8I\ 2B5KL
MM77!S>,J=J*NK2?#\7MTFDXQK>%\_.;]HTO>)//,>[&3]:_JH,_KM$B3@SCR
M2ZV_R=LG,29$TF3,_HNXBMK(+8F)L9=U[WZ3_:77LAF]&)2&OP[/JG7/V^C_
MS2QN@$8#-!D,F[-HD(\&^;L!=LD/9"[5#USSS4K)6Z*&T^JX?2G@0VXV<V\7
MW=ZY_TRVO5F];DBYRJ[6SRC9#A(TD\!)D1GG4P04B[!%@3GZ-\ N5% 0CY!'
M<\B=?3ZW7R#$47OL[/'<WD/<#A+F)*V3E"7".?$R"6488P!IG(9$:4A(DWLT
M@X3,PD!  /9I0AE# "]L#8W"T! &>S T E,R7 "/)M012 %A<1P6Q6$ACI?T
ME@5A[N(\$>'_@(HH4!$"40^HB "5.<B]?=Q%= CFA"Q\"F64IPQYF,=3AN<%
MRY+ZVQ/*<A0G@2!>64#(4OBE!40VIZ (^3019TLO,EPH=##$"2H=#+[?.W,$
ME#'_L&)*ADK"R )4M#8^0A24+K9PWC!>^V >I,6@G]:@*>>PX!XR/Z>X#"_P
MQ&LIQ&%&2^]-O/[!L "&&45*6T%Q60;G% H)@I10_YRRV879"'5RO46?[.6E
MU?9NFJU._<LCLA>NM[ZU?8V[B-_=#$W15ZY.5=LGSU*;Z]Q=ND<IM3"<X-X0
MGDT?-DUJ<=1VR,Q8#<W(,-&R&QNM;.KV-G\!4$L#!!0    (  2JKTPU,*4?
M$@0  $@2   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL?9A=CZLV$(;_
M"N(^!V:,P5XED3:IJE9JI=6IVEZSB9.@PT<*9'/Z[VL^-H=XQKT)X+QCOV/L
MQ\;K>]-^ZR[&],'WJJR[37CI^^M+%'6'BZGR[DMS-;7]Y]2T5=[;Q_8<==?6
MY,<QJ"HCC.,TJO*B#K?KL>RMW:Z;6U\6M7EK@^Y657G[[\Z4S7T30OA9\+4X
M7_JA(-JNK_G9_&'Z/Z]OK7V*'K4<B\K47='406M.F_ 57O9B#!@5?Q7FWBWN
M@R&5]Z;Y-CS\>MR$\>#(E.;0#U7D]O)A]J8LAYJLCW_F2L-'FT/@\OZS]I_'
MY&TR[WEG]DWY=W'L+YM0A<'1G/);V7]M[K^8.2$9!G/VOYD/4UKYX,2V<6C*
M;OP-#K>N;ZJY%FNERK]/UZ(>K_>Y_L\P/@#G 'P$V+;_+T#, >)'0#(F/SD;
M4_TI[_/MNFWN03N]K6L^# IX$;8S#T/AV'?C?S;;SI9^;#.QCCZ&>F;);I+@
M0@(/160K?[2 7 L[).'XW,">*M*8;T&P.8@Q7BQS2/CXA(U/QOADV;YV^F"2
M9*.D'B4K$#+-%@U-N3#"#+7,)&](LH8D3<@3G[+Q*4DH2YV$)HE<^$RT=%\,
M%<DXSG@G&>LDHTXRQTE&&D&9),*1[6E-B6<8*M:)HDZ4XT31=!, I^?V5 69
M4IY>T:P73;VX T[35H32X%C>,[),25_/0,PS("9^5.Q"@&H6K4QF9LV3&ZEB
MX3'C 1)0,^": 3IZ8^&.7D8%RF>&9=<K(#6#KADDS:P A=;$#R-$\$QLX%$'
M@K+*'<:SYCGO%#%V_="ZO .'!R<D!%3>#N9)!Y)X0)(/U="A)^G<%0I]9GAL
M N6F((LA92(FJ4+RLJD.XBQ%#R> QR=0ZJG$=40!NI(:T%W#]IQ0R%B#]GCB
M00J*OG3?(.;Q!Y1_REV?@)(-10K"I3&C XV)KY^1)R R!'37*:1T0Z%4ZNX
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MSK]K['Z#Z,"GDMSX >K\]UH,"8T+QP_^;*8AFPR'_?Q_V/*)RS]02P,$%
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M8*LAH?7A^ ;/=AZSV?!F6'X06[]Q]0M02P,$%     @ !*JO3/I]&Z:S 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL?5-A;]P@#/TKB!]0
M+N2V5:<D4J_3M$JK=.JT[3.7. DJQ"F02_OO!R3-LBWM%\#&[_G9F&Q$\VA;
M $>>M>IL3EOG^@-CMFQ!"WN%/73^ID:CA?.F:9CM#8@J@K1B?+?[R+20'2VR
MZ#N9(L/!*=G!R1 [:"W,RQ$4CCE-Z*OC03:M"PY69+UHX#NX'_W)>(LM+)74
MT%F)'3%0Y_0F.1SW(3X&_)0PVM69A$K.B(_!N*MRN@N"0$'I H/PVP5N0:E
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MG. *3@;904IFWHX@]%C@!'\XGGC;N> @9=ZS%I[!_>I/QEMD8:FY!&6Y5LA
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M#R^;^E\C>@A2-C=AA-KPP69#0>WC\2Z<[3AFH^&QFWX0F[]Q\0M02P,$%
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M_S6B R\EN?$CU/H/MA@*:A>.[_W93&,V&0[[^0>QY1L7OP!02P,$%     @
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MV*[P"$I%HB#CQ\Q)EY01N#Z_LK]/M8=:+L+!(ZKOLO9=0>\IJ:$1@_)/.'Z
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M?S;3F$V&PW[^06SYQN4?4$L#!!0    (  2JKTSJ&/MYM@$  -(#   9
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M]Q&$&G.<XFOBE3>M]0E29#UKX#O8'_U)NX@L*A67T!FN.J2ASO%C>CCN/#X
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M^^#V>GK+4V!5/X\I6?XKBC]02P,$%     @ !:JO3-=B).1R @  (P@  !D
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M<5&QLS+36,]%_VSU"\7;X4GVQO\%FS]02P,$%     @ !:JO3#5Z,FI# @
MR08  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL?97;CILP$(9?!?$
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M\8=#A0]<;B.QIWKLZ0,G;3_2G>%_Q>HO4$L#!!0    (  6JKTR8O\DO7@(
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M@SPQBH,$PSH+4&?Q0-$7$YU/=U6_DUF",DM 9C&264Z.#2,4XIF?$/EP*_F
MTG*&8J8;T>.'A\!NVR \C2+TQQT-@6::&L$]AP* 8N9@$-QU*/R/;.%N04"[
M3+.%0,%(QQO<F!459SM<I)/S2ZW,W32P]@-L@\V-.[)OS6"S-_$'33L5?Q!Q
M+FOI'+C2][F]=4^<*ZIC])]TC(4>Q/V&T9,RRT2O13N-VHWB33=IO7[<9_\
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MK>,?N)+2@,TQ>K)-W=B1GPP&E7';K=VKT/C!,+(;9YI,/Y;\'U!+ P04
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M^N;:^W7E7(&V'CQH[XU^HJ: PE69[4[OQ3BH8Z!X[]X@-#V$Q1]02P,$%
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M@)^Y,)](\=2/C'-*+5+8^ 0X/_9-*02RF)%B/U/@Y]APTAT$V1Y^V/24 (K
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M)OYCP'@)&$.IT(+!@/$ ,-J*(TP$.N,@19@(A(HKO*Q+\B 532R\5J/$Y"!
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MIJ.+(?GD([.CW602PO^5)WIG6[N!VQ_9_VIM+RMW:^)VU3FHC7-C'IO'@-&
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MVZL:*WJ'&]X]PYZS8.A+:N:&5QX.;57<^ZQ8X@\INWT11(B<8006",FMV A
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MV*):CI+/0EX-V3UIF"]:9P>H>E]42ZO.VIIYR&A2I8)N9T%7$[U%'],>:Q3
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M!]KFG6GQMJBE>ZR^U8[@(?D9"\NPHFI7X!6J-W%!A?; X(2:DROB3_>P5'[
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M5R_CBP0,R3S.=W=I7'5PLR,<TO2KDW8:^-<T:%Z7MKOOJ3(Q7@,\KPCNAJ5
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MAZCJC$SYW'&>OC2T:0)$2LXH&MG\:>;05AR:[\*%S:*/;DP0!;,S?T+\]%+
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MMU#C-$$ZCQ07GE??!!K)2#9&9$TAA^K&;SZF)\/<%2(5;#8LS,P'Z>F%LP$
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M7:)U"OPB##UPP1>'C]V%+,2'QZ>S"Y,[^^3)[HM-/. 3_[_ &..."6=SMWO
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M)1Z-!Z>HY]L5FD]LMRTPOU152XOVB'.*-7K%!'&*7A%$I,&1:Z7[PZ--(UX
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MN[QQ)3Y?MS3I?\D7M_#.ER20?$;1%Z:/O)92+S]*%C35JWSM4A[^[3V::>]
M+VN")*ZK^1WH54M&)WTI5FDOR/<_$$S_0##MCV#JX]=^J%*\K<H!(*7]N/D?
M8*-_@(U^5V C?4+V5KV>R.O_4)L\_!:,@7S3?5/KO2GL\^+EV&\/?F'TTWM$
M/Z%G07TVC=P?P]')<)S\+_+3(,],T_$YWAD-7!)>8Y"CL_1B@J<[&+1U4^,H
M(+!&@_;B+B4GX(V)ZN]#A78BP7Y$")2']K+-7'3\'87$B'.$W7^9!VU,?3:=
MI;/A$ [:(!W#!60>:,4I0:(-@-7E?\Q#Z^P1,;7):#),)V?P,\C,X<4DN>2
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MH$MGMPJ3E:9BB;2??*UR-'?!!OX4UE"Q1 W,=]33JC+2= "F+,CC6$D$KX]
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MNAD%5]@ ]K+%*A3WNQ)"JK).QU$Y]$2"\#ST/O!NL2[C( PDJJ!FK]-6RX3
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MAJ-]C3/2L/>VX/@'(_D)4$L#!!0    (  6JKTQ G.1V<0,  -P<   /
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M#,6M/.JF'[Z;QV#2R(BM,3*%K16;R.WA\, <D1%+HFVSA:U*Y?PG=J?B8SI
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M61,461,461,461,469,KRMH=XUJ5S5])/K5>'N:S[J^TV3=02P$"% ,4
M"  $JJ],'R// \     3 @  "P              @ $     7W)E;',O+G)E
M;'-02P$"% ,4    "  $JJ],9O,+8((   "Q    $               @ 'I
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  2JKTPA"0B>[P   "L"
M   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   (  2JKTR97)PC$ 8  )PG   3              "  ;<"  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ !*JO3(<A@@=F @  % @  !@
M         ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   (  2JKTPEP04R;@,  'P.   8              "  90+  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  $JJ],$64WY3D"  "T!P
M&               @ $X#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ !*JO3&5";G#/ @  ^0D  !@              ( !IQ$  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (  2JKTPU,*4?$@0
M $@2   8              "  :P4  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  $JJ],EQ6C@;0!  #0 P  &               @ 'T
M&   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ !*JO3)9*
MJ.VS 0  T@,  !@              ( !WAH  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    (  2JKTSYWQ;FM0$  -(#   8
M  "  <<<  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  $
MJJ],_CR.>+0!  #2 P  &               @ &R'@  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ !*JO3/I]&Z:S 0  T@,  !D
M         ( !G"   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  $JJ],[@;Q8K@!  #1 P  &0              @ &&(@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (  2JKTQ1IKX@L0$  -(#
M   9              "  74D  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ !*JO3)^B@X^O 0  T@,  !D              ( !728
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  $JJ],76#[
M4[,!  #2 P  &0              @ %#*   >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    (  2JKTQT<CS/M $  -(#   9
M  "  2TJ  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M!*JO3$X,$2>U 0  T@,  !D              ( !&"P  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  $JJ],GI:<L+,!  #2 P  &0
M            @ $$+@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    (  2JKTQSJ2OTM $  -(#   9              "  >XO  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ !*JO3'Q1^*=/ @
M/ @  !D              ( !V3$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  $JJ],U5@*ELT!  "<!   &0              @ %?
M-   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  2JKTPP
M\Y6PM0$  -(#   9              "  6,V  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ !*JO3.H8^WFV 0  T@,  !D
M     ( !3S@  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  6JKTQ"PY0#K0(  'H+   9              "
M 4%#  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ !:JO
M3(K1.P." @  8P@  !D              ( !)48  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  %JJ],F+_)+UX"  !J!P  &0
M        @ '>2   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   (  6JKTP1G;YV/0(  -H&   9              "  7-+  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ !:JO3-U,\L9D @  ^@<
M !D              ( !YTT  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  %JJ],T/E&^-T!  !D!   &0              @ &"4
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  6JKTS4]43?
MB@(  '((   9              "  992  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ !:JO3#F"XGSU 0  % 4  !D
M ( !5U4  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  %
MJJ],O:*FF'X#  "*$   &0              @ &#5P  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  6JKTQ7.F&L+P(  !8'   9
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M970T,"YX;6Q02P$"% ,4    "  %JJ], DV-GHX"  "="0  &0
M    @ $7:P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M  6JKTRDBW!$YP$  /<$   9              "  =QM  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ !:JO3,0K("AW @  ]0@  !D
M             ( !^F\  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  %JJ],:0_A2=H!   !!0  &0              @ &H<@  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (  6JKTR:]BEAREP
M 'V; 0 4              "  ;ET  !X;"]S:&%R9613=')I;F=S+GAM;%!+
M 0(4 Q0    (  6JKTRAWP'R6@(  &T,   -              "  ;71  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ !:JO3$"<Y'9Q P  W!P   \
M         ( !.M0  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  6JKTQX
MLDPMN@$  "D;   :              "  =C7  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    (  6JKTP3I$.VM0$  %(;   3
M      "  <K9  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     U #4 90X
' +#;      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>89</ContextCount>
  <ElementCount>197</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Organizationandnatureofoperations</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Intangibles</Role>
      <ShortName>Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Short-Term Promissory Notes and Unsecured Loan</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan</Role>
      <ShortName>Short-Term Promissory Notes and Unsecured Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Convertible Promissory Notes and Warrant Agreements</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Investment Banker Fee</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/InvestmentBankerFee</Role>
      <ShortName>Investment Banker Fee</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Summaryofsignificantaccountingpoliciespolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesTables</Role>
      <ShortName>Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/Intangibles</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/AccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Organizationandbasisofpresentationdetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/Organizationandnatureofoperations</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/GoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/GoingConcern</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Summary of Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesDetails</Role>
      <ShortName>Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IntangiblesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Intangibles (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual</Role>
      <ShortName>Intangibles (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IntangiblesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/AccruedExpensesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Accrued Expenses (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpensesDetails1</Role>
      <ShortName>Accrued Expenses (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/AccruedExpensesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Short-Term Promissory Notes and Unsecured Loan (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails</Role>
      <ShortName>Short-Term Promissory Notes and Unsecured Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Investment Banker Fee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/InvestmentBankerFeeDetails</Role>
      <ShortName>Investment Banker Fee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/InvestmentBankerFee</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Stockbasedcompensationdetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationDetailsTextual</Role>
      <ShortName>Stock-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Incometaxesdetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Stockholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Stockholdersdeficitdetails</Role>
      <ShortName>Stockholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockholdersDeficit</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nmtc-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SubsequentEvents</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nmtc-20180331.xml</File>
    <File>nmtc-20180331.xsd</File>
    <File>nmtc-20180331_cal.xml</File>
    <File>nmtc-20180331_def.xml</File>
    <File>nmtc-20180331_lab.xml</File>
    <File>nmtc-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001213900-18-006399-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-18-006399-xbrl.zip
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M7]OVU[\[80VE[:\OF5O\?C_46Q-%@((X?0F$DDAJH_30D*[]KH#V]!OL#L@
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M8P6$N\)W9UQ>#'NC]J8 \M' ;Z-D#R@\:\1A#L7=@;RKEZD9D?50RC0Y_JM
M]GM6[V[<+CX[=K>O.WN;0-D2N'?&[$6WW>VM!RX?/L#2%S.<D/HF5)U8/TQ$
M!%.ZHFY 6BP9?;A[,G0[(J]R&^#N>^UWE3KV!66?;'7]2O\Z?IC@=@-S)WQ5
M,]9D)[1=<K:^'4"O_[44H)K,C(W:,2[GS7:WKV<'K5S!MO%_9YDQ&G0ZMUT
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M@&YD:!TOY',6+71%7Q>9^UC[+NID7HGS%V-/GN]IH0AJ%DR(D,T/6$*/J*)
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M7CR %S_-=[D&@^A"P7M&)-8T\WFS,V<<9;)'A2P4$\%6#+/R:01Y+)/7D&&
MX&Q,<7'92\W!=%U5?0A6!)HKZ4V>;#O707=RT,%P4&O&"#B&G'6AA6'FO,J.
M]_T(<9Q"N48-LYF!P6DB@3-!:^8EB$-*Y['[+1YO+-2C8<]]QX-S,A6DP6LH
M](_+J(EFU(<Q^ /I(:I+B?X@S_<H$$-A$SEYP$VQIB]MB/47"NMJ<K)-%=H1
M"H7:1KY&BA\OP4"*_ST+EHGQ]]$Y%^6V72?*7\DT%97MV[)>\L*(S$]F*(3>
M:A4*E"'TBC?NX6TCB^6G?V,>D'6JB>ZR3)XQ76KB/2I3)@_:4H:)F.&7US:+
M7!H@1VB1:U'5V@KY)3MWB6,<2##$0#)3J2"8&J-**^!$F,TIN>2*G8GH,*<K
MUP2)K#W(Y;'X8N(GV+ 4RRLLFD\(Q%4E(MHCL&DKEB&+XN,%]@VE0AK1(;U6
M'ZS2 CD1A3H8T=V+;!R ]AGCVG *(NFM4KM6JNWVY^H5B$["%-:%:(L"?+ZB
M=#2E$7B[TKD/V\HK:A_,GL+4GS -5/< F70DU*BJJ":2H$S(U7;HJ9DQ-RS5
M:ZNQ&'\7:N:9YU_AIY^?9<G9U'$6SS^#T"&='J:Y+?(1GNH"_K[ +OPM  /G
MUQ]_^%G> 9  +NCYEZ'W(J([6(C7P^9Q@PA+>-2=Y&^ #Y_8Y)='+_C?7[OO
M7GUMVU__[H1?D89?VNVO_/]?/GSMVE]!/Q>_?_0K B]@OS?25X3ATFBQ-'97
M^QO>M"RH5_L;WE2(]BV+!-Y".1ST /W^PY=75L]2&\3^R=(XE39;@5?K3L_W
MAK5.AW9KC$DP5#G,CGK+IDZ@;9,:6]B0YN!.)4."_=8R49F /Z<R;-Y>-"U:
MA$DV_K=(=\>#PU1X2S#)/7#\.:;O^XGPFN"M@ DPW6(L,,AB7FX@#5F] 5'!
M9_6>97'T(62J0SXVU254\U/*QW=?.%S49#^VV'P11#>\* JLJV_6BUF,!QU
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M&LT:JE5^(&B>S/6I)4J&LZ+U2PFO68ALB ZN$ "=84=T%DZ=*2](R4+J4E@
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MX%"K<ZZ,1>2 .$D2N7SXNO(D5 /P,=/6D_*X1\P6F!HB72^^4O<>IH1XY +
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M\ L5IM._1(6W/_0\*'R_!/.03].HH'RX:PSM;H"V1) ]O"@KE8!-TI(L.[M
MZ.6B\(+GUH6:*H]F\+*1 "V0JQ0TEO-NDD:\2; V&96LWU-=B#:+>-G-O4[Y
M;CZ,6$Z-'HY:G>[%76#88"7]6ZR^?Z?5V\M7W^NV!OW.76#8%8OS*;(U#'Y'
MCA[>E:-O(?DVXI4&8@W[0*INLV#:^'T'6D>_W6OU!OUMO6]W@G0C/BNI@P;V
MNRPUJ]]0R]P&\QSR7>C76[/!SJ"QA]U6Q^YN@)>[X=E0Z594ZK1;G<ZNJ;13
M[;-<!O2J$J P'WQSQNKMEZUZC63TH@RTYBKC8QO,M!X,G5:_W6^U1\WVVVIN
MV@2YAC!K$\8>C%K=7GNGA&D<]6[\<@?RRXUKZ&7\ID?A":?3_#+?MR'6X8EE
M8LF')L&;<AQ8-/214SO]T/I[%C(K'YLLY@:I@=;%Q \^,'K%:,WRF"]]FU9G
M5B-$JZ8CEQY8-QAYY>QKWLOG<>>\K])4J-L;G5X],=ZI-M-49+GJV;!EB BW
M'\6(I(\RQ%Z=7ZIF9<HQU*J-D88>/6P''Z:.'Q:[T<EYR<N&6*N4G?+#*1.@
MU-*(/ZMVNK7H*I26!R#E77]__"$'EC*#1(:/**.?1U=\F!=LA_",)Q=A@3YO
M( @@\=H,K1"IT&Z.\HLPGG]CF@49<?[ 27!9TXJM7%7!!\K"UDWYMGMLMP:=
M?LONM/'3"F%#X^RO& CB6/5AJ-Q K3!$NE'31:LG*\LFXKL?L"Q'$N83$HN2
M+I)%?&&2S>>.7BP2 E$:9X76)$KF8RC]L) :>=YN3HZTGCBZ+EDQ0U1,B%S2
M Z5N<NFZDT?K\%AHMU?@A+K1H<EFLT.I_:LV=77%V,]5$S_76^7JI96G@[8D
MEVSCX7>?)-HT.51'[L3Q ]K16,T(HI U< V\L895JE!? _]B0TM]V*67\<1E
M;=XF$11-$*.ICT!3&YU]:&*L,\\W5@-?%MDX\%U>_Z>)=#54MG8+-^[8'8WD
MK;QIF^-W6T<Q?Y=D<&GV[M;F[%K5.;NMC0?MGE6GZ])#-IZL6YSO]J+"J7/F
MX*$,_AM/$3FQUL-!K=.!HS\R )7T$ICY6+JZT2I:40Q@-4+/@07G0\UFRJ?5
MU/'D540874376MOU++[B!:X""J&R/3]9 ,])WG=XY;#6KP.XAKX4S06 !]+$
M*M:\&&5V<)>O<<0?$54^ZK/GE0NQW!90G2ME1;G<\;2=J\,LM$&<_D35M8-X
MG:34P+$\&+1&$=&IK3P)HR#D*[^JRAHATB602R:2UKQ8UM45 %?*Z/:PEW5=
M82UW/XT4YW#(1D.BWT+Y%,1/^\5F][KNK6G2+M6\&E>7C]CP&F9LO"DXI6<@
MXJ^P&8)^MM']IP6WI((M;R=0M8NX#BP"&ZBSE1JR4:79YNBF)C?P?04(CLJ\
M4Y'$O* Z!U%Z<ZCY_S5I9'BU'!V 7Q?.RRMYIY[3FWW%M .*:-#&M104>@T[
M$XPIKX6M'[RK^F*4K3*IT2L.A&7GWP)O+IGB4IVFTC1L5SPD"^7;A5>(D#-S
M>+L2(!236 )2&TOA"(Z]A@2'ZY5WC\:S[F(PJ$3/]N9^(NHZY^W<HUX[L06O
MTHM$A'H5O7L K\'-DLFA/_YPBZ<WC1G%B[OGHPL^;_0.X*X[J'2#5SRDF:;G
MN<2LB^+D 0K@41!X^5R=XA;_D\41K?.Q/>JT!A==R\O(>96NU<&1V+="W(:.
MC;";M"V%P69A5[9R"2*K'5"$R++W^KA7J15[9=@Q9P;Y/$['.;83^Y/C0NU'
MU?A;=H2,Y)0?JLYO-K#4/#@0A XF,6)P"?#%TEGDR5G'"R#$=Y(N_.3$)A..
MIAP ?H,R*A%$SCT2,H1=(Y0]:HT&G0WZ;-93J935$"31N@W;UQLL7<78KJ9&
MV]UVZV(XX/DHCY]T[/X&(Z2;L&/L$&,*/E02H&#0<\^&M^Z<K&1I381#]%"N
MYC^AO./)4<S+6SG*_HM525-4:3&[0O]-I85N)?FI$*+@YT)J27LQQ+(0*R#_
M-/FS26K5]A6N+JNFK:^.& Z6?(?6P[C:_%;I+H%+FH]!/5,P3P!!R16:4E[*
MN[),=]7H&O7J6^E_CKANK]4?<9L6U941J,>QFTU(^8B(<5GIB T"*C>$ZV7*
M;8<O'7S84G4IFTQ;D@<M<1; 5E<D V=1(CJDRU[FFI^W[H'5VTMJK"QJ&VW7
MW.F;&^3#3FO8[6SCX%1S9BD+^E,^N?2&K2ZL?3L'EU,=6[6U8U'-W"HXP0\&
M\CB_P0PK<P8Z,BUA%/7!2?"F/B&H(?2;9\6*;H@J9LI;(-9,-^G;K0N[+WUE
M:A8S!M"=2JM':G<[84Q>SF=GV-W6P&YK/L.*:.&Q+Q  43:=\="L?2'*1E0K
MV6@,3*".;;Q**/>H"958AJA<1E/^7=Q>J/,1L&,R*D7@JN%%DF+G[78QGE@(
MA**LFCEYGGSQB/>XUQKU^Y:<!UZ3-E]R.P(6  T!F\*CA"PE2?NXVVWU^B)L
MWK XZ@0L0Q;ZK!.N'W@R6'ZOGM"&J71,^K9FY!%.N6T6L_JY[<LAJ<OP73>D
M3_>*>.D$]1;W[?,@AC05RG?6@^,G^D"(*A]K3*4R1YH2 WFZ'-\Q*NP\^HM*
M1M0O?A+%E50+0'] W4K5JRAXKHHDY*9<2JASJZYPHRG$H8N"&3=PZS=7$U[D
M5E;(P1!W;HD!40==T3^V#FD-A@SUK-;DT=WL77O0&O3ZVPD48/8$;0'M\9U6
M=V"OX;#?FL$MIP,)QEHENC50^ZU1N\M!3=/8'V=I3:!%'F?TK:E[>BH+H]0-
M"<6//VQEH<:.,*;<@R6!UGE@6)5U)B7U\!0RF^30)/@06A_<-$)[IE=GSHB+
MT:S4R^Z=AL)[ZPD=F5S8:5@#GQM=Y7/#Y[PT7S\KM- $4H/**@4)K6+!16Y.
ME1^_M+"_Q>'U-,L,M"?-)Y/3T;3& :._%")&U=X)S'%G\$C]]2A@M#>*C@E!
MD%M )7@;1%2YZT)C?X7WL!]J>RS46]R-J29BK*(RQ4M)E]5\JR]U2:R.WC"@
MG"&J@UI-B*W$Z?*7J0Q:_8"#EK-V>$&KF F/-W\@V&?3*:_,JD)?:K91;*B!
M]O>5,*-#,8=36H5YLXW"/B"/\V,;374RU[%]A=WJ\T\<60W[1H8[ZQE!9)B)
M(!_<J XA=B_O!C$'<*EI1B6T2G 5]GFG@W>4SS*C%F__0&!2\I-3:?6 6\6?
M+P*0H^54>W59#>OD$8"\='AYVPBDSCOG1JMPO3MA^AIA.HI,/"DMS1/453$?
M<*\?B4 $L9FPP3%]D(;V\<_&SC8FQ(,E 4HU60RKC:?"?511PW0B5FT;N"RK
MV!]2%JIIF07+(Q\'W-3[AR=+D NT09P*)Y/*^=4J0S17;<ON*6E1M@JD;[7.
M62?AGCO48@%G&=-8TUQ/Z@/$.<82*XD*HT(G?JCCDX=O>>6QZ!9! I;">"2$
ML".'CY(8I^=(GT:)+*0,)'K%4KV(<3<D^XZIH[I<Q%"3-8-78+\/<75].>VY
M]5F.&;*[A6DGB#3V1X:T?\6'AJ'*5JNF@'+N *6JL1).S<8VLO6ADN!+LTFX
MNE_/7W;?J$<W194OLJ;56MT"WDD3]:53."T]K?1%R15&LGSJ86,SGR6M?(0T
MO?4R5C3_V4(;GX87PZD*3JRU'7TV:^BSY!UUJ41W+&=M>)-6N#IJJVC/VE6&
M=UT5U]S%LRGFQHNV%OJ1D_STSB88$SD;N6UQAR+G6Q!,A"AO5;:Y 0:-DC!Z
M^J&2H-!<0:F2<H,%OZC6,)V!9O)Z!5VES&]^2A':3FNXQA56?FSZ\0=RZ.Q.
MTU!7(I&[4:=NY-EL7=&\80<YO'IE&[DG,JME!PJ))\GJ8YBW]I:[-98K(K)&
MA^F4:U!GO.;VWUE82GDRDO_XQ8Z1_ <GP5LG23&@XZ_1-*[4&8X<.'F+TXU,
M2I$PM,[1JK52M.^@X5S]Z^Y?USFI=LJ=Y^JRU7;9C6X;S>B4AKL_#>G^4L>L
M.^Q$5P<G[TZW^0%SN3#9ZIFRW#6HAA'K=DGCJ5*5"35('=UNY/MDV5J-?6'L
MBX=+ H/XP[G>&T[RMZV&;[+!EI;$SRG7@<]"T>$9%;,Z**5C==&\JI\359O%
MZOEB1L8"OXVR1"9,+ZVJKUD6%JMTAJWNT"Y7U4\<5T^M;M84HFY>/&4_=?/+
M(-E"\3RA9=#J=3M&KQF]]G!)8!!_="%ET7"@F.BIY&HUIV\#?P4FS/&3R;T+
M&I95ZHDT.VA.C=*2@S /ZL)N=2[R^GW=UT+O$LC<1 F6.A[4:.BE#0]6:^L]
M-SM  P7;U*Y=>G^ZS0PT9\=R#MI"O[=BFP.[U>ULT-W@U*VK'W\X71UC[*N#
MDZ :"CS&WKZ':NFK8V9+;7W[0]'6%\[A.VSKNYVFOOUST%9X<?^\.S)-?3=J
MZLL3M($U9M2H"78 ,.P-H';ND^(2G7VUWB'+>_KF78*M2_>/S)?1AI />9.S
M8SE&:G5N<]O?J@1XW.EB(]E>@[TF*U[J-.JF#7Z7]_=ML!YNT>3W],W'8;O5
M;_?K;)ME]-AE*]]<@Q_.X+MH=?NU2&DR^(S5<6BKPY#@X"1HZ&#5E)!1=("(
M.AP5L:"V,7KCH*I[H-_JC+IB,U.>0$)U71/17(EW4Y'JM^"R7]6>I@EDU3WF
M<7?8WW+'F%,_-9XNWQK1<7@2:!U3!GF7YXJY^5DOO+Q4A9>FH\KA*6@VT:%)
M\%%K8,(SR^JKE M5S0V9?[0/JT74,LQ?^:6DSA.>S!9PO2C;\X51ZN>:7+36
MD)E@E %*_0VH'PK8WN(V/(B-HQ"+##W1($'DH-U8"]2^2^8D\M!.?L)0)]+Z
M^QN.&7"Q?IQMD0VQ6 2^B^?\O&P\IL8,>N.3C8%:<3[5[BH<L$6PBE+B9 J&
M\+-'BPA/1I25B7FK14Q6UY(4BL%5);QHFRGJIOE*D5N F';?\IP;.F1QDI$3
M(O9A>X6"YL4#([HOY)1/C5&IO!VWZ#S,,UGH30EG3.'[(5,K37)O #_6M>3A
MTD<1XL*A.U3M\#3NSYN%YZZDIJU2LLF>>?X5_OWSLRPYFSK.XOE+-DY?@O$8
M1$D6LR^P27\+(O?;KS_^\',X3]WG;Z@-$3[K-R?\QN+7++^('(_PX1.;_/+H
M!?_[:_?=JZ]M^^O?G? K&H5?VNVO_/]?/GSMVE_!9"Q^_^C7@I MRT(21A-G
M[@<WSU?+6RZZP)KE<EK),A)%4I+1=^1U14E:^/::F@+D7S9)6%UR5N5RO?RN
M%<&:V*V1VCN6N0V2'KTU9[,2)M;39-CX!O"51@L@P'D?KB5GAC4&*?M-_3R.
MTC2:UUU1-*7>?_CRRKHHM$3(V='B_&@!0ZXTG@Q3G3!3E>9BPQ]^C;GF*_(;
M1GA8C- L$@Q//!">6'5R,R0^=1*_9UD<?0A%Z91C/>[S.F\,6,9L B8Q;VG(
MF B&^+E4&'.IX(>%'/ !G>NPA+Q2)GYNJ=<EJ@43+]D6(P=4D4[U-=>.; DE
M@KKJ-70*X:\2YZV8EZ,+9ZN(/%&(7+A6*7B9,_7/SU;:Y&BX*]M>V?4?)B^T
M@K=/?$S["W0O?\94@]^P)NZC<T-'AEV8]^+8<6_<*;F=*]F_SL*M_PUO$ON-
M#.#R3;6_X4UB(Y*]7+ZI^-MI>'N*=K[=+O8^P_#^&3&FI?.N<90>GF[&47IP
M$AC$'P;QRC"8T$NQ@MF+%BGOJ"N4.Z8DA>246P3P[1.M#UKNF(9?"LVFM6:>
MG6&+7Y0/+BJ8(?*-I11\48@\7P#2-8^PEA=%;8%E_\RBOUNM@OMN7_&5O%$K
M^4@KP3O*7=WJ5G*YB/W LH>E["LM+H9W);SIL<=4GHJ*:9,C%DCHDP6EM<;F
M65^12#7$M$58;W3#D*,]/P:+*XJ3EF@:'F(.OR.R9[35EO.]82M@G6"GU;F
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M]S6>X3GFM =SJR9_^M2_$H^<^=,9MAX4K[KA4RM4^>L?643CRF.:<$'SR*G
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MG0J#-P_:2\?\PB;NHV.5K- X^-G21I&S8E?L#DFF@Y^I7B>^@770*6)KETX
MO-(.\5=?,7&-=,$/WVGX@WGMN7.4B&$@ZOL_&)X#1]>/"A=X"+6>8[4C*.^6
MV0NDLEZE>K 2J8I ]OYXJ.,!K95>KW #\A2IB.@%"OVA*%3B2C?QB"J6^=O9
MM>L&V&;[7/NF(4L=#_N=%W!HC[PEFPYMBE-T!_VA-M@CT:^Q7P;[",N9-TX
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M/O_H.H_!:BPS578MH3$^[W3/92ML+V@<)""[Q:Z(4K2X]<!=B.-^?;8AY'I
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M\W3W1N69?TUR&I2Y:R:&491C# 82I>SD^6_W7RX0.PVVK!L@VS#MSEDI3\I
M"YU>^E#M#C6P5Y_)HC.X$3P%Z2]YU_(M:O[B:!4@+=C##/UTN#A8LJYG<J@-
MS#?A'$Y0W<1J5"2(A=F/5%\3\0P%2.H)#Y^H<L%V*Q(DN59EB;,9<Z+/K@/G
M$VB$HAJ._+V;5%.^,YP_<I).TK=UD'-;!^5DISS_=3,\J4%B41=&LA??81
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M=K9:\;5GXI8FX)?0P\R?PX 6PSX+09D0$A<06BI6EJLO3R*M"PN08:MG26(
M+_L-=NDD.:6GAFEKB^J K_A,J?= ?!CYXNMKF">81W6QN#5/>]ZGM))V3ESQ
M\>TI-A4G"XT=6+=-U<$EQ<,NZ05Y$:.^KVN4-W1'E^RC[R/O7O1@@$FGZ)YV
MU3YC&6%['$5-G* %4!:T;8JA+#^8KT9Q90GM@5?\6SLTE%_(7,?,G:)(V?PM
M%&EJZ0H*31'#T4O7@J,+\6^=01HF\-'S[E*S.OYL,"^F03&Z6I)LVQ!W(5(]
M\CP9)B(_/WK@^]1%^;\_F/C-.JH.+!#9J,'QD\2DQZA0%:PB*$Q0>/)BD_.<
M1M%5F'L^Z>].'L7M6S&)IH)0T<:&N -909[R''G_BY-M/^7L1^DN!]5K-F7L
M@"T*H_\/K&ID3+!W2D+H1R;0>1G7M%!:,-FMC7_+7*\L0&N1SU+*-L4]:JD]
MNP]$TZB6JD7:7-)[.:B[!WHWI;&XV?L6BR].,0XUI6R(6Z0;#/._F-&K$,M1
MEDI01T#I&;%KR-<BC96ABJH2:%#WJI5(6J3')7[( TUM$NIM+1IYL^N*JG.C
M->6T)T-2%J>K\05Z)$$<?*7)/:8/F,%Z'K-[<@]_)Q]7%#84FK*V:/%+=F&O
MQB7O\2OVO8_S%,!?Y:4*:GS>@*D#X7KE),ZWQNKVSU;B[D (6-X*R> 6:6>:
MA\(\ (+D"$Y:Y*HY\6$KH .V6;(EDGUGHMND*6,';)%-ZCN:E8QN96E(P)U7
MDPRY[Q+Z%M6:KC%SQ9FR"2Z,,1N^:4_=EB,-"2 >F"4L+W=\M.JTM9W&J[%W
M8'J7O5BZP)\\<GA#B;A)(R 5$5$=?1>*=<:ZAEV]LCEK!Z9"KE2R21[5?H-F
M0]P!G2N.P)NS 1OB]H3\ES2\P>,X](08,51:'G_Q"]*EQ!V 4RV)D$=1$+F&
M+DREA1JR%N6Q^D"/E&*/I6Y5+"W2\R28^72.<71,&'8Y9>DG8E'L<V/YP9:A
M13I6_*-PU?NR=O3M<3A?P5]@[P:+4;A<#CL+C3ZA&>'(3R)AH,#L'GNGE)W&
M/&8X"Z[4#<'U9;4HPE9.FZGQ(JB&(926FIB6UCKJ0F0MG[V8=A<TY%-_KL[2
MI(*BZ%1#\VP5E"<,$O)_WKTN.*@F:L\[JMXBFOC(]";1)7[(BJ4]:L(RY\J_
MCR:FK05S<XO6"KF[@3UY]A0F-SC XGZKII$M0XMTO,&S#(;*788:FA9IHI_G
MT/&I)&FE'J:M12WSK]:Q"7N+]"_?%ESC$Y=1OJ0K["=W=WWX_KO_ U!+ P04
M    "  %JJ],NY'JS[L'  "M60  %0   &YM=&,M,C Q.# S,S%?8V%L+GAM
M;-U<;5/;.!#^WIG^!U_ZM<X+N8/"E'8" 889($PH;;]UA+TANMI23I+STE]_
MDF.G))%EAP9'9IB!D.Q*N\\CK59:.1\_3\/ &0/CF)+C6JO>K#E /.IC\GA<
MN_]R[GZH??[T]LW'OUSW^TG_RNE2+PJ!".=:R@PP^,X$BZ%S]LL]\[&@S/DZ
M;\MIU0_JS7K+D2^_@4^ ^VCVWKE&,Z>U_][9:[8^.,W]HW;[J+WG=*X=UU6]
M!)C\?$ <'&D5X<>UH1"CHT9C,IG4IP\LJ%/VV-AK-MN-5+ VESR:<KPD/6FG
MLJW&]^NK.V\((7(QX0(1[[>6:D:GUSH\/&S$GTI1CH]XK']%/21BG'+M<C(E
MU']N*N:JM]S6GMMNU:?<KRD,& V@#P,G[OY(S$9P7.,X' 7*[/B](8/!<8V$
MPG,5CLWV7/O=*24^$ Z^?,%I@'TDP#]!@7+Y;@@@>,U1K=_W+Y=<H P_8H("
M3B/F01AQ[-4]&C:4;*- HPUEMH<"+PIB?*ZDD4OFPU2 ;,5/'5 -;]6">.Q0
M;ZG30+%%V3)H29\Q)0/$'V)>(NX^(C22_+0.&A (GKZCX#UPFZV$GG?)VS\Z
MG,M>3R/&Y$Q(.PC0 P1QMS_T<HV2K3Q%?&@P+OYXE;H.6S8/,2]M0KY<XVUY
M:"<2#1Z%8=R:BP6$J?Z T= $3]HOU9CI4.8#D_%)AJ>(2QOH2+6/@IHS ?PX
M%/*CTO&]93!"V#^;CM3HS!\->GG[&<CP,Z%DSR9*YO[DSDAIUXXAS\)ZA9!B
MP[Y,A"^)7$$?\4, <U-O0)Q-O2!2"<,%I?X$!X$!_T+JUK)3S/EB$Z-,TJXP
M>L !%A@*+%H:X7*M[7@>B\#?R.ALG1T.IFP/UJ9]MLOVA8"[(67B"[#PA#)&
M)W+LFR*N3KH2G&C=W.;<7D_@U3L_9)8K]V-"19E;:3[FG++9#16@PDV'^,E8
MD;$(&'#=I'A6,U9S\CQ@$K+:]DR=+CR(2[D)9?$>^IZ@4(XQ_ M\F6.%. KS
M UW1%JRF<V,X$B;_MH?))TX66TLM822+BFHL/=\08X@(+F=[7UG >Y%01SHJ
M 3/08%2SFQ>SQ_:EFG>">C^'-)!V\;/_(BQFIMQ@7;A<:V6<&8 <[7YLR5<4
M1& P5R>]P]&3#;5F![_NIGVS^Y2&(26%J%@3K00/ZP[:-X$[OH_G-MPB+).I
M4S3" IGV]%D:E: DTUW[DL<^"(0)^&>($;4;D?EN%"ITP>_" 'O8E#<64*X$
M7T5 L#I;E OY1FMDKJH=^8O1+4.R:>LZA(7:DBBWY+93R)$&Q#/G^B:M"G)D
M!*'@LE4UGW62!=>!QDK]\]/;-[]_MEW3O1/R=TQ-;] ; 8M[Y7+_',G%3)59
MMU/ES>MF%W7?/)M*+C@E)I#'I#IF"A#KLF67QRZ 2!,"=5;FAYA@+I1!8T@,
M,MB>I[G3*F8F":OS.]=_&\O,?> @$1E*J[LPAH".U/#/I\RL5PW"<GRWL01]
M ^*2R!@&5Y2;HL&R7+D)S@+_0I;JI'>XN&L!7ATX6@_MRS336L7<RF1<2P?-
M%72]BNV49/M:0E%-]G,Z1#*!O23G"+/X]*4W2 Y7TW1Q)L-,6GF(:TWJ(F,7
M&!['JT16I6TK;=O*WA;1L^]$Y0)API77P'OD;*KB183Y4*TQO8$J3IDRHEQ=
M6RG=P/N")RG:S<]+;GK4I<#S@$Y>=L^CZ6776QZ-2>7G-\J(6T;'6/IY,KOG
MJN:^6' [GISM>771#1JI2OZVPW1Z<TI60\&*TS9N@SK^OQ&/SZ/.*>O,+PK$
MX!@K$UDZ%>?+ (:->Z*[(6)P@N*X%JJ\+X^X#(6*LY8%0['$J"AE61DP)<K\
M- OOD5N&B8='VM)>GD9%B<@%HEB^4W+@>S*]YWE9%W./1D0DV;8I .;J5I3)
M#<!)./W'*DX7\7NQC>(7ZC?X,J#? 1MCSYA %6R@ZNP6A"FA>/]% V@?QG+?
MFXRT9'2I ;?)4<%&;524O&> E?!W4!Y_JV<7A0A;4WHU#*W#D5#RP::H^=+'
M-94D<_/3G,-L3MWR297[3@8R)^["_.\E67[>T'@4GJ-:<4KSH5ELU"VG=/WY
MIHUHU:B_.FIU$*7T6G40D^'\.29(;J/^[ !0UTC9-\*I!^#S<TGZDP>.<E87
MD]9NRP ;4K5^<]P QS;KJ1E)V]/^+SF/U'<^_-X+=#BG'E9GY-^P&&8_'Y:5
MW6VI]4HRO%5X2ZC@/C6U+U?!65(163RF>2]71"]B,H12I#M;?$XKKX/9(G#9
M5YR]7=BL+#REW/C%#CKI2K)G=#__?-+='4WQ[=DTBA3G2Z/V2HC3 9)_&EDZ
M@\I?=<5;_E&7GL<H4.;? L/47\U3#8QNU,P.&7Z.NYIZ:>$-0,$LZ17"H9TT
M!5.%C/OT?W"I)-E@I5=.N^I!HN YWXB6T= +7PW)Z+7LPL66OYOE#\]T%TU[
M"I1SR$[U-9*[_>:M/""7LCF=GU9>TIC;*0/! #B/S5'&%AXC68K5H*HH"MN]
MHF&>&GGY6+9L-3 W^%K*M8J4:S23_F5>I5B1JAZT"_^V>T/"#&JZUG7\L:(U
M;_BNB5</YG6/;;R]T!-#8.O^W5#BY0;Z?-UJL+8!%H5O)VARWH^+;Q26__P/
M4$L#!!0    (  6JKTPPR6"AMQT   7N 0 5    ;FUT8RTR,#$X,#,S,5]D
M968N>&UL[5W;<MLXMGT_5?,//NG7<1Q9=J<[-3E3\JW;54ZL8SO)U+RP:!*6
M,$V1;H)TK/[Z 4"1(B7<2 ($K/BEV[$!$ L+U[6!O?_QS^=%M/<$4@23^..;
MT=MW;_9 '"0AC&<?WWRYN]C_Y<T__^]O__./_]W?_]?)S=7>61+D"Q!G>Y]P
MF@<(PKWO,)OOG?^U?Q["+$GWOA9E[8W>OG_[[NUH#__X#80Q0*&__/O>)W^Y
M-_KY[WN'[T:_[+W[^<-X_&%\N#?YM+>_3[X2P?B/>Q^!/5RK&'U\,\^RQP\'
M!]^_?W_[?)]&;Y-T=G#X[MWXH$SXIDCYX1G!1NKOXS+MZ.!?GZYN@SE8^/LP
M1ID?!^M<I!A6OM&OO_YZ0/^*DR+X ='\5TG@9[2=I/7:XZ8@_]HOD^V37^V/
M#O?'H[?/**SJA=.$6?69>@''!\4?WY#F\M,@32)P Q[V5C]^N;G<S@;C[""$
MBX-5F@,_BO"72!T^9,M'\/$-@HO'")2_FZ?@@0NQ_#ZI^3&I\T^DM(,>M<$_
M@YATF?T0//AYE&FLVW;9FFJ:+'P8FZEH472O>M(B]A=@<0]2G95LE-NGAG-<
MF33([\%^!5QC/5FE]ZEMG&03K4-F52"M4UDA6>'Q(@OVR;3Y;EQ,%C_=YHN%
MGRZ3AULXB_%<'/AQ-@F")(\S/'M/DP@&$* [_SX"Z,W>)EI2RR2%,QC[$4KR
M- "+','@;9 L#BCJ5L7WA'*=SOP8_D5G5S\.\=0(4?+PF *$EQKZVQ!D/HRZ
MX% O>Q ^SCH#:5?^D&!&IM&,!H5S:!K.X:!PQJ;AC/O"N<0#,9Y!,I-T'QZ,
M0OJV\CQ)LSN0+J9ILH ()>GR<Y(!-(G#+S$"09Z"\"KQXQY#NN47>@(Z36*\
MU<](&VU_\)N?IH3E60H V>'WH*+;=VR NP//6>Y'0V$L/]>W8V9)0,\/(:[.
M(][A]%PBQ>7IJ.P)*?RT5GCO]E<J5D?5YTD4XC,M/D#@.2_KV<CLPGJO!O<(
M_)GC?G;^U&_@\DJB%225CB%IY2M<FT8]<7,#W%_"LJ:D,$,[32H3)$'C\Q$Y
MF"<I<S=.=^(//KJGV_$<[<]\_Q%ORT?O#T"4H?(WI$7?[[\;K4[B/ZU^[9T1
MT" \ 3'^(9M&>"Z&*(@2A*=FW S@,@,+5'XX\N]!1*OCM<KOO2M:>$!<1!$)
M\PA</VS7$*VK6+2Z %^K<KS19D^:I$W$^,A5?FQU^FHE9SS@F;A;^Y>U2/K!
MVTM2/+X_OL$%Y@C7/7FDQPY207H&_! D<89'RWE$UP4\PL&,_+#^.RX0A!_?
M9&D.!N\4%SY,O_I1#DZ6U8^_0Y#BEIXOK\ 3B";/4-3;U0KP#DUT X&FL-TM
M6O/*[A[*>+G]PAK%GX!/$-+=R7;=SQH"EXAIE7*\L0G">7+<-MOJ-$EH5@3[
MH[--9MVUVFJ,]:9<;)WV"K5[]%_&CWF&*.3QIX8L+")[.Y=W9(12EEXMH%-U
M%$I89<)SC[LKZ-_#"#<V0"O@X75\0[2!%.^.3XB<28X[)[@N?ZBPVJ8\[]@B
MWSVW;ET!ESU@]**ZP)<XP4>W](GL5VC'QG].X@#GHN=BW3U$]7/>SS]&!VK1
M'F7_.K3>O]:;X D^:8<PRC/X!&X), KV_#F(<GRJO\ M2T26O#"77#^<^VF,
MD:,I2&_G?@I4>I?^CWGO7V[?,M(:9<\:LWO605/ ,2KIJ!O=!N[S)[B>,4!H
M$OR90U1"E\HXHFQ6U1M&Q=#)LO8O=0%'K2@+&HZD\:5#3!G8RU9O3C&L)(*A
MGX'P',\J9!Z1Z#6\+$XI-.KTL3N" *0SNWU6':6G<GXFVX*+J,G527)/3]%.
MDR-*B5Z^W!-"B%T+[[+\E&[A)?K'=F*KLH=X9'#6/A8$#6QLVQ[);[SZ;F\2
MA_1$=/TPK>WV5@;9R3W*4C_(&*W?K2"K D6[?4EG@.X($@S ^!P2D*K/\$+]
M-2'VVDN\1<)XLB)5NCY!J&VK%0JT(BITIX\]1#M#=V9292 X RA(X6-Q5"WK
M3">M9;M>("C(RK%_ /;%D-V9!(J+3XA6D]YIJ55<O OB9O-^V0%*)0#=D?T8
M?8]*2=,4!B*E0)C/^W4'*)0AE AL0VYH2;70)4(Y"&GM2CU0M*_EY?%&[W:
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M)TADD.H!3+WJB/1.Q/Z3=&'2^1G;OC@$M++[@6;PSJQY+[+O.+(3LMR)W-M
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MYWG'IINUZX>-H_?O( I/EBN0OR=1R-?AU4NPZ'+9")?MD#ODEIX5L0IE9"]
M%HYO<QC,-P-6K>)9R:2J7@5;= )M3-'JW2!:7.._P*A#.Z=ZM8'NI//]88(/
MV7-6/23Q?/!://6['X/(GG=J&S27D+6$ 'AYD8CL>:BV0?8F=)/Q!+CX2B4
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MY+3$X*Z8A\)=6J3[+78&4PY#E/?#W)96(V:-PIF-L#YF'-D*ZZ+(/3'L2XQ
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M\E&$#UL1,9!T1GJEM,Q7U3#&;+"DMARZ#HH'COA0G&V"8 ]L^OTW-"F+^C?
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M;J9[W^&PDU;2\,;,JO>:PP+EUP[:#9+QWGDT(H.<G2EP5:DO!?DR3BM8T^?
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MTA: Z_@$*?B!]<PQ*FD!;H*779FF$CPCUV$BJ1MQ>C1TG?V3V'G>9U;9 /T
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M0J!>I?^YH#K.XPC:>F-[L8#K+(])%_F^(NU=/J"QM)JD!9J*ZH)'PKL]TWO
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M8VC&RSB-2\IO%Y[V]>;R8NTMNI#&/V2UF0:54 DZU:W5?J-[?!VTT#S$+?3
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MW"LC$_*9R^4^;SN'SXW244(]2&54& [#U$2YU5C.$$*AOJN4;0RY>^QRE#%
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M:<ZNFE-;0U[UH9\35'0<.J=S[!@CR/EE,(?@VK5KXNT9IM_/S]&A20[PJ/5
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MD^_[5IW_0<?[NHY-R4[BU&:W:%W\J5:V="0YV;,O* @8DO,%!!A<=,E?OS,
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M3)TGJ?@6L-72F[P?HQPX2&H1?(*YBB7+91*7EM^[!4&?71<Y?:U$#W+B>YF
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M#6@NW*>T-FG6A@9KS#*1,!L%/WYH/#>P]2,W>BZ]Q?-%+O%WJI!Y$UASEXF
M97CXX4NCG+=J$]:;P)JTK%Z;*!@73";"O'-\YP^?RIO &KZZ2UD"SH7SEY%I
M3,#+":PUK+O,Q=A<.&;=U ,MH?[F1P4K;E70VIO 6KTD(N+Z#EDX'+" M.*H
M9,+<;>H=PQJTC"3) N&$!S@,<37H&Q^3B_ZIO\*Y+_(><BB\8^A0* .I"K"X
ML,_>TN?S,0K/_32FYKII$!3+(J(AA$TZ2ZZ<Y<3>,:RYRTCD:K!<V'+WV:-U
MNO*.86U71M)EPW#!M"$[9'9P*GO'@[%A=;\9<Q'VI@3#"PG?KN;P&A]N_?Y"
M&'R=EB,-R]/@#4K+UP3*5QI>!Z..)U>&Z,#]9QMK]91D6N0+,G/_VDQLJ1[L
M$@)'GMN4/P.:"Q<F%LC++"NTA5X1 <>PVQ=X \N%"Q0+H)I+24()' )O7^S;
MV%RX/K4L/@;;O0(U<!Q]-QU0PV?OS#T(/=#8Y@54P*'UUN3.P.6"8WD/H71W
MYU  A^!;EG.#B9]T8\0R5MO4A8_'QQR1+P'&3^W14>2#,)W(2D8>_'$732/<
M#$K!9,*A +"2K-D7S^N\]PJCY]( VT+X7.5,(A$0!RP>7U!,\$4T*CA<XKA,
M.)GC1[1&*Y"PA!+8YB$4&UO2<D .R/N62(-P<D%0GJ%'%"4K.@WDTA;2 9L[
M#&0M@V/-I@7SH'^/(SHK-; 5PT":+ @NO AO<%6[UE62*0ERTQK8&&&^V6Y!
M<,' 7#^VJ8"M]?0;$A\ V23 E@9MH0IPP%J3.:_,R-!.%WX\1Y?QA8_3TOIU
M/5M'W]<^Z1>R<]1/9\KG5AFFY4M2_%B>&1ABM=8WL 5"6?XV ;M@>O[BXSBC
M2QJYB,?GSW29*W"VJ*[W]'V6Z+ MHP4V5&@O"BJ K-F95Z7)Y!%([F0**.W?
M6^V LP%HRW-W\/9LQG#'KSJ8L'9]?/8S'- ; XZ*'(4*5A#%'J"3 6A+6P.7
M"X9E"5QS!8!.&* C1R--:*<2&+$"_([H@TO"$'(V\>?H6[%\0.GU;,^JKK D
MZ'8%G7U >VTP =B;*V(@.M*"K;YVF'4(G9S 2/SZFB1F0%]+SN \6S3]Z$64
M/,$YMEHNRF8P>@'!>V0 +BYZ327#N$F31TRD]?GE>T83I#3VJ&E [@]5)+H<
MFWYGPPD09@F#?^37A^G 8<#L/@>[BYO)2N6JYTABZFGXSZ(J3IU]2^* \.J2
M3(GL/KE% ?D=1V@+]GUB;[GH^]/ WCF;JG< 5KG@;-BPZ2))IU6FIZJ>J(H6
M[M! Y_4^@,AERK;/$2?6O/K"OEV#771H8Q) 9PX'4Q N.P:9/)$PAR*OO7'7
M\4V*"7M6S+0 $@KH/.('%[F<']9<F;#'H-8R5_EASG 6)$6<K_USHAU$1@N=
MO1QN)U'@C#4/YT".T8V3-_M"_XM"LHG>H?01!\)H)+4.@+V=0SB32-ACS7=J
MJ$Z<3>@6/?I1L9X(:^6G\T$GAD*G#V W*M!&I<DAV/<]*IJR&R^BI!J[1-!>
MUB$H XLG+GAH^XVM ?;2PFTW2JSI[KS[5.E/C.;4OP$5H!FDB-SESE#U_Q;'
MUOG#U-[L*'8"[=:U:9730^U"!H%]Q#=;]>2T5&2;%-I_JRE,58W8!]G9A#;,
M56._2(J6,NR30^>B[TDAV$#=J REOKA:\2)#)[.W[%S40&TO+!PNRI2#>/W>
MVT[H@: SZ 3Z5F,/)#A=\.T1R %"879!.-DJ]".YXPBHH'/K&XJ2K1<2G*#1
M)QQ#1WO(-!T'3?BX,>Y-LRP),#W@_([S!;^R$\\B8J=WZ%S\5G3$,C\&Z>1K
MP[LE)^Z7=9Q@4^7M.SE]!P4=6N*S7+T&O4#G\.]'.=1PN^'UNVF04ERG228L
M1<QH#9W\W^X>PL;7_:PYA OK!ER9%ZA> M5EOD\&72.@)^&S@7;WJPU!"]19
M9N6N 5U2P*J&Z,%VX1TDA4N+5I'_T<3KCWY$9\@-2G$2[AIV!/JBTPU\F0*3
M6ZDN0A=RE%"P$J%#5R(P%V:[PD!G&].JU ,RF#0?L*@&D[Y66U06$]-6HCJ/
M@;;G&GKM[277T*PT?L8A8YNAL611DI%KB8*!L&O7WO$8S84V4 \R2H85T7.+
MRKI']XF^M<BP.^\8UH1H1;P,>T '=@ _$."H2UWYO7VKF>9YBA^*$E-CZ-A!
M5)4LU52F7C[F'<-:(OM2M=Z8!>U1-=1$U8@_W7Z\8UAC)93^L/C0H_'RT _E
MK].Y'Z\C[/TXC/V<\"R9)4WBYT,_BV\/:/-XG^I:F>JLX4,KL??F7;]*?F4;
M_4/DDN:-FV9QR,IHY6;LGXF,8Y1E9R@+4KQ:HR.:3E].D'ER0XAI >U[HCN?
MR9C_,.&7C>\"/]^WI0N<PW/?K',E6<>7A(9$D74=I;'Z<L/9']N="98#;EN
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MB M!0)N=8$JNCR&."FI[OZ,L*=ET_AQ$18C"JD#?DO!CG9IRU[2G%"-K_6/
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M+3(P,3@P,S,Q+GAM;%!+ 0(4 Q0    (  6JKTR'-A7[NPX  (FA   1
M          "  :.I  !N;71C+3(P,3@P,S,Q+GAS9%!+ 0(4 Q0    (  6J
MKTR[D>K/NP<  *U9   5              "  8VX  !N;71C+3(P,3@P,S,Q
M7V-A;"YX;6Q02P$"% ,4    "  %JJ],,,E@H;<=   %[@$ %0
M    @ %[P   ;FUT8RTR,#$X,#,S,5]D968N>&UL4$L! A0#%     @ !:JO
M3#1(M\_I5@  SP(% !4              ( !9=X  &YM=&,M,C Q.# S,S%?
M;&%B+GAM;%!+ 0(4 Q0    (  6JKTPO-1J!P#$   5J P 5
M  "  8$U 0!N;71C+3(P,3@P,S,Q7W!R92YX;6Q02P4&      8 !@"* 0
&=&<!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
